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Abstract 
Vagal baroreflex sensitivity (BRS) is a measure of short term blood pressure (BP) 
regulation through alterations in heart rate. Low BRS reflects impaired autonomic system 
regulation and has been found to be a surrogate marker for cardiovascular health. In 
particular, it has found to be associated with the pathogenesis of adult hypertension. 
However, only limited information exists as to the negative consequences of childhood 
BP on baroreflex function. The objective of this study was to investigate BRS in children 
with 2 different BP profiles while controlling for the effects of age, maturation, sex, and 
body composition. A preliminary subsample of 11-14 year-old children from the HBEAT 
(Heart Behavioural Environmental Assessment Team) Study was selected. The children 
were divided into 2 BP groups; high BP (HBP; 2:95tl1 percentile, n=21) and normal BP 
(NBP; <90th percentile, n=85). Following an initial 15 minutes of supine rest, 5 minutes of 
continuous beat-to-beat BP (Finapres) and RR interval (RRI) were recorded (standard 
ECG). Spectral indices were computed using Fast Fourier Transform and transfer 
function analysis was used to compute BRS. High frequency (HF) and low frequency 
(LF) power spectral areas were set to 0.15-0.4 Hz and 0.04-0.15 Hz, respectively. Body 
composition was measured using body mass index. After adjusting for body composition, 
maturation, age and sex ANCOV A results were as follows; LF and HF BRS, LF and HF 
RRI, and RRI total power were lower in the HBP versus NBP participants (p<0.05). As 
well, LF IHF SBP ratio was significantly higher in the HBP compared to the NBP group 
(p<0.05). The regression coefficients (unstandardized B) indicated that in changing 
groups (NBP to HBP) LF and HF BRS decreases by 4.04 and 6.18 ms/mmHg, 
respectively. Thus, as BP increases, BRS decreases. These data suggest that changes in 
11 
autonomic activity occur in children who have HBP, regardless of age, sex, maturation, 
and body composition. Thus, despite their young age and relatively short amount of time 
having high BP compared with adults, these children are already demonstrating poor BP 
regulation and reduced cardiovagal activity. Given that childhood BP is associated with 
hypertension in adulthood, there is a growing concern in regards to the current 
cardiovascular health of our children and future adults. 
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Chapter 1: Introduction 
1.1.0 Preamble 
Chronically elevated blood pressure (BP), commonly referred to as arterial 
hypertension, has traditionally been a concern in the adult population as it is a well 
known risk factor for heart disease I. Ifhigh BP is left untreated the potential for 
developing atherosclerosis, coronary artery disease, kidney failure, left ventricular 
hypertrophy, a stroke or heart attack, substantially increases 2. Researchers have 
extensively studied the benefits of anti-hypertensive drugs to aid in the management of 
high BP. However, future research should be aimed to go beyond traditional disease 
management to explore the relative aetiologies and preventative processes associated 
with high BP. Recent studies support the association of poor autonomic nervous 
system regulation with the development of hypertension in adults 3-8. Heart rate 
variability (HRV) and arterial baroreflex sensitivity (BRS) are two such measures of 
autonomic nervous system function that have been found to be associated with high BP 3-
8 , as well as cardiovascular disease and mortality in adults9, 10. Nevertheless, in recent 
years childhood hypertension has become more prevalent}} . Given that childhood 
hypertension predicts adult hypertension, there is a need for more research in this area 12, 
13. By identifying underlying mechanisms associated with high BP before the condition 
progresses to damaging consequences, such as atherosclerosis, researchers and health 
care professionals alike can intervene while there is little to no damage done to the 
arteries. By measuring autonomic function through HRV and BRS, we can assess the 
early effects of elevate BP in childhood. 
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Both HRV and BRS measures evolve from the variability in heart rate (HR) and BP 
8.14-16. Spectral analysis ofHRV is a time series computation of beat-to-beat alterations 
in HR from an electrocardiogram. This non-invasive tool is used to evaluate cardiac 
autonomic activity and has been found to be highly correlated with adult hypertension4, 
as well as demonstrating promising findings in the area of childhood hypertension 1.3-8. 
17. Diminished arterial BRS suggests a deregulated autonomic system and is often found 
to be depressed in cardiovascular disease 18. Genovesi and colleagues (2008) and 
Krontoradova et al. (2007) are the only investigators to date to have looked at BRS and 
high BP in children. Both Genovesi et al. (2008) and Krontoradova et al. (2007) report 
lower BRS in hypertensive vs. normotensive children, even after accounting for body 
composition 17.19. Although these findings are promising, both studies have their 
limitations. First, both Genovesi et al. and Krontoradova et al. failed to account for the 
effects of sex and maturationl7. 19. As well, the age of the subject group in the study by 
Krontoradova et al. (2007) was quite broad, defining children as being between the ages 
of 11-21 yearsl9. Age and sex have been shown to affect BRS in both adults18and 
children2o. 21, while maturation has been shown to have -an effect on arterial stiffuess, an 
important determinant ofBRS22. Therefore, although several studies to date highlight the 
negative consequences of childhood BP on arterial baroreflex function, more studies are 
required that control for the effects of age, sex, maturation and body composition. 
1.2.0 Objective 
The objective of this study was to provide a solid foundation for future autonomic 
regulation studies in children by investigating HRV and arterial BRS in 11-14 year olds 
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with varying BP profiles while controlling for the effects of age, maturation, sex and 
body composition. 
1.3.0 Hypothesis 
Based on previous literature, we anticipate lower HRV and BRS in children with 
higher BP when compared to controls. By investigating autonomic function and how it is 
affected by childhood BP, we can assess and identify the early consequences of elevated 
BP at a young age. As well, since childhood hypertension carries into adulthood, early 
diagnosis and treatment may help to reduce adult hypertension, in tum, lessening the 
burden placed on our already taxed health care system. 
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Chapter 2: Literature Review 
2.1.0 Healthy Blood Pressure Regulation 
Heart rate (HR) and BP are known to rise and fall to meet workload demands and 
maintain a homeostatic environment. BP homeostasis ensures adequate blood flow to the 
brain and organs while inhibiting an inordinately high BP, which can damage the 
vasculature 23. BP is a measure of the pressure exerted on the arterial walls as the blood 
moves through the bodJ4• This pressure is affected by both arterial blood volume and 
arterial compliance (vascular tone), which is in tum affected by both cardiac output (HR 
multiplied by stroke volume) and peripheral resistance25• Both HR and BP are impacted 
by the autonomic nervous system and humoral regulation, which are linked by various 
feedback mechanisms including the cardiopulmonary and arterial baroreflex, 
chemoreflex, cerebral ischemic responses, re-absorption of tissue fluids, release of 
endogenous vasoconstrictor substances and renal conservation of salt and water26• 
However, for the purpose of my thesis I will focus on the role that the arterial baroreflex 
has on regulating BP. 
2.1.1 Autonomic Regulation of Heart Rate 
The autonomic nervous system is divided into the sympathetic and 
parasympathetic (vagal) nervous systems. To maintain a homeostatic environment, the 
sympathetic and parasympathetic nervous systems reflexively balance one another in an 
antagonistic manner24• While sympathetic stimulation increases HR, 
parasympathetic/vagal outflow lowers HR. Thus, HR depends on the amount of vagal 
4 
outflow versus sympathetic drive. Parasympathetic pathways originate in the medulla 
oblongata and synapse on or within the myocardium, near the sinoatrial and 
atrioventricular nodes26. This innervation slows sinoatrial firing and impedes 
atrioventricular conduction resulting in a reduced HR26. In essence, acetylcholine binds 
to muscarinic cholinergic receptors quickly, activating potassium channels and allowing 
vagal stimulation of the heart to have a latency of only 50-100 ms. This results in a 
reduced HR within 1-2 seconds26, 27. As well, an abundance of cholinesterase found at 
the sinoatrial and atrioventricular nodes provides a rapid decay of this stimulus as 
cholinesterase acts to quickly hydrolyze acetylcholine26• Overall, this process allows for 
beat-to-beat regulation of parasympathetic outflow. 
Sympathetic pathways originate in the lower cervical and upper thoracic divisions 
of the spinal cord and innervate the sinoatrial node, atria, ventricles, and permeate the 
myocardium, coronary vessels and the overall conduction system of the heart. 
Sympathetic stimulation results in release of the neurotransmitter norepinephrine 
(noradrenaline). Maximal secretion of norepinephrine can only facilitate minor 
adjustments in cardiac activity in comparison to the abundant production of acetylcholine 
during maximal parasympathetic stimulation. Sympathetic activity also relies on cyclic 
adenosine monophosphate, mediated by f31 receptors and known as a second messenger, 
thus making sympathetic activation a slower process than parasympathetic stimulation, 
which is mediated through direct acetylcholine-regulated potassium channels. Thus, 
sympathetic activation is capable of mediating HR fluctuations at a slower rate 
(approximately 15-20 seconds)27, compared to parasympathetic input (1-2 seconds) 26. 
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Due to the antagonistic relationship between the sympathetic and parasympathetic 
nervous systems, , cardiac activity produces spontaneous oscillatory frequencies referred 
to as HRV 14-16.28.29. These variations in HR are the result ofthe relationship between 
the sympathetic and parasympathetic components of the autonomic nervous system 14.15 
Measures used to analyse HRV segregate the contributions of sympathetic and 
parasympathetic influences in order to evaluate cardiac autonomic regulation ofHR. 
2.1.1.1 Heart Rate Variability 
Researchers have been developing various methods to provide insight into the 
rhythmic variations ofHR since the early 18th century 15. The first record of HRV was 
documented in 1733 by Steven Hales who observed BP, respiratory cycles, and pulse 
patterns of a horsel6. 30. Later, cardiac rhythms were measured using galvanometers, 
kymographs, and ink writing polygraphsl6. With the development ofHRV used in 
clinical research, investigators Hon and Wolf (1958 and 1967) associated HRV and 
activity of the nervous system when evaluating fetal distress and sudden cardiac deathl6. 
30. These early methods derived a measure ofHRV by collecting short term tachograms 
and processing numerical estimates from the longest to shortest cardiac cyclel6. 
Since the works ofHon and Wolf, more contemporary measurements have been 
devised. Digital signal processing systems are now used to divide measurements ofHRV 
into either time domain (heart beats plotted vs. time) and frequency domain variables 
(heart beats plotted vs. frequency) 14. Chess et al. (1975) and Sayers (1973) were the first 
to analyse HRV using spectral analysis l6. Power spectral analysis is a series of 
algorithms and computations used to quantify the frequency components ofHRV 15. In 
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1981, Akselrod et al. introduced spectral measurements for quantifying beat-to-beat 
cardiovascular control3o. They identified the frequency-specific contributions of the 
sympathetic and parasympathetic nervous system to HR (respiration was related to vagal 
control, while slower frequencies were related to both vagal and sympathetic inputi6, 30. 
Modem frequency domain analysis techniques employ either the discrete Fourier 
transform, known as the Fast Fourier Transform (FFT) (non-parametric), or the 
autoregressive model (parametric) 15. The FFT is a technique that uses all data in the 
spectral distribution 16. In comparison, the autoregressive model excludes 'noise' by 
using a best-fit model to concentrate on the more significant peaks 16. The autoregressive 
model provides a better frequency resolution in small samples, whereas the FFT is often 
used in larger samples 1,5,16. As well, the FFT method produces reproducible results, has 
a high processing speed, whereas disadvantages include requiring experience with 
overlapping and windowing to filter the power spectrum31 • Nevertheless, both methods 
produce similar results and are significantly correlated29. For the purpose of this paper, 
HRV measures will be done using FFT analysis because ofthe selected sample size and 
experience of the investigators with overlapping and windowing. 
In order to determine HRV, abnormal beats (ectopic origin, arrhythmias, 
preventricular contractions) need to be removed as they alter cardiac rhythms and result 
in difficult or unfeasible interpolationsl6• HRV analysis relies on the assumption that 
cardiac rhythms are generated at the sinoatrial node, thus offering insight into 
physiological mechanisms holding this relationship l6. Abnormal beats can distort the RR 
interval (RRI) characteristics. This results in a compromised assumption of the 
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underlying analytical methods exercised in HRV analyses that reflect autonomic 
function l6. 
The FFT method, used for assessing cardiac reflexes, uses computer processing to 
plot a frequency spectrum. This spectrum can be separated into two bands. High 
frequency (HF) ranges from 0.15-0.4 Hz, while the low frequency (LF) component 
ranges between 0.04-0.15 Hz 14. HF bands are also referred to as respiratory peaks or 
respiratory sinus arrhythmias because of the mechanical influence respiration has on 
HRV 15. HF reflects a predominance of parasympathetic activity, while LF reflects both 
sympathetic and vagal activity 15. Therefore, the ratio ofLF to HF (LF/HF) is also used to 
identity the predominance of sympathetic to parasympathetic activity. Total spectral 
power (TP), as a function of frequency, is measured by calculating the total area for both 
the LF and HF components 16. Decreased total power suggests sympathetic overdrive, 
vagal withdraw, and/or depressed vagal activity 14.32. A reduced LF could indicate 
reduced sympathetic input and/or reduced vagal activity, while a low HF component 
represents diminished parasympathetic outflow. 
2.1.2 Autonomic Regulation of Blood Pressure 
The baroreflex is a reflex loop which continuously monitors BP33. Input from the 
pressure sensitive mechanoreceptors located in both the carotid sinus and aortic arch, also 
known as arterial baroreceptors, provides a beat-to-beat negative feedback mechanism 
that controls fluctuations in both mean arterial pressure (MAP determinants = cardiac 
output x total peripheral resistance) and pulse pressure 23. 34. 35. Stimulation of this reflex 
provides a rapid adjustment of BP by 'mediating sympathetic and vagal effects under the 
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influence of neural impulses,26. The signal from the arterial baroreceptors is sent to the 
nucleus tractus soliarius (NTS) in the medulla oblongata via the glossopharyngeal and 
vagus nerves (cranial nerves IX and xi6• Stimulation ofthe NTS inhibits sympathetic 
activity, while repressing the NTS increases sympathetic activity inducing 
vasoconstriction26. Thus, an increase in BP sensed by the baroreceptors results in an 
increase in firing rate, in tum adjusting autonomic activity by inhibiting sympathetic 
outflow and augmenting parasympathetic stimulation36. This reflexively slows heart rate, 
reduces cardiac contractile force and vasodilates the peripheral vasculature, which 
ultimately results in a decrease in BP 23,24,34-36. Conversely, a fall in arterial pressure 
reduces the impulse firing rate transmitted to the NTS, reflexively increasing BP36. 
2.1.2.1 Baroreflex Sensitivity 
Baroreflex sensitivity (BRS) is a measure of the arterial baroreceptors ability to 
regulate beat-to-beat BP variability 37, 38. With computer processing, dynamic estimates 
ofBRS are now possible and elicit a quick measure of autonomic cardiovascular 
regulation 37. Initial assessment ofBRS began in1854 when Vierordt designed the first 
instrument used to measure human arterial pressure39. This led to the discovery that HR 
slows when BP increases (Marey 1859)39. Considerable progress was made over the next 
hundred years, leading to the development of four 'spot' estimates ofBRS. These 
methods are not estimates of spontaneous behaviour, but do evaluate the reflex response 
ofBP and HR to various forms of stimuli37. These stimuli include neck suction, 
pharmacological injections, and passive orthostatic hypotension through head-up tilt 
and/or lower-body negative pressure37. 
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The neck suction technique was originally designed to 'counteract neck distension 
during positive pressure breathing' for pilots and was first published by Emsting and 
Parry in 195739. By applying a negative or positive neck pressure to the outside of the 
carotid sinus, baroreceptor function is stimulated and the result is a linear increase or 
decrease in arterial diameter39• Alterations in HR and BP by neck suction/pressure do not 
occur as the result of decreasing/increasing pressure within the carotid sinus, but rather 
through changes in vessel distension by decreasing/increasing the pressure within the 
adjoining tissue. By altering pressure in the adjoining tissue, the pressure gradient across 
the arterial wall is altered, initiating the baroreflex response 40. This method requires no 
cannulation of arteries or physiological modifications related to drug use39• Rather, neck 
suction chambers are a non-invasive method of measuring BRS by means of mechanical 
stimuli 39. When compared to the pharmacological method, neck suction allows for a 
wider rage of pressures to be used when studying baroreflex responses39• This was seen 
when Sprenkle et al. (1986) used a range of neck pressures between 40 to -65 mmHg to 
measure baroreflex function 39. However, neck suction does have its disadvantages; 1) 
different neck chambers are designed differently (around the entire neck, anteriorly and 
laterally), inducing varying responses, 2) the investigators are limited by their equipment, 
some chambers have finer control of stimulus parameters than others, 3) there are no 
accurate measures of pressure transmission through neck tissue, thus real stress applied to 
the baroreceptors cannot be measured and therefore this influence cannot be accurately 
accounted for 40, 4) rate of neck pressure change and duration of stimuli applied varies 
among studies, 5) responses found with neck suction compared to neck pressure differ, 
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lastly, 6) influence of tracheal receptors may contribute to the responses seen with neck 
pressure changes39. 
In contrast to neck suction techniques, pharmacological methods of examining 
BRS (often referred to as the oxford method) are invasive and require intravenous 
injection of a pressure agent (either phenylephrine or sodium nitroprusside) 33,41 to 
increase or decrease BP42. The resultant BP changes stimulate the baroreflex to decrease 
or increase HR 43 and peripheral resistance in an attempt to regulate BP 33, 44, 4S. By 
plotting systolic blood pressure (SBP) on the x-axis against RRI on the y-axis, the slope 
of the plotted values provides a measure ofBRS or 'gain' in ms/mmHg 46. Smyth et al. 
(1969) were the first researchers to use linear regression analysis to relate RRI to SBP 
following injection of the pressor drug angiotensin-II39. Pressure changes, by injection 
of phenylephrine, often induce BP elevations in humans greater than 20-30 mmHg and as 
great as 142 mmHg in dogs (Rea & Eckberg 1987; Pawelcxyk & Raven 1989)39. The 
primary advantage to the oxford method is that the stimulus for baroreflex measurement 
is arterial pressure39. As well, this technique does not require additional forms of 
equipment (i.e. neck suction) and non-invasive finger photoplethysmography can be used 
to accurately track BP changes 39,47. However, disadvantages include; 1) the injected 
drugs alter arterial pressure and thus this method cannot independently evaluate 
baroreflex control of arterial pressure, 2) some vasoactive drugs alter BRS by means 
other than pressure elevation/reduction, such as that reported by Peveler et al. (1983) 
where phenylephrine independently reduced carotid sinus diameter when BP was rising 48, 
3) cardiopulmonary afferent activity may also be altered by vasoactive drugs49, 4) altered 
responses may be seen due to the drug effects on central or efferent limbs of the reflex 
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arc, for example, Eckberg et al. (1971) observed cardioacceleration rather than 
cardiodeceleration in patients with severe heart disease following phenlyeprine 
administrationSo, 5) excessive use ofthese agents, seen during serial measurements, may 
exceed metabolic and excretory capacities, thus accumulating and altering baseline 
autonomic activity39. 
Baroreceptor firing can also be altered by abrupt changes in body position or 
applying lower body negative pressure39• The proximity of the heart to the head identifies 
the capacity of cerebral perfusion pressure during standing, while the distance from the 
heart to the feet determines the hydrostatic force of venous poolingSl . In an upright 
standing posture the body uses skeletal muscle as a second heart to pump enough blood 
back to the right ventricle in order to maintain a functioning level of cardiac outputSl . 
Passive head-up tilt exaggerates the reduction in venous return to the heart as seen 
during standing by preventing the skeletal muscles from acting as a secondary pumpS2. 
The diminished venous return triggers ventricular mechanoreceptors and provokes 
vasovagal syncope in predisposed individuals, thus providing a means to examine neuro-
circulatory responses ofthis processS2. Thus, passive head-up tilt is a non-invasive 
method of eliciting a baroreflex response. Similar to head-up tilt, lower body negative 
pressure is used to study cardiovascular responses, particularly the baroreflex response, 
by simulating orthostatic stressS2. By applying a vacuum to the lower body, the suction 
serves to generate a negative pressure, in tum impeding venous return and reducing 
central blood volumes2. Mechanistically, the negative pressure unloads cardiopulmonary 
and arterial baroreceptors, thus, reflexively inducing peripheral vasoconstriction and an 
increase in HR in an attempt to maintain Bps3. The baroreflex is essential for regulating 
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orthostatic responses and therefore lower body negative pressure also provides a non-
invasive method of arterial baroreflex stimulations3 • However, pediatric researchers have 
found this method to be intimidating to children because of the unfamiliar feeling of 
lower body negative pressure and the loud vacuums used for suction. 
Although the aforementioned traditional methods have limitations, they do hold 
some practical importance. These older methods allow investigators to evaluate the 
entire stimulus-response curve of the baroreflex over a short intermittent time period37• 
Furthermore, these techniques provide a much more robust measure ofBRS compared to 
modem techniques, due to the fact that both environmental conditions and stimulus 
properties are controlled, where this is not always the case when using modem 
methods37• 
The modem methods used to quantify BRS they include both the sequence 
technique (time domain) and transfer function analysis (frequency domain). Both these 
methods provide a non-invasive measure ofBRS by monitoring naturally occurring beat-
by-beat fluctuations in HR and Bp33, 39, allowing investigators to evaluate BRS without 
the effects of mechanical devi"ces, or physiological alterations due to pharmacological 
drugs39• 
The sequence technique employs computer processing to plot the beat-to-beat 
fluctuations ofSBP against concordant RRI changes3S, 37, 39. Using a regression 
calculation, spontaneously occurring sequences of three or more consecutive beats where 
SBP increases or decreases (ramps) are plotted against the corresponding RRe7• When 
SBP increases, RRI lengthens, and vice versa 3S, 37. These short progressive 
increases/decreases are interpreted as bursts of sympathetic and parasympathetic 
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modulation by the autonomic nervous system to control beat-to-beat BP and HR. The 
slope of the regression line is then used as a measure of BRS 35, 37. In 1986 Fritsch et al. 
observed that BRS estimates using the sequence technique were similar to those 
measured by pharmacological injection (phenylephrine)39. 
Spectral analysis, as described above (section 2.1.1.1), is used to split the 
autonomic signals into LF and HF components. Once these components have been 
plotted, cross spectral analysis is used as a means to obtained either the alpha (ex)-
coefficient or the transfer function gain measure of BRS 33. Digital processing used to 
associate RRI and arterial pressure were developed by Penaz (1978i4, Sayers (1982i5, 
deBoer (1987i6, Robbe (1987)42 and Baselli (1988)57 and their coUeagues39. The a-
coefficient is defined as the square root of the ratio between RRI and SBP powers at both 
the LF and HF range37. As for transfer function gain, it is also the square root of the ratio 
between RRI and SBP powers while also adjusting for the input variable, that of SBP 20, 
37. When both methods are compared, transfer function gain yields a lower number 
compared to the a-coefficient. However, both methods are very similar and yield 
proportional results2o. Both the a-coefficient ~nd the transfer function gain represent 
fluctuations in RRI in response to SBP as a function of frequency, reflecting a measure 
of sympathetic and parasympathetic activity39. When comparing these spectral techniques 
to the sequence method, spectral indices reflect much smoother changes in SBP when 
estimating BRS, thus representing spontaneous behaviour that is more regularly sampled 
and an average measure of the entire data see7. In contrast, the sequence technique is 
more variable and obtains measures from various scattered fragments of the whole data 
window37. , Disadvantages of both the sequence and spectral techniques include; 1) the 
14 
requirement oflong periods of data recording (1-6 min), and 2) only the linear portion of 
the sigmoidal baroreflex relation is delineated as the calculations are done under resting 
conditions 39. However, the spectral technique has been highly correlated with the 
phenylephrine method in healthy adults (r=O.94; n=8) 58. Studies using animals have also 
found that transfer function analysis has a significant linear relationship with the neck 
suction method (r=O.63, p<O.OOI, n=26) for comparisons between normotensive and 
hypertensive rabbits33• Watkins et al. (1996) also found a significant correlation between 
BRS estimates derived from phenylephrine-induced changes in SBP and RRI (r=0.48, 
p<O.OOI, n=42) to that of cross-spectral estimates in hypertensive adults59. As well, they 
found a strong relationship between cross-spectral and sequence-derived estimates 
(r=O.076, p<O.OOI, n=42) 59. Thus, measures of spectral indices provide valid measures of 
BRS when compared to both pharmacological manipulation and the alternative sequence 
technique method59• As for reproducibility, cross spectral analysis measures of BRS in 18 
animals on 5 separate occasions (each occasion separated by 1 week) yielded a maximum 
variance of 17% 33. The above finding demonstrates that cross spectral analysis is a 
reliable and valid measure ofBRS. For the purpose of this paper only transfer function 
analysis will be further discussed as it is used in the present study to measure BRS. 
2.1.3 Prognostic Significance of Impaired Autonomic Regulation 
Evidence for an association between cardiovascular disorders and HRV and BRS 
can be found throughout the literature 18.60. BRS becomes depressed in the presence of 
cardiovascular disease (hypertension, coronary artery disease and congestive heart 
failure) 18. BRS is also impaired in several pathological conditions associated with 
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autonomic failure such as cardiac insufficiency, diabetes mellitus or uraemia 9, 21, 61-65, A 
reduced BRS or HRV emulates diminished vagal control which affects cardiac control 
and is correlated with increased mortality by sudden cardiac death 38,66-69, BRS and HRV 
are also associated with obesity, myocardial infarction, ventricular fibrillation and 
hypertension 14,60,67,68,70, The assessment ofHRV and BRS reflects cardiovascular 
autonomic activity and provides markers and predictors of cardiac health, 
2.1.4 Humoral Factors 
HR and BP are not only regulated by autonomic regulation, but can also be 
influenced by hormonal factors, Humoral regulation is important for the prolonged 
(minutes to hours) control of orthostatic Bp51 , Ifvasoconstriction, activated by 
sympathetic vasomotor fibers, is prolonged, BP regulation is supported by circulating 
hormones 51, Hormonal factors indirectly influence BP by affecting peripheral 
vasculature, cardiac contractility and plasma blood volume26, 51, 
Vascular resistance and cardiac performance can be altered by adrenomedullary 
catecholamines 26, The adrenal gland releases the hormones epinephrine and" 
norepinephrine into the circulatory system, which have an effect on peripheral 
vasculature26, Dependent on the amount of epinephrine released into skeletal muscle, 
low concentrations can have a f3-adrenergic effect, while high concentrations can have an 
a-adrenergic effect causing dilation and constriction of the resistance vessels, 
respectively6, Vasoconstriction of skin vessels is obtained through epinephrine, and in 
all vascular beds by norepinephrine26, Infusion of norepinephrine in resting dogs has 
shown a rise in left ventricular pressure, where myocardial contractility was proportional 
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to norepinephrine concentrations in the blood26. Thus, vascular resistance and cardiac 
contractility, which is known to affect BP, is influenced by adrenomedullary 
h I . 26 catec 0 ammes . 
Cardiac performance can also be altered by thyroid hormones 26. Secretion of 
thyroid hormones enhances Ca ++ uptake and hydrolysis of adenosine troposphere by the 
sarcoplasmic reticulum, increasing cardiac contractiliti6. The opposite is seen with a 
reduction in thyroid hormone secretion26. Thyroid hormones also affect myosin 
isoenzyme composition in the myocardium and increase '~-adrenergic receptors andlor 
their signals', thus altering myocardial contractility and sympathetic activity26. These 
alterations in cardiac performance affect cardiac output, thus affecting BP26. 
Hormonal reflexes act on the kidneys to regulate plasma volume and BpSl . By 
controlling renal water and sodium loss through retention and excretion, hormonal 
reflexes exert an efferent role in maintaining long term BpSl . The Renin-Angiotensin-
Aldosterone system (primarily angiotensin II) and arginine vasopressin or antidiuretic 
hormones have a large and direct effect on plasma blood volume regulationSl . A 
considerable fall in mean arterial BP, seen by a drop in blood volume> 1000 ml, causes 
antidiuretic hormone or vasopressin release, which facilitates water reabsorption in the 
tubules of the kidneysl. Vasopressin also has' little or no effect on osmotic water 
clearance', thus also increasing sodium retentionsl . Therefore, the release of this 
hormone causes an increase in blood volumesl . Similarly, angiotensin II is released by a 
fall in mean arterial BP (> 1 000 ml of blood loss), which stimulates the release of 
aldosteronesl . The release of aldosterone increases both water and renal sodium 
retention, therefore increasing blood volumesl . The release of angiotensin II also 
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stimulates vasoconstriction of the renal system, decreasing renal blood flow, causing a 
decrease in glomerular filtration rate and thus reducing urine volume to increasing blood 
volumeS!. These two mechanism increase blood volume and contributes to the resetting 
of the baroreflex therefore imparting a prolonged BP effect 71. 
The humoral effects vary depending on the tissue exposed and the circulating 
concentrations, however it is clear that they do affect BP and HR regulation. Studies have 
shown that even after cardiac denervation in the dog, 'increased renal free-water 
clearance' is attributed to vasopressin regulationS!. Therefore, hormonal factors 
contribute to BP regulation in spite of denervation. Although hormonal effects should be 
considered in long term BP regulation the present study only focuses on the short-term 
regulation ofBP and therefore will not focus further on the humoral effects. 
2.2.0 Hypertension 
Hypertension is chronically elevated BP. In adults it is defined as having a 
diastolic blood pressure (DBP) 2:90 mmHg and or a SBP of 2:140 mmHg 36. Pre-
hypertension is identified as having a DBP between 80-89 mmHg and a SBP between 
120-139 mmHg, while normotensive individuals are identified as having a BP <120 
(systolic) mmHg over 80 (diastolic) mmHg 72. Because children's BP are known to 
fluctuate as they grow, pediatric hypertension is classified as being 2: the 95th percentile, 
while pre-hypertensive children are identified as being 2: the 90th percentile and < the 95th 
percentile ofBP adjusted for age, sex and height 13,73. In both adults and children, three 
measures from three or more separate occasions are required to make a conclusive 
diagnosis of hypertension 74. 
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2.2.1 HRV in Adult Hypertension 
Hypertension is an established independent risk factor for cardiovascular diseases 
such as coronary atherosclerosis and congestive heart failure 1. Research has shown that 
the management ofBP is strongly influenced by autonomic regulation 3,71,75,76. Singh 
and colleagues (1998) found overall HRV to be lower in hypertensive men and women 
compared to their normotensive counterparts 3. As well, Singh and colleagues (1998) 
found in those with new-onset hypertension (development of hypertension within 4 
years), logistic regression analysis suggested that the presence of a reduced LF 
component was predictive of the development of hypertension in men, even more so than 
body mass index (BMI) 3. The results of Singh and colleagues (1998) reflect a shift 
towards altered function of the sympathetic nervous system or vagal withdrawal and the 
deregulation of the autonomic nervous system. Abnormalities of the cardiovascular 
control system have also been investigated by Huikuri et al. (1996) for long standing 
hypertension treated by antihypertensive medications for a minimum of 4 years 4. 
Huikuri and colleagues (1996) identified an overall decrease in TP, LF:HF, LF, and 
blunted autonomic responses (normalized LF and HF) with alterations in body posture 
(supine to sitting) for hypertensive patients when compared to normotensive matched 
controls 4. Similarly, Takalo and colleagues (1994) found evidence indicating altered 
function of sympathetic tone in pre-hypertensive participants5• 
Altered measures ofHRV in hypertensive populations can also been seen during 
periods of orthostatic stress. Guzzetti and colleagues (1988) observed measures ofHRV 
during passive tilt 6. They found that hypertensive subjects had a greater LF power and a 
smaller HF power at supine rest (vs. normotensive) 6. While in response to passive tilt, 
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the nonnotensive subjects experienced larger increases in LF and decreases in HF 
compared to the hypertensive participants 6. LF at rest and altered LF and HF responses 
during tilt correlated with the degree of hypertension 6. Guzzetti and colleagues (1988) 
concluded that in the hypertensive subjects cardiac sympathetic tone was increased and 
vagal tone reduced, suggesting that sympathetic control could be impaired 6. Other 
researchers using various methods of evaluating autonomic regulation in hypertensive vs. 
nonnotensive adult participants have also found the same trend of increased sympathetic 
activity 7, 8. Lower HRV spectral power is associated with increased cardiac mortality 
and risk of cardiac events 3,10,67,77. Therefore, the identification of a diminished HRV 
for hypertensive individuals has prognostic significance for cardiovascular health. 
2.2.2 BRS in Adult Hypertension 
Assessment ofBRS also has prognostic significance in tenns of cardiovascular 
disease78. High intra-arterial pressures seen in hypertension increase the stiffness of the 
carotid sinus, causing it to be less defonnable and consequently reducing BRS26. It can 
be argued that the reverse occurs, altered autonomic activity precedes hypertension, 
regardless of which comes first, hypertensive conditions raise the set point of the 
baroreceptor threshold, causing the receptors to be 'less sensitive to changes in 
transmural pressure,26. Therefore, an increase in BP for hypertensive populations results 
in a smaller diminution in BP when compared to nonnotensive individuals26. Parati and 
colleagues (1988 and 1995) monitored alterations of the HR baroreflex in nonnotensive 
and hypertensive participants over a 24-hr period 8, 79. In the nonnotensive individuals, 
BRS increased during sleep compared to daytime values, however in the hypertensive 
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subjects this heightened nocturnal BRS was attenuated 8,79. In another study by Palmer 
and colleagues (1990), phenylephrine was administered to evaluate BRS in 64 
hypertensive (>90 mmHg DBP) and 32 normotensive «90 mmHg DBP) participants 80. 
Similar to other studies, Palmer and colleagues (1990) found lower BRS in the 
hypertensive subjects 80. Baroreflex control in pre-hypertensive and hypertensive (BP 
130 to 159/85 to 99 mmHg) volunteers was assessed by Watkins and colleagues (1996) 
using spectral analysis, the sequence technique and phenylephrine 59. When comparing 
the non-invasive vs. invasive methods of measuring BRS, all were significantly 
correlated and found to be accurate estimates ofBRS 59. However, as mentioned before, 
phenylephrine can influence HR unrelated to the baroreflex response, therefore these 
researchers suggested that non-invasive methods are optimal when measuring BRS 40. 
Nevertheless, Watkins and colleagues (1996) found BRS to be significantly reduced in 
the pre-hypertensive and hypertensive group when compared to normotensive controls in 
all measures ofBRS59• 
Adult hypertension has been found to be associated with reduced HRV and BRS 
14,18,33,81. Attenuated HRV and BRS reflect an under-responsive cardiac autonomic 
system. Autonomic irregularities of the sympathetic and vagal systems have been shown 
to increase the risk of cardiac mortality 38, 66-68, 82. Therefore, it is important to look at 
autonomic regulation in childhood since diminished HRV and BRS values are predictive 
of cardiovascular disease. 
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2.2.3 HRV and BRS in Childhood Hypertension 
Childhood hypertension has been identified as an independent risk factor for adult 
hypertension and is associated with early identifiers of cardiovascular disease such as left 
ventricular hypertrophy, intima-media thickening, arterial compliance, atherosclerosis 
and diastolic dysfunction 13, 83. Since hypertension begins years before organ damage is 
recognized, the importance of early identification is crucial for children and adolescents 1. 
Adult hypertension is associated with increased sympathetic drive and diminished HRV 
and BRS 3-6,8,79,80. Findings support a deregulated autonomic system in hypertensive 
children, seen in studies by Urbina et al. (1998)1, Krontoradova et al. (2008)19, and 
Genovesi et al. (2008)17. Urbina and colleagues (1998) evaluated LF/HF ratios during 
cardiovascular reactivity testing (supine to standing, isometric handgrip, cold pressor and 
Val salva maneuver) in 39 13-17 year olds. Urbina and colleagues (1998) controlled for 
BMI and used FFT to compare high to low BP groups and found LF IHF ratios of HRV to 
increase more in the low BP group compared to the high BP group during all reactivity 
testing 1. Although these findings did not reach statistical significance, it implies a shift 
towards heightened sympathetic activity in the high BP group, similar to that reported in 
adult hypertensives 1, 5. A study of BRS in children, adolescents and young adults was 
recently published by Krontoradova et al. (2008) who tested 34 hypertensive and 52 age-
matched controls. They investigated whether BMI and BRS were independent factors 
associated with high BP in 11-21 year 01ds19. These researchers found that the 
hypertensive participants had a significantly lower BRS and higher BMI than controls. 
Although no correlations were found between BMI and BRS, regression analysis 
identified both BRS and BMI (p<0.05) to be independent variables associated with a 
22 
greater risk of hypertension. As for Genovesi and colleagues (2008), they continuously 
recorded HR and BP for 10 minutes of rest, followed by 10 minutes of standing in 
hypertensive (n=38), pre-hypertensive n=16) and normotensive (n=21) children (mean ± 
SE 9.75 ± 0.22 yrs). As anticipated, the pre-hypertensive and hypertensive children 
displayed a significant baroreflex impairment (a-coefficient) and a trend towards early 
vagal impairment when compared to the normotensive controls17• BRS progressively 
decreased in value from the normotensive to pre-hypertensive and the pre-hypertensive to 
hypertensive group during rest. This finding remained significant even after controlling 
for BMI. As for the effects of standing, significant increases in normalized LF and 
decreases in HF were observed in all three groups. However, standing-induced changes 
in BRS were significantly greater in the normotensive group when compared to the pre-
hypertensive and hypertensive groups, even after controlling for BMI 17. Therefore, there 
js strong evidence to suggest that impairment in spontaneous BRS indices for 
hypertensive and prehypertensive children exist as young as the age of 9 years. 
2.3.0 Factors Affecting Autonomic Measures and BP Regulation 
Several factors are known to influence autonomic activity. Measures of both 
HRV and BRS can be influenced by age, maturation, anthropometric variables, and sex. 
All these factors are discussed below. 
2.3.1 Age, Maturation and Autonomic Function 
2.3.1.1 Effects of Age and Maturation on Autonomic Function 
Adult aging is associated with both functional and structural cardiovascular 
modifications 84. As adults age, autonomic regulation declines, in part by a reduction in 
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BRS 18,20,85. BRS has been shown to decrease in adulthood (20 years of age) and is 
significantly diminished by 70 years of age 20,86-88. Both Veerman and colleagues (1994) 
and Barnett and colleagues (1999) found diminished LF and HF values with age89, 90. 
Veerman and colleagues (1994) suggest that the decrease in overall HRV in the elderly 
might be related to reduced BRS and cardiac sympathetic modulation, thereby weakening 
the baroreflex feedback loop 89. Monahan et al. (2001), along with Hunt and colleagues 
(2001) identified important underlying mechanisms of the age associated decrease in 
BRS 85. These researchers found that both reduced carotid artery compliance and neural 
deficits contribute to the observed reduction in BRS in sedentary men (aged 20-75 years) 
85. Laitinen and colleagues (1998) also examined both HRV and BRS among 117 healthy 
men and women (aged 23 -77 years) and found a reduction in both 18. Furthermore, 
Laitinen and colleagues (1998) proposed that the decrease in BRS that occurs with age 
could be the cause for the associated increase in BP with age rather than vice versa 18. 
There is almost universal agreement that autonomic activity becomes reduced as 
adults' age. There are significant decreases that occur with adult aging in all parameters 
ofI-iRV and BRSI8. However, the effect of age on autonomic function in pediatric 
populations is relatively unknown. Few studies have researched these changes in 
children and adolescents. Yeragani and colleagues (1994) found children (4-12 yrs) to 
have a significantly higher supine LF (0.02-0.07 Hz) and HF (0.2-0.5 Hz), along with a 
lower mid (0.07-0.15 Hz) to HF ratio when compared to adults (21-43 yrs), suggesting 
relatively lower sympathovagal balance in children vs. adults 91. Another study by Finley 
and colleagues (1986) found LF power to be significantly lower in both supine and 
upright positions when comparing preadolescents (1 0-12 years) to children ( 5-7 years), 
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and young adults (20-24 years) to children92. As well, supine LF/HF ratio was also 
higher in the children compared to the preadolescents and young adults. Likewise, 
Tanaka and colleagues compared 6-12 to 13-16 year olds and found LF and HF 
components to be lower in the 13-16 year olds, while LF/HF was higher. These finding 
indicate that there may be developmental alterations in autonomic regulation up to the 
age of 16 years. There is speculation that these findings could indicate immature 
autonomic regulation in the younger group and/or be related to cardiac volume increases 
with age92. 
In conjunction with the above studies, Lenard and colleagues (2004) measured 
both HRV and BRS in 137 volunteers subdivided into four age groups; children (7-10 
years old), pre-adolescents (11-14 years old), post-adolescents (15-18 years old) and 
young adults (19-22 years old) 20. Contradictory to the aforementioned studies, HRV 
indices (LF and HF) presented significant increases from pre- to post-adolescents. As for 
BRS , Lenard et al. found it to be smaller in children and pre-adolescents compared to 
post- adolescents2o• These observations suggest that changes in autonomic function do 
not occur until after the age of 14, attaining a peak level at adolescence 20. However, in a 
recent study by Zavodna et al. (2006), a significant correlation between BRS 
(mHz/mmHg) and age was observed across ages 11-20 years93. Although uncertainty 
exists around the crucial age for autonomic development, the above studies suggest that 
age plays an important role in the development of autonomic regulation throughout 
childhood. 
Nevertheless, age is not the only factor that must be considered when 
investigating BRS in children, the effects of maturation could also influence 
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cardiovascular autonomic regulation. Dietrich and colleagues (2006) did a study in pre-
adolescents (Tanner 1) and adolescents (Tanner 2-5) between 10-13 years old 21. As 
reported by Dietrich et al. (2006), both age and pubertal status did not negatively 
correlated with BRS in the supine position. Therefore, supporting the findings of Lenard 
and colleagues (2000), between the ages of 10-13 years there are negligible age and 
maturation related changes in BRS20• However, in looking at the above studies there is 
much controversy. In fact, other than Dietrich et al (2006), no study included maturation 
as an influencing factor. Rather, each study used age as a surrogate for maturation. 
Although Dietrich et al. (2006) did compare Tanner staging, they grouped their 
participants in either Tanner stage 1 or Tanner stage 2_521 • By combining Tanner stage 2-
5, the authors fail to provide the reader with an even distribution of maturation or 
pubertal development. Maturation is the process of attaining full development, 
particularly mature germ cells. This process is accompanied by various hormonal 
influences. In adults (animal and human), sexual steroids are known to affect autonomic 
function2o• 94. 95, therefore when studying pre- to post-adolescents, the influence of these 
hormones becomes important. For example, El-Mas et al. (1997) investigated whether a 
reduction in endogenous estrogen levels resulted in a decrease of BRS in ovariectomized 
rats, with one group receiving 2 doses of 1713-Estradioe4• These authors found a 
significant increase in BRS in the rats receiving doses of estradiol compared to rats not 
receiving hormone therapy. This difference suggested that ovariectomy results in an 
significant attenuation ofBRS, implying BRS is influenced by endogenous estrogen94• 
This finding is supported by Huikuri et al. (1996) who compared middle aged post-
menopausal women who were receiving estrogen replacement therapy to those who were 
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not96• Women with estrogen replacement therapy had significantly higher BRS than age-
matched controls96• Huikui et al. (1996) showed hormone replacement therapy to have a 
positive affect on cardiovascular autonomic regulation in postmenopausal women94, 96. In 
2001, El-Mass et al. also investigated whether the male hormone, testosterone, influences 
baroreflex responsiveness comparable to that found with estrogen replacements95. Similar 
to their previous study in female rats, 3 groups of male rats were compared, shame-
operated, castrated and treated with a vehicle, and castrated and treated with testosterone 
replacement95. All 3 groups had comparable baseline and peripherally mediated 
elevations in BP95. However, castrated rats had a significant reduction in BRS, measured 
by phenylephrine administration when compared to sham-operated rats, while the 
testosterone replacement rats had BRS similar to that found in the sham-operated rats95. 
However, these results were not found in tachycardiac responses, suggesting testosterone 
or endogenous androgens facilitate vagal modulation ofBRS95. Therefore, it is important 
to evaluate maturational effects on autonomic activity in children and adolescents who 
have different hormone levels influencing their growth and development into 
adulthood2o• 
2.3.1.2 Measurement of Maturation 
Although growth is linear, the timing and magnitude of growth is variable for 
each individual97. Maturity assessment is particularly relevant during pre-, post- and 
adolescent years because of the variability between subjects of the same chronological 
age in somatic and biological development 98. Estimates of maturation can be achieved by 
collecting and quantifying circulating hormonal levels, determining dental maturity, 
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identifying sex characteristics (Tanner staging) or by assessing skeletal development. 
There is no 'gold standard' measure for maturation, however, all of these methods 
evaluate various factors of maturation and have their limitations. 
Skeletal development during pre-, post- and pubertal years has been studied for 
decades because of the marked acceleration in bone height and bone mineral accrual 
preceding sexual maturity97, 99. During maturational years, increases in sex hormone 
secretion increases bone growth and masslOO, 101. Growth in stature has a definitive and 
measurable end point, providing an accurate landmark to associate other body dimension 
velocities between and within participants98, 102. This maximal growth in stature during 
adolescents is described as the age at peak height velocity (PRV) and is an indicator of 
somatic maturitY7. Age at PRV is reached approximately 8 months before peak bone 
mineral accrual lO\ where growth in bone mineral accrual is known to be more of a 
function of pubertal stage than chronological age (during adolescence)97, 104. Growth 
hormones are principal contributors to linear bone growth and also coincide with PRV IOI . 
Growth hormones and sex steroids act in concert to influence bone during and beyond 
pubertylol. Oestrogen, a sex hormone found in both boys and girls, influences many 
aspects of bone growth and development, including linear bone growthlOI . Thus, body 
measurements, such as velocities oflongitudinal growth, can be used as an indicator of 
maturityl05. Age at PRV provides a benchmark of maximal growth, and if maximal 
growth dimensions are available, then the amount of height attained at various ages 
throughout growth can be used as an indication of maturity 105. For instance, two youths 
of the same sex, age, and height may have acquired different percentages of their total 
adult height, therefore the youth who has attained a greater percentage of adult height is 
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closer to a mature state lO5• To predict the adolescent growth spurt in height, the timing 
of both leg length and sitting height velocities are used to predict age at PHyI02. By 
subtracting chronological age at time oftesting from predicted age at PHY, investigators 
can determine a continuous measure of biological maturity, years from PHy102, 106. 
Using the differential timings of growth (height, sitting height, leg length) for each sex, 
years form PHY provides an estimation of maturity offset98. 
The Saskatchewan Growth and Development Study (1964-1973) tested 207 boys 
annually for weight, height, and sitting height lO7• Assessment of the hand-wrist x-rays 
from when the participants were 11 years old were correlated to the years from PHy98. A 
maturational commonality was found between the two measures (r=0.83), identifying a 
relationship between skeletal age (x-ray) and maturity offset (years from PHy)98. Thus, 
years from PHY provides a prediction of somatic maturity in relation to growth by using 
a maturational benchmark, that ofPHy98. 
2.3.2 Anthropometry and Autonomic Function 
2.3.2.1 Anthropometric Measurement 
Excess adiposity and body weight in childhood is associated with being 
overweight in adulthood and is linked to long term health consequences such as 
morbidity and mortalityI08-112. Adiposity, or the distribution of adiposity, can be 
measured by various technical and costly methods, including but not limited to, 
hydrostatic weighing, magnetic resonance imaging, dual x-ray absorbtiometry, computed 
tomography and bioelectrical impedance. However, anthropometries can be measured by 
more simple techniques such as, BMI, skinfolds, waist to hip ratio and waist girth. 
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BMI (kg/m2) is easy to obtain, relies on simple computations, and is less costly 
than the techniques mentioned earlier. BMI is a valid and reproducible method of 
measuring indirect values of body fat and levels of adiposity in children 1 13-115. Sampei et 
al. (2001) found a strong correlation between BMI and bioelectrical impedance analysis 
in both 10-11 and 16-17 year old girls (r-0.91 and 0.75 respectively)116. Pietrobelli et al. 
(1998) validated BMI as a measure of adiposity in 188 5-19 year olds. Researchers 
compared total body fat and percent body fat by dual x-ray absorbtiometry to BMI. BMI 
was strongly associated with total body fat (R2=0.85 and 0.89 for boys and girls), and 
percent body fat (R2=0.63 and 0.69 for boys and girls). BMI has also been widely used in 
large epidemiological studies to characterize child fatness, although interpretation of 
measures should be done with caution115, 117. Daniels et al. (1997) observed sex, race, 
sexual maturation and distribution of fat (waist to hip ratio) to have significant 
independent effects on the relationship between BMI and body fatness, as measured by 
dual x-ray absorbtiometry (multiple R2=0.77). Thus, consideration of body type 
(distribution of fat), sex, race and stage of maturation should be considered when 
. . I 115 118 mterpretmg resu ts ' . 
2.3.2.2 Effects of Anthropometry on Autonomic Function 
In recent years there has been a substantial increase in the prevalence of 
childhood obesity 119. Findings from The Fourth Report on the Diagnosis, Evaluation, 
and Treatment of High Blood Pressure in children and adolescents report that 
approximately 30% of overweight children have hypertension and as BMI increases so 
does the prevalence ofhypertension74• Childhood obesity is becoming increasingly 
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common in conjunction with childhood hypertension 11.110.120-126. Most recently, 
Krontoradova et al. (2008) found hypertensive 11-20 year olds to have a significantly 
higher BMI compared to controls. Also, Genovesi et al. (2005) observed a significantly 
higher percentage of overweight children to have high BP compared to normal weight 
children127. Obesity-induced hypertension is suggested to be associated with sympathetic 
over activity 120. This finding is in agreement with Riva et al. (2001) who found 
significantly lower TP, higher LF:HF and higher LF in obese versus non-obese children 
(13-15 yrs) 128. Therefore, it is important to evaluate anthropometric variables that 
measure fatness or fat distribution, such as BMI, to identify any influence body fat may 
have on HRV and BRS values. 
2.3.3 Autonomic Function and Sex 
Adult females exhibit lower BRS and HRV measures when compared to males of 
the same age 18.60. Laitinen et al. (1998) found young and middle-aged men to have 
higher BRS compared to young and middle aged women 18. Additionally, inter-
individual variation ofBRS was greater in women than in men 18. Piccirillo and 
colleagues (2001) also identified higher LF and TP in adult males compared to females 
60. Although a sex difference has been established in adults, few studies have examined 
this effect in children. When comparing HRV in boys and girls (6-12 years old), Tanaka 
and colleagues (1994) found females to have less sympathetic activation compared to 
their male counterparts 129. Also, Dietrich et al. found girls have a lower BRS than boys 
(10-13 years old, Tanner stage 2-5) in supine (14.3 +/- 8.7 vs 16.4 +/- 9.4 ms/mmHg) and 
standing positions (8.4 +/- 4.4 vs 9.5 +/- 5.4 ms/mmHg,) independent of age, pubertal 
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stage, BMI, and physical activitl1. Based on these findings, consideration of sex 
differences is important in both adults and children when measuring autonomic function. 
2.3.4 Additional Factors Affecting Autonomic Function: Exclusion Criteria 
Autonomic regulation can be altered in individuals who have heart disease, 
diabetes mellitus, abnormal heart beats, and in those who are on medications that alter BP 
or autonomic activity (antihypertensive, vasovagal medications)78. 130. Some conditions 
of coronary heart disease have been regarded as responsible for altered BRS including 
atherosclerosis, acute myocardial ischemia, myocardial infarction, and heart failure78. 
However, there are lifestyle modifications and curative procedures (orthotopic heart 
I .) h· hh b h BRS·· 78131-134 transp antatton w IC ave een s own to reverse ImpaIrment' . 
A significant reduction in BRS is evident in both type I and II adult diabetics 
when compared to age and sex-matched non-diabetics 62.78. It is speculated that these 
changes in BRS could be linked to glycemic control, microalbuminuria, high sensitivity 
C-reactive protein, hyperinsulinemia, insulin resistance, structural defects of bar ore flex 
pathways, and physical exercise. However, no one cause has been credited78• In 
children, Pozza et al. (2007) investigated whether this same reduction in BRS was found 
in 208 type I diabetics between 8-22 years of age130. With no significant group 
differences in age, weight, height or BMI, BRS and HF were significantly lower, and LF 
and LFIHF significantly higher in the diabetic children compared to the control group130. 
After adjusting for age and sex, multiple regression analysis revealed a negative 
correlation between BRS and duration of diabetes 130. Furthermore, Faulkner and 
colleagues (2005) compared 13-18 year olds with type I and type II diabetes and found 
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type II diabetics to have significantly lower HRV values compared to type 1135. Thus, an 
impaired autonomic system can be seen in both diabetic adults and children. 
The above factors are reported to alter responses in autonomic activity. 
Comparative evaluation of subjects with heart disease, diabetes mellitus, abnormal heart 
beats, and those on BP medications to healthy matched controls reveals irregular 
autonomic activity in both children and adults. Thus, the above criteria are considered 
exclusion factors for the present study. 
2.4.0 Objectives 
Childhood BP is associated with hypertension in adulthood 13, 7\ and given that 
autonomic activity becomes depressed in the presence of cardiovascular disease18, it is 
important to investigate the relationship between autonomic regulation and elevated BP 
in pediatric populations. Although previous studies have looked at this relationship, none 
of them have accounted for all the factors known to influence autonomic activity. To 
date, there are no studies that have appropriately accounted for the influence of 
maturation when examining autonomic activity in pediatric and youth populations. Thus, 
based on preliminary studies and their limitations, the purpose of this study was to 
investigate HRV and BRS responses between children aged 11-14 years who have high 
and low BP while controlling for maturation, sex, age and body composition. 
2.5.0 Hypothesis 
Based on previous literature in adult hypertensive populations and preliminary 
pediatric studies, we anticipate to find a decrease in HRV and BRS in children with high 
BP when compared to low BP controls. 
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Chapter 3: Methodology 
3.1.0 Study Population 
After being approved by the Brock University Research Ethics Board and the 
Niagara Catholic District School Board, this cross-sectional study was conducted in 50 
Niagara regional schools (school screen), as well as the Applied Health Sciences 
laboratories at Brock University (lab based data collection). The target population for the 
school screen was situated in the Niagara Region because of its population base in excess 
of 411 ,000 persons with 25% of them under the age of 18 years. This region provides a 
blend of urban and rural communities, and a spread of socioeconomic and ethnic 
diversity. To examine high BP in children entering both puberty (physiological 
adaptations) and adolescence (social effects) we focused on grades 6 to 8, comprising of 
about 5,800 students from 50 different regional schools. Schools were randomly selected 
for screening based on stratification across community-level socioeconomic status using 
ecological-level data which ranks and stratifies neighbourhoods and municipalities based 
on average household income and education. This information was collected from the 
2001 census data and regional resource inventory (including child resource inventory). 
To build the school screen sampling frame we tested 1,931 children for BP, body 
composition, demographic information, and parent questionnaires. Demographic data 
was collected in the class room, and included sex, grade, birth date, number of children in 
the household, household living arrangements, birth place, school absences due to illness 
or a doctor/dentist appointment within the last 2 weeks. Once the demographic 
questionnaires were completed, students went to the school library to have their BP and 
body composition recorded. Using the BPM-300 BP monitor (VSM MedTech Ltd., 
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Coquitlam, BC, Canada) 6 resting BP measures were collected at 1 minute intervals136. 
Participants were asked to relax in a seated position with feet flat on the floor, their right 
arm was situated so that it rested at the midpoint of the sternum for 15 minutes. Cuff size 
was based on the circumference of the child's arm, with 2:80% of the cuff s bladder 
encircling the arm and 2:40% ofthe arm circumference was used to gage cuff width 137. 
Following the European Youth Heart Study protocol 136 participants had the first 3 BP 
measures used to familiarize themselves with cuff pressurization, while the final three 
measurements were used to provide an average of both SBP and DBP. After adjusting for 
age, sex and height, students were classified as either normal BP (NBP) if systolic and/or 
diastolic BP was < the 90th percentile, normal but high BP (NHBP) if SBP or DBP was < 
95th and 2: 90thpercentile, and high BP (HBP) was classified as 2: 95th percentile for either 
SBP andlor DBp13. 138. 
Anthropometric measures were taken without shoes, in loose clothing worn for 
physical education classes, while participants had relaxed breathing with arms at their 
side. Using a portable standiometer height was recorded (em), and weight was recorded 
(kg) using a calibrated electronic medical scale. Waist circumference was taken around 
the narrowest point or around the belly button, and hip circumference was measured at 
the greatest protrusion of the gluteal muscles139. Waist and hip circumferences (em) were 
averaged based on 3 separate measures. 
Based on the 1,285 children that had completed data from the school screen and 
parent questionnaires, 226 children stratified across BP levels (NBP, NHBP and HBP) 
were recruited to laboratory testing where they were given a thorough assessment of their 
heart, blood, maturational offset, anthropometries and autonomic regulation. Of these 
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participants, 2 children did not complete laboratory testing and 8 children were removed 
from further analysis because they fell into one of the exclusion criterions (outlined in 
section 2.3.4). Those participants who consistently remained in the same BP group (HBP, 
NHBP, and NBP) (after data cleaning seen in section 3.5.0) for both the school screen 
and lab based data collection were included for further analysis. However, due to the low 
number of HNBP subjects (n=4), only those subjects in the NBP and HBP groups were 
included in the analysis (n=106). Methodological procedures listed below are for the lab 
based data collection involving HRV and BRS measures. 
3.2.0 Experimental Measurements 
A large number of experimental measures were conducted. However, because this 
study is a smaller study within the overall protocol only measurements of anthropometry, 
maturation, BP, and HR are highlighted below for the laboratory testing component. 
3.2.1 Anthropometry 
Anthropometric classification and comparisons were made on all participants. 
Subjects were assessed without shoes and in athletic wear. Height (em) was measured 
using a wall mounted standiometer. Body weight was assessed (kg) using a calibrated 
electronic medical scale. BMI was calculated from weight and height (kglm2). The same 
investigator completed all anthropometric testing in order to eliminate inter-observer 
variability. 
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3.2.2 Maturation 
Somatic maturity was estimated by calculating years from PHV using the equation 
described by Mirwald et al (2002) (Appendix E). This method has been widely used as 
an indication of maturation statusl03 . Subjects were seated with legs crossed (right over 
left) to have their sitting height (cm) taken upon expiration. Leg length was calculated by 
subtracting sitting height from standing height. True age was rounded to the nearest 0.01 
years. The somatic maturity measurements were performed by the same investigator for 
all subjects to eliminate inter-observer variability. 
3.2.3 Blood Pressure and Heart Rate 
Automated BP values were collected with the same BpTRU Vital Signs Monitor 
(BMP-300, VSM MedTech Devices Inc., Canada) as in the field screen. The exact same 
procedure that was performed in the schools during the population screen was used in the 
laboratory. The BMP-300 is self calibrating and does a diastolic check before each use. 
The unit took 6 measures of resting BP and the last 3 were averaged to represent 
automated BP. Beat-by-beat BP values were collected noninvasively using 
photoplethysmography (Finapres, Omeda 2300, Arnhem, Netherlands). A 
photoplethysmograph cuff was attached to the left middle finger to collect beat-to-beat 
measures of SBP, DBP and mean arterial pressure (MAP). As well, manual BP was 
assessed on the right arm using a standard mercury sphygmomanometer. While resting in 
the supine position, participants had 3 manual BP readings taken before and after 
cardiovascular measures were collected. Averages of the last 2 BP measures were 
calculated to represent a resting brachial artery BP for both pre and post-cardiovascular 
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data collection. The pre BP average was used to adjust the beat-by-beat BP values 
obtained using the Finapres at the finger. The post BP average was taken to ensure the 
subject was still at rest and to insure Finapres accuracy. 
RRI and/or HR was recorded using a standard single lead, 3-electrode 
electrocardiogram. Resting beat-to-beat BP and RRI were recorded for 5-7 minutes. Both 
BP and RRI were sampled at 1000 Hz providing a basic resolution of 1 ms, which is 
considered to be an optimal digitization rate l40. 
3.3.0 Experimental Protocol 
The experimental protocol highlighted below is a shorter version of the entire 
protocol, as other measures were collected but do not pertain to the overall purpose of my 
thesis. 
The night before lab testing, participants were asked to refrain from eating or 
drinking after their dinner. Upon arrival to the laboratory, all participants and 
parents/guardians signed a letter ofinfonned consent (Appendix C) and provided a list of 
existing medical conditions and/or medications (Appendix D). Following consent, 
whole blood was collected and lipid profiles were obtained. Participants were asked to 
void their bladder, as this is known to effect sympathetic nerve activity, consequently 
altering Bp141. Then, height, sitting height, and weight were recorded. Afterwards, a 
350 calorie breakfast was consumed. 
Following 15 minutes of rest in an upright seated position with the right ann at 
the level of the heart, automated BP measures were taken. Following BP measurements, 
subjects then entered the cardiovascular and hemodynamics laboratory for beat-by-beat 
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recordings ofRRI and BP. Participants laid in a motionless supine position, resting for a 
minimum of 15 minutes prior to any cardiovascular measurements. Manual BP was 
obtained and supine motionless beat-by-beat recordings of both RRI and BP were 
collected for 5-7 minutes. The entire protocol (including additional measures) took 
approximately 1 Yz hours. 
3.4.0 Data Analysis 
Calculations ofBMI and years from PRV were performed after testing was 
completed. Average RRI was calculated using the average time (ms) from R peak to R 
peak within the last 1 minute of data collection. Average BP was calculated using the 
school screen average (last 3 of 6 measures) and automated lab based data averages (last 
3 or 6 measures). Mean arterial pressure was calculated by adding 1/3 SBP and 2/3 DBP 
from the average automated cuff measures. 
3.4.1 HRV and BRS 
From the Chart 5 (ADInstudments; 2003) recorded beat-by-beat RRI and BP data 
were transferred into excel (Ms Windows, 2003). The cleanest or most stable 5 minutes 
worth of data was used for further analysis. The R-R sequences were visually inspected, 
and the data considered as artifactual were manually replaced by interpolated data. The 
amount of abnormal beats was, in principle, less than 2%. Then using Matlab 11. I, 
suitable series of both RRI and SBP were detrended to remove any linear trends, and re-
sampled by using the mean cardiac frequency to obtain an equal interval between 
samples. A low-pass Butterworth filter was chosen and set at 0.95 Hz. 
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Variability was measured using FFT spectrum. The FFT used a Welch's 
periodograrn method. In this method, the RRI and SBP data were first divided into 
overlapping segments. Using a Hanning window, each segment was then windowed to 
~th of the signal length and Y2 of an overlap. FFT spectrums were calculated for each 
windowed segment and the segment spectra were averaged. Two frequency bands were 
considered, LF (0.04-0.15 Hz) and HF (0.15-0.4 Hz), while TP represented the sum ofLF 
and HF. Both absolute and normalized (for TP) RRI and SBP power spectral areas were 
calculated. 
BRS was calculated using mean transfer function gain of both the LF and HF 
regions. Gain relationships were only accepted when the coherence was 2:0.5, in line 
. h ··fi . 4 142 143 Th· d h ·d·fi 1· . WIt current SCIentI IC practIces' . . IS square co erence 1 entI Ies meanty 
between RRI and SBP signals (O=none and 1 =perfect correlation)39. 
3.5.0 Data Cleaning 
Subjects with diabetes (2), heart disease (1), on vasovagal medications (1), 
ectopic beats (1), preventricular contractions (1), too much movement ofthe 
photoplethysmograph (1), or loss of consistent pressure from the photoplethysmograph 
(1), did not have their spectral variability or BRS measures included in the data set. The 
same investigator analyzed all spectral variability and BRS variables to eliminate inter-
observer variability. 
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3.6.0 Statistical Analysis 
Analysis were completed using SPSS software version 15.0 Windows (SPSS Inc, 
Chicago, IL), and level of significance for all measures was set to p ~ 0.05. All analysis 
compared NBP «90th) and HBP (2:95th) participants. Descriptive evaluation (using an 
independent t-test) of all variables were expressed as mean ± standard deviation, for both 
physical (anthropometrics, age, sex, maturational offset) and cardiovascular variables (BP 
and RRI). 
A one-way analysis of covariance (ANCQV A) was used to compare all 
autonomic measures (spectral variability and BRS) controlling for the effects of age, sex, 
BMI (body composition) and years from PHV (maturation). As well, Pearson correlation 
was performed to determine factors associated with BP in children. A multivariate linear 
regression was performed to identify the association between BP and spectral variability 
and BRS variables, while controlling for the effects age, sex, BMI and years from PHV. 
Lastly, a statistical interaction was performed to identify any cumulative effects ofBMI 
and SBP on BRS as suggested in other studies19. 
41 
Chapter 4: Results 
4.1.0 Sample Size 
From the school screen both child BP and parental questionnaires were collected 
from at total of 1285 families. A sub-sample of226 children stratified across three BP 
classifications (2:95th; <95th and 2:90th; <90th percentile) were randomly selected from the 
school screen to come into the Brock University Cardiovascular and Hemodynamics 
Laboratory.- Of the 226 participants only 2 children did not complete laboratory testing 
and are not included in the following analysis. There were 106 NBP, 46 HNBP and 72 
HBP participants recruited for laboratory testing. However, the two-pronged sampling 
approach used to categorize the participants resulted in the sample size decreasing from 
224 to 112 children (see Figure 1). Of the initial 46 HNBP children, only 4 participants 
(9%) remained in the same category following the laboratory BP screen. Approximately 
74% (34 participants) moved from the HNBP to the NBP group. Similarly, the HBP 
group had 61 % ( 44 participants) of its initial participants move to the NBP classification 
after the second BP screen. In total 24 subjects moved to a higher BP group, while 84 
participants moved to a lower BP category after the second BP screen (see Figure 1). 
With each BP screen the prevalence of elevated BP diminished, this trend is consistent 
with other studies and is often reported as 'white-coat hypertension,ll. Following the 
second BP screen it was determined that the HNBP group had a sample size (4 subjects) 
which was too small to include in any further analysis. Those participants with consistent 
BP measures <90th percentile (NBP) or 2:9Sth percentile (HBP) from both the school 
screen and the lab based data collection are represented in the following analysis. After 
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excluding diabetics, those on medications, individuals with abnormal cardiac rhythms 
and irregular photoplethysmograph recordings, our sample size equaled 106 children. 
Figure 1 Two-pronged Sample Approach for Categorizing Children with Normal Blood 
Pressure (NBP), High but Normal Blood Pressure (HNBP) and High Blood Pressure 
(HBP) 
Screen 
HBP Total 
School NBP 8 106 
Screen HNBP 34 4 8 46 
HBP 44 6 72 
Total 168 18 38 224 
Participants with consistent blood pressure measures from both the school screen and the lab based data collection 
4.2.0 Physical, Maturational and Cardiovascular Characteristics 
Average physical, maturational and cardiovascular characteristics for all subjects 
and are shown in Table 1. HBP subjects had significantly higher values for both weight 
and BMI compared to NBP participants (Table 1). Additionally, BP was significantly 
higher in the HBP group compared to the NBP group, while RRI was significantly lower 
(Table 1). 
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Table 1 Baseline Characteristics of Children with Normal Blood Pressure (NBP) and 
Children with High Blood Pressure (HBP) 
NBP (n=85) HBP (n=21) 
Demographic Variable 
Sex (n=Male, n=Female) 56,29 11,10 
Age (years) 12.8 ± 0.8 13.1 ± 0.9 
Height (cm) 158.0 ± 9.3 160.6 ± 9.4 
Weight (kg) 49.7 ± 11.9 68.6 ± 21.5t 
BMI (kg/m2) 19.8 ± 3.6 26.4 ± 7.1t 
Somatic Maturity (years from PHV) -1.71 ± 0.81 -1.68 ± 1.04 
Cardiovascular Variable 
SBP (mmHg) 91 ± 5 110 ± 6t 
DBP (mmHg) 55± 5 71 ± 5t 
MAP (mmHg) 67 ±4 84 ± 5t 
RRI (ms) 808 ± 97 715 ± 93t 
PP (mmHg) 35± 5 40 ± 8t 
Mean ± SD, tPaired t-test p:'S 0.001 significantly different from group 1, BMI = body mass index, PHV = years from 
peak height velocity, SBP = systolic blood pressure, DBP = diastolic blood pressure, MAP = mean arterial pressure, 
RRI = RR interval, PP = pulse pressure. 
4.3.0 RRI Variability 
After running an ANCOV A (controlling for the effects of age, sex, somatic 
maturity, and BMI) for HF, LF and TP frequency components, HBP participants were 
significantly lower than NBP children (Table 2). In terms of normalized measures, LF/TP 
and HF/TP did not reach statistical significance. Likewise, no significant difference was 
found between groups regarding LFIHF ratio. 
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Table 2 RRI Variability of Children with Normal Blood Pressure (NBP) and Children 
with High Blood Pressure (HBP) 
NBP (n=85) HBP (n=21) 
LF (ms2) 730 ± 520 449 ± 330t 
HF (ms2) 909 ± 959 445 ± 581t 
TP (ms2) 1612 ± 1343 904 ± 787t 
LF/HF 1.1 ± 0.7 1.6 ± 1.0 
LFITP 0.5 ± 0.1 0.6 ± 0.2 
HFITP 0.5 ± 0.1 0.4 ± 0.2 
Mean ± SD, t ANCOV A P :S 0.01 significantly different from group 1; LF = low frequency, HF = high frequency, TP= 
total power, LF/HF = low frequency to high frequency ratio, LF/TP = low frequency divided by total power, HF/TP = 
high frequency divided by total power. 
4.4.0 SBP Variability 
Table 3 lists the SBP variability properties in both BP groups. There were no 
significant differences in LF, HF, TP, LF ITP, or HF ITP among groups after controlling 
for age, sex, BMI and years from PHV. However, LF/HF was significantly higher in the 
HBP group (6.5 ± 3.9) compared to the NBP group (4.0 ± 2.6). 
Table 3 SBP Variability of Children with Normal Blood Pressure (NBP) and Children 
with High Blood Pressure (HBP) 
NBP (n=85) HBP (n=21) 
LF (mmHg2) 5.1 ± 4.3 7.6 ± 4.9 
HF (mmHg2) 1.5 ± 1.3 1.4 ± 0.9 
TP (mmHg2) 6.6 ± 5.1 8.9 ± 5.4 
LF/HF 4.0 ± 2.6 6.5 ± 3.9t 
LFITP 0.7±0.1 0.8 ± 0.1 
HFITP 0.3 ± 0.1 0.2 ± 0.1 
Mean ± SD, tANCOVA p:S 0.05 significantly different from group 1; LF = low frequency, HF = high frequency, TP= 
total power, LFIHF = low frequency to high frequency ratio, LF/TP = low frequency divided by total power, HF/TP = 
high freql,lency divided by total power. 
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4.5.0 Baroreflex Sensitivity 
Depicted in Figure 1, BRS is significantly lower in HBP subjects compared to 
NBP subjects for both LF (10.5 ± 6.8 vs. 15.1 ± 6.8 ms/mmHg) and HF (16.0 ± 9.4 vs. 
22.8 ± 11.4 ms/mmHg) gain after controlling for age, sex, BMI and years from PHV. 
Figure 2 BRS of Children with Normal Blood Pressure (NBP) and Children with High 
Blood Pressure (HBP) 
20 .4-------------
4.6.0 Entire Cohort Determinants 
Results regarding correlations in this section can be seen in Table 4. When 
analyzed as an entire cohort, BP group and autonomic measures (HR and SBP variability 
and BRS) significantly correlated ranging from r = -0.292 to 0.332, excluding HF SBP 
and TP SBP. When examining the relationship between average SBP and spectral 
indices and BRS measures, significant correlates ranged from r = -0.296 to 0.327, 
excluding HF RRI and HF SBP. RRI correlated with all RRI variability and BRS 
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measures, ranging from r = -0.286 to 0.551. Additionally, RRI also correlated with BP 
group (r = -0.361), SBP (r = -0.256), DBP (r = -0.317), and sex (r = 0.241). 
As for the BMI, strong correlations existed for several of the spectral variability 
and BRS measures ranging from r = -0.301 to 0.359. As well, BMI positively correlated 
with BP group (r = 0.511), SBP (r = 0.651), DBP (r = 0.496), and PP (r = 0.404). 
Table 4 Univariate Correlations 
BP group SBP DBP RRI PP Age Sex BMI PHV 
SBP 0.830** 
DBP 0.791** 0.845** 
RRI -0.361** -0.256** -0.317** 
PP 0.341** 0.528** 0.123 0.049 
Age 0.139 0.200* 0.081 0.180 0.139 
Sex 0.112 0.131 0.042 0.241* 0.098 0.238* 
BMI 0.511** 0.651** 0.496** -0.091 0.404** 0.095 0.053 
PHV 0.013 0.112 0.026 0.147 0.094 0.744** 0.158 -0.060 
LFRRI -0.226* -0.193* -0.277** 0.361** -0.057 0.235* 0.097 -0.036 0.165 
HFRRI -0.199* -0.174 -0.201* 0.328** -0.068 0.170 -0.008 0.009 0.088 
TPRRI -0.221* -0.195* -0.248* 0.361** -0.066 0.199* 0.045 0.004 0.109 
LF/HF RRI 0.276** 0.327** 0.254** -0.286** 0.150 0.057 0.000 0.299** 0.035 
LFITP RRI 0.257** 0.296** 0.221* -0.271** 0.160 0.055 0.039 0.219* 0.037 
HFITP RRI -0.257** -0.296** -0.221* 0.271** -0.160 -0.055 -0.039 -0.219" -0.037 
LF SBP 0.224* 0.273** 0.107 -0.104 0.180 0.048 0.013 0.392** -0.016 
HF SBP -0.062 -0.002 -0.075 -0.023 0.052 -0.005 -0.090 0.096 0.022 
TPSBP 0.177 0.234* 0.074 -0.094 0.167 0.040 -0.010 0.359** -0.008 
LF/HF SBP 0.332** 0.301** 0.203* -0.128 0.156 0.056 0.063 0.293** -0.018 
LFITP SBP 0.292** 0.278** 0.187 -0.097 0.120 0.030 0.024 0.301** -0.037 
HFITP SBP -0.292** -0.278** -0.187 0.097 -0.120 -0.030 -0.024 -0.301** 0.037 
LF Gain -0.263** -0.231* -0.201* 0.449** -0.060 0.174 0.142 -0.235* 0.174 
HF Gain -0.240* -0.245* -0.234* 0.551** -0.063 0.155 0.096 -0.204* 0.109 
** Correlation is significant at the 0.01 level (2-tailed), * correlation is significant at the 0.05 level (2-tailed), SBP = 
systolic blood pressure, D~P = diastolic blood pressure, RRI = RR interval, PP = pulse pressure, Sex male = 0 & 
female = 1, BMI = body mass index, PHV = years from peak height velocity, LF = low frequency, HF = high 
frequency, TP= total power, LF/HF = low frequency to high frequency ratio, LF/TP = low frequency divided by total 
power, HF/TP = high frequency divided by total power, , LF Gain = low frequency gain of systolic and RR interval 
variability, HF Gain = high frequency gain of systolic and RR interval variability. Need to mention somewhere how sex 
was coded so the reader understands what a positive/negative relationship means. 
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As for the multivariate linear regression analyses between BP group and BRS, the 
p-values for each of the independent variables showed that BP group alone significantly 
predicted BRS (BP group for LF gain p=0.04 and HF gain p=0.05). The regression 
coefficients (unstandardized B) indicate that for an increase in BP group (NBP to HBP) 
LF and HF BRS decreased by 4.0 and 6.2 ms/mmHg respectively. None of the other 
dependent variables (BMI, sex, age or years from PHV) significantly predicted LF or HF 
BRS. Again using a multivariate linear regression to determine the relationship between 
absolute SBP and BRS, only the relationship between SBP and HF BRS had a significant 
R and adjusted R2 value of 0.338 and 0.070 respectively. Although the entire model was 
significant (p=O.03), only SBP independently predicted HF BRS (p=0.05). The 
unstandardized B coefficient indicated that for every increase of 1 mmHg HF BRS 
decreased by 0.3 ms/mmHg. 
4.7.0 Effects of Independent Variables 
To ensure that BMI and BP group, as well as BMI and SBP did not have a 
cumulative effect on BRS, a statistical interaction was performed. It was found that BMI 
and BP group, along with BMI and SBP did not interact. Thus, the effect of BMI on BRS 
does not depend on BP and vice versa. 
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Chapter 5: Discussion 
5.1.0 Introduction 
The effects of elevated BP on autonomic activity, as measured by both BP and 
HR variability and BRS, were evaluated in a sample of 106 11-14 year olds. The 
principle finding of this study was that children with elevated BP had significantly 
reduced cardiovagal activity compared to children with normal BP levels, even after 
controlling for age, sex, body composition and maturation. Furthermore, as BP 
increased, BRS decreased. 
5.2.0 Spectral Variability Parameters 
5.2.1 RRI Variability 
To our knowledge this is the first study to demonstrate significant reductions in 
HRV measures among children with elevated BP compared to those with normal BP 
levels while controlling for the confounding variables age, sex, body composition and 
~aturation. The HRV values found in the present study in normal BP children (LF: 730 
± 520 ms2, HF: 909 ± 959 ms2, TP: 1612 ± 1343) coincide with previous reports20. Also 
similar to recent reports17, the present study found HBP participants to have lower LF, 
HF, TP, and HF/TP RRI variability compared to NBP subjects, while LF/HF and LF/TP 
means were higher. 
To date, Genovesi et al. (2008) and Urbina et al. (1998) are the only researchers 
who have looked at HRV measures in hypertensive and normotensive children/youth1, 17. 
Genovesi and colleagues (2008) found a significant reduction in resting HRV measures 
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when comparing normotensive (97 .1±2. 7/57 .3±2.0 mmHg) to hypertensive 
(128.4±1.9/80.1±1.6 mmHg) children (9.7±0.22 years)l7. However, after Genovesi and 
colleagues controlled for BMI, LF and HF RRI variability were no longer significant17• 
In the present study, LF, HF, and TP remained significantly different between groups 
after controlling for all covariates, including BMI. 
The lower RRI HF variability observed in the HBP group compared to NBP 
children reflects a reduced parasympathetic (vagal) modulation in HBP participants IS. 
Similarly, the lower LF RRI variability in the HBP versus NBP subjects reflects a 
reduction in autonomic regulation, that of both sympathetic and parasympathetic activity. 
However, due to the reduction in vagally mediated HF power, the observed reduction in 
LF power is predominantly indicative of reduced parasympathetic versus sympathetic 
activityl5. Likewise, diminished TP in HBP compared to NBP participants suggests 
sympathetic overdrive, vagal withdraw, and/or depressed vagal and sympathetic 
activityl4, 32. 
In accordance with earlier findings, this study did not find significant BP-related 
differences in LF/HF, LF/TP, and HF/TP RRI variability measures 17. Urbina et al. 
(1998) found a trend towards reduced LF/HF ratios in youths (13-17 year oIds) with high 
BP versus those with low BP, however these findings were not significant l . 
5.2.2 SBP Variability 
In contrast to past studies, the present investigation reports both RRI and SBP 
variability in children with varying BP profiles, providing a complete picture of 
autonomic regulation and how it differs by BP. After controlling for age, sex, body 
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composition and somatic maturity, the present study found a significantly elevated LF/HF 
ratio in the HBP group (6.5 ± 3.9) compared to NBP group (4.0 ± 2.6) . This elevated 
LF/HF ratio in HBP subjects suggests sympathetic predominance in children with higher 
BP. Although not significant, HBP participants also had wider SBP variability for LF, 
HF, and LF/TP compared to NBP participants. Studies in adults have also reported a 
significantly wider SBP variability in isolated systolic hypertension 144 compared to 
nonnotensive subjects, suggesting poorer BP regulation for hypertensives. 
5.3.0 BRS Parameters 
Unique to this study is the finding that even after controlling for age, sex, body 
composition, and somatic maturity, children with elevated levels ofBP have significantly 
reduced arterial BRS. Coinciding with previous studies, the LF BRS values for NBP 
children in the present study (15.1 ± 6.8 ms/mmHg) coincide with previously reported 
transfer function analysis estimates21 • As well, the attenuated BRS found in HBP 
subjects is similar to the results of Genovesi et al. (2008) and Krontoradova et aL (2008), 
both of whom found significantly reduced resting measures ofLF BRS in hypertensive 
children! youth versus controls 17,19. Genovesi and colleagues' (2008) findings 
remained significant even after correcting for BMII7. Similarly, Krontoradova et al. 
(2008) found both BMI and BRS to be independent factors associated with elevated BP 
in 11-21 year 01ds19• However, they did not control for BMI, but rather used correlations 
and logistic regressions to conclude that both BMI and BRS are independent variables 
associated with an increased risk ofhypertensionl9. 
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The attenuated BRS observed in HBP children aligns quite nicely with the 
spectral results. BRS describes the relationship between reflex changes in RRI for a given 
change in BP8. As previously mentioned, LF represents both parasympathetic and 
sympathetic modulation, while HF is a measure of parasympathetic predominance. A 
lower LF, HF and TP RRI variability, coinciding with an elevated LF, HF and TP SBP 
variability displays altered autonomic regulation, suggesting that HBP children have 
greater BP fluctuations due to a lower BRS. Hence, an overall smaller change in RRI for 
a given change in BP. Therefore, by finding a diminished LF and HF BRS (ms/mmHg) in 
children with elevated BP (HBP), we can conclude that cardiovagal baroreceptor function 
is reduced in children with higher BP. The fact that the overall ability to regulate BP 
through changes in RRI in children with high BP is reduced is very important, as 
baroreceptors playa vital role in BP regulation, preventing excessive increases and/or 
decreases in BP throughout daily activities26, 145. As well, attenuated BRS has been linked 
to cardiovascular disease, morbidity and mortality in adults 9,61,65,146. Since childhood 
BP is associated with hypertension in adulthood, there is a growing concern in regards to 
the present and future cardiovascular health of these children13, 74,147. 
Furthermore, multiple linear regression analysis found that both average SBP and 
BP group are independent variables that significantly predict BRS. In moving from the 
NBP to HBP group classification, both LF and HF BRS was found to decrease by 4.1 and 
6.2 ms/mmHg respectively. Thus, as BP increases, BRS decreases. 
It is important to note that the absolute SBP and DBP values of our HBP 
participants (110 ± 6 and 71 ± 5 respectively) are not "truly" hypertensive, or even pre-
hypertensive according to the National High Blood Pressure Education Program and 
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Working Group on High Blood Pressure in Children and Adolescents (2004) (see 
Appendix F for BP levels for boys and girls by age and height percentiles)74. However, 
the relationships found in this study between BP elevation, spectral variability (RRI and 
SBP) and arterial BRS are comparable to studies using much higher hypertensive cut-offs 
than those used in the current study (eg. Genovesi et al. 17 and Krontoradova et al. 19 had 
SBP/DBP values of 128.4±1.9/80.1±1.6 and 125±14171±9 mmHg respectively), 
suggesting that impainnent in autonomic function starts before a child is hypertensive 
and is seen as early as the onset of pre-hypertension. In fact, the findings of the current 
study coincide with those made by Honzikova et al. (2006). These authors found that in 
children, adolescents, and young adults with white-coat hypertension BRS was lower 
than in healthy controls, despite the fact that they had nonnal BP values over 24-hours 
and hence no reason for remodelling of the vessel's wall 148 . Thus, the conclusion set forth 
by the investigators was that lower BRS precedes BP increasel48. 
5.4.0 Limitations 
While this study presents important and novel findings, there are several 
limitations that need to be acknowledged and addressed. The first limitation concerns the 
relatively small number of children in the HBP group. A small number of participants in 
this group could account for the limited number of significant findings. An increase in 
the number ofHBP subjects would provide more statistical power, in tum an increase in 
significance. However, we did find significance for BRS, our main variable of interest. 
BP grouping or classifications were based on two separate BP readings. 
According to the National High Blood Pressure Education Program and Working Group 
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on High Blood Pressure in Children and Adolescents (2004), a diagnosis of hypertension 
should only be made after more than three BP measures on separate occasions 74. The 
rationale behind this guideline stems from the finding that the incidence of hypertension 
decreases after each separate measure I 1. Studies have shown that following a single BP 
measure the prevalence of individuals with a reading above the hypertensive cut-off 
(2:95th percentile based on age, sex, and height) is approximately 19%1l. However, after a 
second BP reading the prevalence drops to approximately 9.5%, while after a third 
measure the prevalence is only 4.5% II. Therefore, by using only 2 separate measures in 
the current study, we could be over diagnosing or improperly grouping some participants. 
However as stated previously, the absolute BP values for the HBP participants in the 
current study were significantly less than the hypertensive cut points reported in the 
National High Blood Pressure Education Program and Working Group on High Blood 
Pressure in Children and Adolescents (2004)74. As well, by only including subjects with 
consistent BP readings on 2 separate occasions in the analysis, we attempted to avoid the 
possibility of improperly grouping participants. 
The present study used only the 2 extreme BP groups (SBP and/or DBP <90th 
percentile and 2:95th percentile), eliminating the middle BP group (SBP and/or DBP 2:90th 
but <95th percentile). By having a middle BP group, we could make clearer distinctions 
regarding the relationship between progressively increasing BP values and autonomic 
activity. However, after eliminating subjects with inconsistent BP on two separate 
occasions (described above), we were only left with 4 subjects in the middle BP group, 
not enough to be statistically relevant. Another limitation to address is the level of sexual 
maturation. Somatic maturity was determined by uSIng an equation developed by 
54 
Mirwald et al. (2002) to determine how many years a child is from reaching their PHV. 
The literature describes alterations in autonomic activity with variations in sex steroids 
such as estrogen and testosterone94-96• Although years from PHV provides an estimate of 
maturational offset, measuring circulating hormonal levels would provide a direct 
measure of sexual maturation and could lend insight into the influences of estrogen and 
testosterone on autonomic regulation. However, years from PHV is non-invasive, 
provides a continuous measure of maturity and is simple to determine. 
Lastly, another limitation is the lack of longitudinal tracking. Longitudinal 
tracking allows researchers to observe changes over time. This could particularly be 
useful when examining the associations between autonomic activity and maturation, 
growth and development, ageing and changes in body composition. As well, a 
longitudinal study would provide us with key insight into the timing of BRS function 
limitations and BP elevation. In essence, is it a reduction in BRS that precedes BP 
elevation or vice versa? 
5.5.0 Future Considerations 
High BP places a sheer force acting on the endothelium and causing micro tears in 
the vessel walls 71. The tom areas are vulnerable to plaque and fatty deposits and soon 
develop a fibrous tissue cap (scar-forming fibroblasts) over the plaque deposits34• 
Eventually these fibrous caps calcify and cause the artery to become stiff and less 
distensible34• Reduced BRS in hypertensives is often ascribed to reduced distension from 
stiffening ofthe vessel walls l49• Therefore, it is difficult to distinguish whether the 
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changes in BRS are caused from high BP or are a secondary outcome caused by arterial 
stiffening. 
In 2004 Komet and colleagues were the first to differentiate between mechanical 
stretch and neural involvement of the baroreflex in hypertensivesl50• By determining the 
distention rate of the carotid artery for a given response in BP changes, the researchers 
were able to examine the relationship between spontaneously occurring carotid diameter 
changes and the RRI relationship150. This carotid diameter change to RRI produced a 
'stretch derived' BRS indices rather than the traditional 'blood pressure derived' (SBP 
changes for a given change in RRI) indicesl50, 151. The 'stretch derived' BRS measure 
allowed Komet and colleagues to quantify the neural effects of BP related changes on the 
heart rate reflexes by 'excluded the influence of the arterial wall stiffness' 150. When 
comparing hypertensives to normotensives less than 50 years of age, hypertensives 
demonstrated lower BRS values versus normotensive controlsl50• This diminished BRS 
in hypertensives was attributed to both decreased 'distension and reduced sensing and 
processing of neural signals' 150. These findings indicate that neural activity ofthe 
baroreflex is altered in hypertensives 'irrespective of changes occurring in arterial wall 
structure' 150. These findings are in line with Honzikova et al. (2006) (mentioned earlier 
in section 5.3.0) who found white-coat hypertensives to have lower BRS values than 
healthy controls, despite normal BP values over 24-hours and hence no reason for 
remodeling of the vessel's wall148• Both Komet et al. and Honzikova et al. suggest 
neurological alteration ofthe baroreflex in hypertensives l48, 150. Thus, a future direction 
for the present investigation would be to segregate the mechanical from neural influences 
ofBRS in these children, to determine how much, if any, neural alterations might have 
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occurred in those with high BP. Another future direction would be to identify the 'white-
coat hypertensives' or in the present study those children who were first grouped as HBP 
or HNBP after the school screen, and were then switched into the NBP classification after 
the lab screen. By identifying these 'white-coat hypertensives' it can be determined if 
these children have reduced BRS versus normotensive children despite remodeling of the 
vessel walls, as is expected in those with chronically elevated BP. Therefore, in support 
of the conclusions set forth by the aforementioned investigators, this study could consider 
these finding in future works to better understand the process of BRS and its relationship 
to elevated BP. 
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Chapter 6: Conclusions 
Children with even slightly elevated BP levels have significantly reduced 
autonomic activity even after controlling for age, sex, body composition and somatic 
maturity. Despite their young age and relatively short amount of time having elevated 
BP, these children are already demonstrating poor BP regulation. Given that childhood 
BP is associated with hypertension in adulthood, and the fact that attenuated BRS has 
been linked to cardiovascular mortality in adults, there is a growing need for more 
research in regards to the present and future cardiovascular health of these children. 
58 
References 
Reference List 
(1) Urbina E.M., Bao W., Pickoff A.S., Berenson G.S. Ethnic (black-whit) contrasts 
in heart rate variability during cardiovascular reactivity testing in male 
adolescents with high and low blood pressure: the Bogalusa Heart Study. The 
American Journal 0/ Hypertension 1998; 11: 196-202. 
(2) American Heart Association: High Blood Pressure. American Heart Association 
2008;A vailable at: URL: 
http://www.americanheart.org/presenter. ihtml?identifier=21 14. AccessedOctober 
6,2008. 
(3) Singh J.P., Larson M.G., Tsuji H., Evans J.C., O'Donnell C.J., Levy D. Reduced 
heart rate variability and new-onset hyptertension: insight into pathogenesis of 
hypertension: the Framingham heart study. Hypertension 1998;32:293-7. 
(4) Huikuri H.V., Ylitalo A., Pikkujamsa S.M., lkaheimo M.J., Airaksinen J.K.E., 
Rantala A.O., Lilja M., Kesaniemi Y.A. Heart rate variability in systemic 
hypertension. The American Journal of Cardiology 1996;77(12): 1 073-7. 
(5) Takalo R., Korhonen I., Turjanmaa V., Majahalme S., Tuomisto M., Uusitalo A. 
Short-term variabity of blood pressure and heart rate in borderline and mildly 
hypertensive subjects. Hypertension 1994;23:18-24. 
(6) Guzzetti S., Piccaluga E., Casati R., Cerutti S., Lombardi F., Pagani M., Malliani 
A. Sympathetic predominance in essential hypertension: a study employing 
spectral analysis of heart rate variability. Journal o/Hypertension 1988;6(9):711-
7. 
(7) Mancia G., Ferrari A.U., Gregorini L., Parati G., Pomidossi G., Bertinieri G., 
Grassi G., Di Rienzo M., Pedotti A., Zanchetti A. Blood pressure and heart rate 
variabilities in normotensive and hypertensive human beings. Circulation 
Research 1983;53:96-104. 
(8) Parati G., Saul J.P., Di Rienzo M., Manicia G. Spectral analysis of blood pressure 
and heart rate variablity in evaluating cardiovascular regulation. Hypertension 
1995;25:1276-86. 
(9) La Rovere M.T., Bigger J.T., Marcus F.I., Mortara A., Schwartz P.J. Baroreflex 
sensitivity and heart-rate variability in prediction oftotal cardiac mortality after 
myocardial infarction. Lancet 1998;351(9101):478-84. 
59 
(10) Fsuji H., Venditti F.J., Manders E.S., Evans J.C., Larson M.G., Feldman C.L., 
Levy D. Reduced heart rate variability and mortality risk in an elderly cohort. The 
Framingham heart Study. Circulation 1996;90:878-83. 
(11) Sorof J .M., Lai D., Turner J., Poffenbarger t., Portman R.J. Overweight, ethnicity, 
and the prevalence of hypertension in school-aged children. Pediatrics 
2004; 113(3):475-82. 
(12) The fourth report on the diagnosis, evaluation, and treatment of high blood 
pressure in children and adolescents. Pediatrics 2004; 114(2):555-76. 
(13) Hansen M.L., Gunn P.W., Kaelber D.C. Underdiagnosis of hypertension in 
children and adolescents. The Journal of the American Medical Association 
2007;298(8 reprinted):874-9. 
(14) Task Force. Heart rate variability: standards of measurement, physiological 
interpretation, and clinical use. European Heart Journal 1996;17:354-81. 
(15) Akselrod S. Components of heart rate variability: basic studies. In: Malik M., 
Camm A.J., editors. Heart rate variability.Armonk, NY: Futura Publishing 
Company Inc.; 1995. p. 147-63. 
(16) Berntson G.G., Bigger J.T.Jr., Eckberg D.L., Grossman P., Kaufmann P.G., Malk 
M., Nagaraja H.N., Porges S.W., Saul J.P., Stone P.H., Van Der Molen M. Heart 
rate variability; origins, methjods and interpretive caveats. Psychophysiology 
1997;34:623-48. 
(17) Genovesi S., Pieruzzi F., Giussani M., Tono V., Stella A., Porta A., Pagani M., 
Lucini D. Analysis of heart period and arterial pressure variability in childhood 
hypertension: key role of bar ore flex impairment. Hypertension 2008;51(5):1289-
94. 
(18) Laitinen T., Hartikainen J., Vanninen E., Niskanen L., Geelen G., Lansimies E. 
Age and gender dependency of bar ore flex sensitivity in healthy subjects. Journal 
of Applied Physiology 1998;84(2):576-83. 
(19) Krontoradova K., Honzikova N., Fiser B., Novakova Z., Zavodna E., Hrstkova 
H., Honzik P. Overweight and decreased baroreflex sensitivity as independent 
risk factors for hypertension in children, adolescents, and young adults. 
PhYSiological Research 2008;57(3):385-91. 
(20) Lenard Z., Studinger P., Mersich B., Kocsis L., Kollai M. Maturation of 
cardiovagal autonomic function from childhood to young adult age. Circulation 
2004;110:2307-12. 
60 
(21) Dietrich A., Riese H., van Roon A.M., van Engelen K., Ormel J., Neeleman J., 
Rosmalen J.G.M. Spontaneous baroreflex sensitivity in (pre)adolescents. Journal 
of Hypertension 2006;24:345-52. 
(22) Ahimastos A.A., Formosa M., Dart A.M., Kingwell B.A. Gender difference in 
large artery stiffness pre- and post puberty. Journalof Clinical Endocrinology and 
Metabolism 2003;88(1):5375-80. 
(23) McArdle W.D., Katch P.I., Katch V.L. Exercise physiology: Energy, nutrition 
and human performance. 5 ed. Baltimore Maryland: Lippincott Williams and 
Wilkins; 2001. 
(24) Oxford medical dictionary. NY, NY: Oxford University Press Inc.; 2007. 
(25) Berne R.M., Levy M.N. Cardiovascular physiology. 7th ed. st. Louis, Missouri: 
Mosby Year Book, Inc.; 1997. 
(26) Levy M.N., Pappano A.J. Cardiovascular physiology. 9th ed. Philadelphia, PA: 
Mosby Elsevier; 2007. 
(27) Rowell L.B. Human circulation: Regulation during physical stress. New York, 
NY: Oxford University Press; 1986. 
(28) The fourth report on the diagnosis, evaluation, and treatment of high blood 
pressure in children and adolescents. Pediatrics 2004; 114(2):555-76. 
(29) Eckberg D.L. Physiological basis for human autonomic rhythms. Annals of 
Medicine 2000;32:341-9. 
(30) Akselrod S., Gordon D., Ubel F.A., Shannon D.C., Barger A.C., Cohen J.J. Power 
spectrum analysis of heart rate fluctuation: A quantitative probe of beat-to-beat 
cardiovascular control. Science 1981;213(4504):220-2. 
(31) Silva G.J.J., Ushizima M.R., Lessa P.S., Cardoso L., Drager L.F., Atala M.M., 
Consolim-Colombo F.M., Lopes H.F., Cestari I.A., Krieger J.E., Krieger E.M. 
Critical analysis of autoregressive and fast Fourier transform markers of 
cardiovascular variability in rats and humans. Brazilian Journal of Medical and 
Biological Research 2009;42(4):386-96. 
(32) De Ferrari G.M., VanoH E., Schwartz P.J. Cardiac vagal activity, myocardial 
ischemia and sudden death. In: Zipes D.P., JaHfe J., editors. Cardiac 
electrophysiology. From cell to bedside.Philadelphia PA: WB Saunders Co; 1995. 
p.422-34. 
(33) Head G.A., Lukoshkova E.V., Burke S.L., Malpas S.C., Lambert E.A., Janssen 
B.J.A. Comparing spectral and invasive estimates of bar ore flex gain: Can power 
61 
spectral analysis reproducibility estimate changes in barorefelx gain? IEEE 
Engineering in Medicine and Biology Magazine 2001 ;20(2):43-52. 
(34) Sherwood L. Human physiology from cells to systems. 5 ed. Toronto, ON: 
Thomson Learing Inc.; 2004. 
(35) Lanfranchi P .A., Somers V.K. Arterial baroreflex function and cardiovascular 
variability: interactions and implications. American Journal of Physiology -
Regulatory, Integrative and Comparative Physiology 2002;283:R815-R826. 
(36) Lilly L.S. Pathophysiology of heart disease: A collaborative project ofmedical 
students and faculty. 3ed ed. Baltimore, Maryland: Lippincott Williams and 
Wilkins; 2003. 
(37) Di Rienzo M., Castiglioni P., Manicia G., Pedotti A., Parati G. Advancements in 
estimating baroreflex function: Exploring different aspects of autonomic control 
of the heart through the sequence technique. IEEE Engineering in Medicine and 
Biology Magazine 2001;20(2):25-32. 
(38) Allen M.T., Matthews K.A., Kenyon K.L. The relationships ofrestign baroreflex 
sensitivity, heart rate variability and measures of impulse control in children and 
adolescents. International Journal of Psychophysiology 2000;37: 185-94. 
(39) Eckberg D.L., Sleight P. Human baroreflexes in health and disease. New York, 
NY: Oxford University Press; 1992. 
(40) Eckberg D.L., Cavanaugh M.S., Mark A.L., Abboud F.M. A simplified neck 
suction device for activation of carotid baroreceptors. Journal of Pediatric Health 
Care 1975;85(167):173. 
(41) Robbe H.W., Mulder J.1., Ruddel H., Langewitz W.A., Veldman J.B., Mulder G. 
Assessment of baroreceptor reflex sensitivity by means of spectral analysis. 
Hypertension 1987; 1 0:538-43. 
(42) Robbe H.W., Mulder J.J., Ruddel H., Langewitz W.A., Veldman J.B., Mulder G. 
Assessment of baroreceptor reflex sensitivity by means of spectral analysis. 
Hypertension 1987;10:538-43. 
(43) Robbe H.W., Mulder J.J., Ruddel H., Langewitz W.A., Veldman J.B., Mulder G. 
Assessment of baroreceptor reflex sensitivity by means of spectral analysis. 
Hypertension 1987;10:538-43. 
(44) Robbe H.W., Mulder J.1., Ruddel H., Langewitz W.A., Veldman J.B., Mulder G. 
Assessment of baroreceptor reflex sensitivity by means of spectral analysis. 
Hypertension 1987;10:538-43. 
62 
(45) Kotchen T.A., Kotchen J.M., Guthrie G.P., Berk M.r., Knapp C.F., McFadden M. 
Baroreceptor sensitivity in prehypertensive young adults. Hypertension 
1989;13:878-83. 
(46) Robbe H.W., Mulder J.1., Ruddel H., Langewitz W.A., Veldman J.B., Mulder G. 
Assessment of baroreceptor reflex sensitivity by means of spectral analysis. 
Hypertension 1987;10:538-43. 
(47) Parati G., Casadei R., Groppelli A., Di Rienzo M., Manicia G. Comparison of 
finger and intra-arterial blood pressure monitoring at rest and during laboratory 
testing. Hypertension 1989;13:647-55. 
(48) Peveler R.C., Bergel D.H., Robinson J.L., Sleight P. The effect of phenylephrine 
upon arterial pressure, carotid sinus radius and baroreflex sensitivity in the 
conscious greyhound. Clinical Science 1983;64:455-61. 
(49) Petrove L., Karachiviev D., Bredy-Dobreva G. Participation ofthe 
cardiopulmonary baroreceptors in the buffering of fast changes in the arterial 
pressure. Acta Physiologica et Pharmacologica Bulgarica 1979;5:19-26. 
(50) Eckberg D.L., Drabinsky M., Braunwald E. Defective cardiac parasympathetic 
control in patients with heart disease. The New England Journal of Medicine 
1971;285:877-83. 
(51) Rowell L.B. Human cardiovascular control. New York, NY: Oxford University 
Press, Inc.; 1993. 
(52) Kaufinan H. Head-up tilt, lower body negative pressure, pacemakers and 
vasovagal syncope. Clinical Autonomic Research 1994;4(5):231-2. 
(53) Brown C.M., Hecht M.J., Neundorfer B., Hilz M.J. Effects oflower body 
negative pressure on cardiac and vascular responses to carotid baroreflex 
stimulation. Physiological Research 2003;52:637-345. 
(54) Penaz J., Honzikova N., Fiser B. Spectral analysis of resting variability of some 
circulatory parameters in man. Physiologia Bohemoslovaca 1978;27:349-57. 
(55) Sayers B.McA., Cicchiello L.R., Raftery E.B., Mann S., Green H. The assessment 
of continuous ambulatory blood pressure records. Medical Informatics 1982;7:93-
108. 
(56) DeBoer R.W., Karemaker J.M., vanMontfrans G.A. Hemodynamic fluctuations 
and baroreflex sensitivity in humans: a beat-to-beat model. American Journal of 
Physiology 1987;253:H680-H689. 
(57) Baselli G., Cerutti S., Civardi S., Malliani A., Orsi G.; Pagani M., Rizzo G. 
Parameter extraction from heart rate and arterial blood pressure variability signals 
63 
in dogs for the validation of a physiological model. Computers in Biology and 
Medicine 1988;18(1):1-16. 
(58) Robbe H.W., Mulder J.1., Ruddel H., Langewitz W.A., Veldman J.B., Mulder G. 
Assessment of baroreceptor reflex sensitivity by means of spectral analysis. 
Hypertension 1987;10:538-43. 
(59) Watkins L.L., Grossman P., Sherwood A. Noninvasive assessment of bar ore flex 
control in borderline hypertension. Hypertension 1996;28(2):238-43. 
(60) Piccirillo G., DiGuseppe V., Nocco M., Lionetti M., Moise A., Naso C., Tallarico 
D., Marigliano V., Cacciafesta M. Influence of aging and other cardiovascular 
risk factors on baroreflex sensitivity. Journal of American Geriatrics Society 
2001 ;49: 1 059-65. 
(61) La Rover M.T. Baroreflex sensitivity as a new marker for risk stratification. 
Zeitschrift fur Kardiologie 2000;89(Supplement 3):44-50. 
(62) Frattola A., Parati G., Gamba P., Paleari F., Mauri G., Di Rienzo M., Casiglioni 
P., Mancia G. Time and frequency domain estimates of spontaneous baroreflex 
sensitivity provide early detection of autonomic dysfunction in diabetes mellitus. 
Diabetologia 1997;40(1470):1475. 
(63) Agarwal A. AISSV, Chugh D.S. Effect of dialysis and renal transplantation on 
autonomic dysfunction in chronic renal failure. Kidney International 
1991 ;40:489-95. 
(64) Rudiger H., Bald M. Spontaneous baroreflex sensitivity in children and young 
adults calculated in the time and frequency domain. Autonomic Neuroscience: 
Basic and Clinical 2001;93:71-8. 
(65) Gerritsen J., Dekker J.M., TenVoorde B.J., Kostense P.J., Heine R.1., Bouter 
L.M., Heethaar RM., Stehouwer C.D.A. Impaired autonomic function is 
associated with increased mortality, especially in subjects with diabetes, 
hypertension, or a history of cardiovascular disease. Diabetes Care 2001 ;24: 1793-
8. 
(66) Martin G.J., Magid N.M., Myers G., Barnett P.S., Schaad J.W., Weiss J.S., Lesch 
M., Singer D.H. Heart rate variability and sudden death secondary to coronary 
artery disease during ambulatory electrocardiographic monitoring. American 
Journal of Cardiology 1987;60(1):86-9. 
(67) Bigger J.T.Jr., Fleiss J.L., Steinman RC., Rolnitzky L.M., Kleiger RE., Rottman 
J.N. Frequency domain measures of heart period variability and mortality after 
myocardial infarction. Circulation 1992;85(164):171. 
64 
(68) Malik M., Farrell T., Cripps T., Camm A.1. Heart rate variability in relation to 
prognosis after myocardial infarction: Selection of optimal processing techniques. 
European Heart Journal 1988;10(12):1060-74. 
(69) Kleiger R.E., Miller J.P., Bigger J.T.1r., Munn N., Moss A.1., the Multicenter 
Post-infarction Research Group. Decreased heart rate variability and its 
association with increased mortality after acute myocardial infarction. American 
Journal of Cardiology 1987;59(4):256-62. 
(70) Kleiger R.E., Miller J.P., Bigger J.T.Jr., Munn N., Moss A.J., the Multicenter 
Post-infarction Research Group. Decreased heart rate variability and its 
association with increased mortality after acute myocardial infarction. American 
Journal of Cardiology 1987;59(4):256-62. 
(71) Kaplan N.M. Primary hypertension: pathogenesis. In: Kaplan N.M., editor. 
(72) 
Clinical Hypertension.Baltimore MD: Williams and Wilkins; 1990. p. 54-111. 
Chobanian A.V., Bakris G.L., Black H.R., Cushman W.C., Green L.A., Izzo J.L., 
JonesD.W., Materson B.J., Oparil S., Wright IT., Roccella E.J. The seventh 
report of the Joint National Committee on prevention, detection, evaluation and 
treatment of high blood pressure: The JNC 7 Report. The Journal of American 
Medical Association 2003;289(10):2560-71. 
(73) The fourth report on the diagnosis, evaluation, and treatment of high blood 
pressure in children and adolescents. Pediatrics 2004; 114(2):555-76. 
(74) National High Blood Pressure Education Program Working Group on High Blood 
Pressure in Children and Adolescents. The fourth report on the diagnosis, 
evaluation, and treatment of high blood pressure in children and adolescents. 
Pediatrics 2004; 114(2):555-76. 
(75) Julius S. Autonomic nervous sytem dysregulation in human hypertension. 
American Journal of Cardiology 1991 ;67 :3B-7B. 
(76) Malik M., Camm A.1. Components of heart rate variability: what they really mean 
and what we really measure. American Journal of Cardiology 1993;72:821-2. 
(77) Salo T.M., Viikari J.S.A., Antila K.J., Voipio-Pulkki LM., Jalonen O.J., Valimaki 
I.A.T. Antihypertensive treatment and heart rate variability in diabetic patients: 
role of cardiac autonomic neuropathy. Journal of the Autonomic Nervous System 
1996;60(1-2):61-70. 
(78) Skrapari 1., Tento10uris N., Katsi1ambros N. Baroreflex function: detenninants in 
healthy subjects and disturbances in diabetes, obesity and metabolic syndrome. 
Current Diabetes Reviews 2004;2(3):329-38. 
65 
(79) Parati G., Di Rienzo M., Bertinieri G., Pmidossi G., Casadei R., Groppelli A., 
Pedotti A., Zanchetti A., Manda G. Evaluation ofthe baroreceptor-heart rate 
reflex by 24-hour intra-arterial blood pressure monitoring in humans. 
Hypertension 1988;12:214-22. 
(80) Parmer RJ., Cervenka J.H., Stone R.A., O'Connor D.T. Autonomic function in 
hyptertension. Are there racial differences? Circulation 1990;81: 1305-11. 
(81) Aortic stiffuess in children of parents with hypertension. Journal of Human 
Hypertension 2006;20:225-6. 
(82) Kleiger R.E., Miller J.P., Bigger J.T.Jr., Munn N., Moss A.J., the Multicenter 
Post-infarction Research Group. Decreased heart rate variability and its 
association with increased mortality after acute myocardial infarction. American 
Journal of Cardiology 1987;59(4):256-62. 
(83) The fourth report on the diagnosis, evaluation, and treatment of high blood 
pressure in children and adolescents. Pediatrics 2004;114(2):555-76. 
(84) Ferrari A.U. Modifications ofthe cardiovascular system with aging. American 
Journal of Geriatric Cardiology 2002;11(1):30-3. 
(85) Monahan K.D., Dinenno F.A., Seals D.R., Clevenger C.M., Desouza C.A., 
Tanaka H. Age-associated changes in cardiovagal baroreflex sensitivity are 
related to central arterial compliance. American Journal of Physiology: Heart and 
Circulatory Physiology 2001;281:H284-H289. 
(86) Tank: J. BRM, Fender A., Baevski A.R, Graves K.F., Ploewka K., Weck M. 
Reference values of indices of spontaneous baroreceptor reflex sensitivity. 
American Journal of Hypertension 2000;13:268-75. 
(87) Kardos A., Watterich G., de Menezes R, Csanady M., Casadei B., Rudas L. 
Determinants of spontaneous baroreflex sensitivity in a healthy working 
population. Hypertension 2001;37(3):911-6. 
(88) Gribbin B., Pickering T.G., Sleight P., Peto R Effect of age and high blood 
pressure on baroreflex sensitivity in man. Circulation Research 1971 ;29:424-31. 
(89) Veerman D.P., Irnholz B.P., Wieling W., Karemaker J.M., van Montfrans G.A. 
Effects of aging on blood pressure variability in resting conditions. Hypertension 
1994;24:120-30. 
(90) Barnett S.R., Morin RJ., Kiely D.K., Gagnon M., Azhar G., Knight E.L., Nelson 
J.C., Lipsitz L.A. Effects of age and gender on autonomic control of blood 
pressure dynamics. Hypertension 1999;33:1195-200. 
66 
(91) Yeragani V.K., Pohl R., Berger R., Balon R., Srinivasan K. Relationship between 
age and heart rate variability in supine and standing postures: a study of spectral 
analysis of heart rate. Pediatric Cardiology 1994;15(14):20. 
(92) Finley J., Nugent S.T., Hellenbrand W. Heart-rate variability in children. Spectral 
analysis of developmental changes between 5 and 24 years. Canadian Journal of 
Physiology and Pharmacology 1986;65:2048-52. 
(93) Zavodna E., Honzikova N., Hrstkova H., Novakova Z., Moudr J., Jira M., Fiser B. 
Can we detect the development of bar ore flex sensitivity in humans between 11 
adn 20 years of age? Canadian Journal of Physiology and Parmacology 
2006;84(12):1275-83. 
(94) EI-Mas MM, Abdel-Rahman A.R.A. Estrogen enhances baroreflex control of 
heart rate in concious ovariectomized rats. Canadian Journal of Physiology and 
Parmacology 1998;76:381-6. 
(95) EI-Mas MM, Afify EA, Mohy EI-Din MM, Omar AG, Sharabi FM. Testosterone 
facilitates the baroreceptor control of reflex bradycardia: role of cardiac 
sympathetic and parasympathetic components. Journal of cardiovascular 
pharmacology 2001;38:754-63. 
(96) Huikuri H.V., Pikkujamsa S.M., Airaksinen J., Ikaheimo M.J., Rantala A.O., 
Kauma H., Lija M., Kesaniemi Y.A. Sex-Related Differences in Autonomic 
Modulation of Heart Rate in Middle-aged Subjects. Circulation 1996;94(2):122-5. 
(97) Baxter-Jones A.D.G., Mirwald R.L., McKay H.A., Bailey D.A. A longitudinal 
analysis of sex differences in boen mineral accrual in healthy 8-19-year-old boys 
and girls. Annals of Human Biology 2003;30(2): 160-75. 
(98) Mirwald R.L., Baxter-Jones A.D.G., Bailey D.A., Beunen G.P. An assessm~nt of 
maturity from anthropometric measurements. Medicine & Science in Sports & 
Exercsie 2002;34(4):689-94. 
(99) Mentzel H.J., Vilser C., Eulenstein M., Schwartz T., Vogt S., Bottcher J., Yaniv 
1., TsorefL., KaufE., Kaiser W.A. Assessment of skeletal age at the wrist in 
children with a new ultrasound device. Pediatric Radiology 2005;35:429-33. 
(100) Kaplan N.M., Lieberman E. Clinical Hypertension. 6th ed. Baltimore: Williams & 
Wilkins; 1994. p. 23-
46,343-66,191-281. 
(101) MacKelvie K.J., Khan K.M., McKay H.A. Is there a critical period for bone 
response to weight-bearing exercise in children and adolescents? a systematic 
review. Journal of Sports Medicine 2002;36:250-7. 
67 
(102) Sherar L.B., Mirwald RL., Baxter-Jones A.D.G., Thomis M. Prediction of adult 
height using maturity-based cumulative height velocity curves. Journal of 
Pediatrics 2005;147(4):508-14. 
(103) Bailey D.A., McKay D.W., Mirwald R.L., Crocker P.RE., Faulkner RA. A six-
year longitudinal study of the relationship of physical activity to bone mineral 
accrual in growing children: The University of Saskatchewan Bone Mineral 
Accrual Study. Journal of Bone and Mineral Research 1999;14(10):1672-9. 
(104) Bailey D.A., Faulkner RA., McKay H. Growth, physical activity, and bone 
mineral acquisition. Exercise and Sports Science Reviews 1996;24:233-66. 
(105) Malina R.M., Bouchard C. Biological Maturation: Concepts and assessment. 
Growth, maturation, and physical activity. 1st ed. Champaing, IL: Human 
Kinetics; 1991. p. 231-49. 
(106) Baxter-Jones A.D.G., Kontulainen S.A., Faulkner RA., Bailey D.A. A 
longitudinal study of the relationship of physical activity to bone mineral accrual 
from adolescence to young adulthood. Bone 2008;43:i 101-7. 
(107) Mirwald RL. The Saskatchewan Growth and Development Study. In: Ostyn M., 
Beunen G., Simons J., editors. Kinanthropometry II.Baltimore, Maryland: 
University Park Press; 1978. p. 289-305. 
(108) Guo S.S., Roche A.F., Chumlea W.C., Gardner J.D., Siervogel R.M. The 
predictive value of childhood body mass index values for overweight at age 35 y. 
American Journal ofClincal Nutrition 1994;59:810-9. 
(109) Serdula M.K., Ivery D., Coates RJ., Freedman D.S., Williamson D.F., Byers T. 
Do obese chidren become obese adults? A review of the literature. Preventive 
Medicine 1993;22:167-77. 
(110) Ogden C.L., Troiano RP., Briefel RR, Kuczmarski RJ., Flegal K.M., Johnson 
C.L. Prevalence of overweight among preschool children in the United States, 
1971 through 1994. Pediatrics 1997;99(4):e1-e7. 
(111) DiPietro L., Mossberg H-O., Stunkard A.J. A 40-year history of overweight 
children in Stockholm: life-time overweight, mobidity, and mortality. 
Internaltional Journal of Obesity 1994; 18:585-90. 
(112) Nieto F.J., Szko M., Comstock G.W. Childhood weight and growth rate as 
predictors of adult mortality. American Journal of Epidemiology 1992; 136:201-
13. 
(113) Luciano A., Livieri C., DiPietro M.E., Bergamaschi G., Maffeis C. Definition of 
obesity in childhood: criteria and limits. Minerva Pediatrica 2003;55(5):453-9. 
68 
(114) Wang Y. Epidemiology of childhood obesity-methodological aspects and 
guidlines: what is new? International Journal of Obesity and Related Metabolic 
Disorders- Journal of the Internation Association for the Study of Obesity 
2004;28(suppI3):S21-S28. 
(115) Pietrobelli A, Faith MS, Allison DB, Gallagher D, Chiumello G, Heymsfield SB. 
Body mass index as a measure of adiposity among children and adolescents: a 
validation study. Journal of Pediatrics 1998;132(2):204-10. 
(116) Sampei M.A., Novo N.F., Juliano Y., Sigulem D.M. Comparison of the body 
mass index to other methods of body fat evaluation in ethnic Japanese and 
Caucasian adolescent girls. Internaltional Journal of Obesity 2001;25:400-8. 
(117) Dietz WH, Bellizzi MC. Inroduction: the use of body mass index to assess obesity 
in children. American Journal of Epidemiology 1999;70(suppl): 123S-5S. 
(118) Daniels S, Khoury P, Morrison J. The utility of body mass index as a measure of 
body fatness in children and adolescents: differences by race and gender. 
Pediatrics 1997;99:804-7. _. 
(119) The fourth report on the diagnosis, evaluation, and treatment of high blood 
pressure in children and adolescents. Pediatrics 2004; 114(2):555-76. 
(120) Sorof J., Daniels S. Obesity hypertension in children: a problem of epidemic 
proportions. Hypertension 2002;40:441-7. 
(121) Muntner P.He J., Cutler J.A., Wildman R.P., Whelton P.K. Trends in blood 
pressure among children and adolescents. The Journal of the American Medical 
Association 200;291 (17):21 07 -13. 
(122) Morrison J.A., Barton B.A., Biro F.M., Daniels S.R., Sprecher D.L. Overweight, 
fat patterning, and cardiovascular disease reisk factors in black and white boys. 
Journal of Pediatrics 1999;135(4):451-7. 
(123) Freedman D.S., Dietz W.H., Srinivasan S.R., Berenson G.S. The relation of 
overweight to cardiovascular risk factors among children and adolescents: The 
Bogalusa Heart Study. Pediatrics 1999;103(6):1175-82. 
(124) C N.F., Rimm E.B., Wang D.J., Liou H.S., Shieh S.M. Clustering of 
cardiovascular disease risk factors among obese schoolchildren: the Taipei 
Children Heart Stduy. American Journal ofClincal Nutrition 1998;67:1141-6. 
(125) Guilaume M., Lapidus L., Beckers F., Lambert A., Bjomtorp P. Cardiovascular 
risk factors in children from the belgian province of Luxembourg: the Belgian 
Luxembourg Child Study. American Journal of Epidemiology 1996;144:867-80. 
69 
(126) Venna M., Chhatwal J., George S.M. Obesity and hypertension in children. 
Indian Pediatrics 1994;31(1065):1069. 
(127) Genovesi S., Giussani M., Pieruzzi F., Vigorita F., Arcovio C., Cavuto S., Stella 
A. Results of blood pressure screening in a population of school-aged children in 
the province of Millan: role of overweight. Journal of Hypertension 2005;23 :493-
7. 
(128) Riva P., Martini G., Rabbia F., Milan A., Paglieri C., Chiandussi L., Veglio F. 
Obesity and autonomic function in adolecence. Clinical and Experimental 
Hypertension 2001;23(1&2):57-67. 
(129) Tanaka H., Thulesius 0., Borres M., Yamaguchi H., Mino M. Blood pressure 
responses in Japanese and Swedish children in the supine and standing postition. 
European Heart Journal 1994;15:1011-9. 
(130) Pozza R.D., Bechtold S., Bonfig W., Putzker S., Kozlik-Feldmann R., Schwarz 
H.P., Netz H. Impaired short-tenn blood pressure regulation and autonomic 
dysbalance in children with type 1 diabetes mellitus. Diabetologia -
2007;50(12):2414-23. 
(131) Ellenbogen K.A., Mahanty P.K., Szentpetery S., Thames M.D. Arterial baroreflex 
abnonnalities in heart failure. Reversal after orthotopic cardiac transplantation. 
Circulation 1989;79:51-8. 
(132) Somers Y.K., Conway J., Johnston, Sleight P. Effects of endurance training on 
baroreflex sensitivity and blood pressure in boerderline hypertension. Lancet 
1991;337:1363-8. 
(133) Gutin B., Howe C.A., Johnson M.H., Humphries M.C., Snieder H., Barbeau P. 
Heart rate variability in adolescents: relations to physical activity, fitness, and 
adiposity. Medicine & Science in Sports & Exercsie 2005;37(11):1856-63. 
(134) Levy W.C., Cerqueira M.D., Harp G.D., Johannessen K.A., Abrass I.B., Schwartz 
R.S., Stratton J.R. Effect of endurance exercise training on heart rate variability at 
rest inhealthy young and older men. American Journal of Cardiology 
1998;82(10):1236-41. 
(135) Faulkner M.S., Quinn L., Rimmer J.H., Rich B.H. Cardiovascular endurance and 
heart rate variability in adolescents with type 1 or type 2 diabetes. Biological 
Research for Nursing 2005;7(1):16-29. 
(136) Riddoch C., Edwards D., Page A., Froberg K., Anderssen S.A., Wedderkopp N., 
Brage S., Cooper A.R., Sardinha L.B., Harro M., Klasson-Heggebo L., van 
Mechelen W., Boreham C., Ekelund U., Andersen L.B., the European Youth 
Heart Study Team. The European Youth Heart Study - Cardiovascular Disease 
70 
Risk Factors in Children: Rationale, Aims, Study Design, and Validation of 
Methods. Journal of Physical Activity and Health 2005;2: 115-29. 
(137) Pickering T.G., Hall J.E., Appel LJ., Falkner B.E., Graves J., Hill M.N., Jones 
D.W., Kurtz T., Sheps S.G., Roccela E.J. Recommendations for blood pressure 
measurement in humans and experimental animals. Part 1: blood pressure 
measurement in humans. A statement for professionals from the Subcommittee of 
Professional and Public Education of the American Heart Association Council on 
High Blood Pressure Research. Hypertension 2005;45:142-61. 
(138) The fourth report on the diagnosis, evaluation, and treatment of high blood 
pressure in children and adolescents. Pediatrics 2004;114(2):555-76. 
(139) Wang J., Thorton J., Bari S., Williamson B., Gallagher D., Heymsfield S., Horlick 
M., Kotler D., Laferrere B., Mayer L., Pi-Sunyer F., Pierson R.Jr. Comparison of 
waist circumferences measured at 4 sites. American Journal of Clincal Nutrition 
2003;77:379-84. 
(140) Benetos A., Zureik M., Morcet J., Thomas F., Bean K., Safar M., Ducimetiere P., 
Guize L. A decrease in diastolic blood pressure combined with an increase in 
systolic blood pressure is associated with a higher cardiovascular mortality in 
men. Journal of the American College of Cardiology 2000;35(3):673-80. 
(141) Fagius J., Karhuvaara S. Sympathetic activity and blood pressure increases with 
bladder distension in humans. Hypertension 1989;14:511-7. 
(142) Hughson R.L., Quintin L.., Annat G., Yamamoto Y., Gharib C. Spontaneous 
baroreflex by sequence and power spectral methods in humans. Clinical 
Physiology (Oxford, England) 1993;13:663-76. 
(143) Pagani M., Lombardi F., Guzzetto S., Rimoldi 0., Furlan R., Pizzinelli P., 
Sandrone G., Malfatto G., Dell'Orto S., Piccaluga E., Turiel M., Baselli G., 
Cerutti S., Malliani A. Power spectral analysis of heart rate and arterial pressure 
variabilities as a marker of sympatho-vagal interaction in man and conscious dog. 
Circulation Research 1986;59: 178-93. 
(144) Muneta S., Murakami E., Sumimoto T., Iwata T., Hiwada K., Sato Y., Imamura 
Y. Blood pressure and heart rate variability in elderly patients with isolated 
systolic hypertension. Journal of Human Hypertension 1991;5(5):393-8. 
(145) Powers S.K., Howley E.T. Exercise physiology: Theory and application to fitness 
and performance. 5th ed. New York, NY: McGraw-Hill; 2004. 
(146) La Rover M.T., Pinna G.D., Hohnloser S.H., Marcus F.I., Mortara A., Nohara R., 
Bigger J.TJr., Camm A.J., Schwartz P.J., ATRAMI Investigators.Autonomic 
Tone and Reflexes After Myocardial Infarction. Baroreflex sensitivity and heart 
71 
rate bariability in the identification of patients at risk for life-threatening 
arrhythmias: Implications for clinical trials. Circulation 2001; 1 03(16):2072-7. 
(147) Lauer R.M., Clarke W.R. Childhood risk factors for high adult blood pressure: 
Muscatine Study. Pediatrics 1989;84(8):663-41. 
(148) Honzikova N., Novakova Z., Zavodna E., Padirova J., Lokaj P., Fiser B., 
Balcarkova P., Hrstokova H. Baroreflex sensitivity in children, adolescents, and 
young adults with essential and white-coat hypertension. Klinische Padiatrie 
2006;218(4):237-42. 
(149) Van Merode T., Hick P.J.J., Hoeks A.P.G., Rahn K.H., Reneman R.S. Carotid 
artery wall properties in normotensive and borderline hypertensive subjects of 
various ages. Ultrasound in Medicine and Biology 1988;14:563-9. 
(150) Komet L., Hoeks A.P.G., Janssen B.J.A., Houben A.J., DeLeeuw P.W, Reneman 
R.S. Neural activity of the cardiac baroreflex decreases with age in normotensive 
and hypertensive subjects. Journal of Hypertension 2005;23:815-23. 
(151) Parati G., Lantelme P. Mechanical and neural components of the cardiac 
baroreflex: new insights into complex physiology. Journal of Hypertension 
2005;23:717-20. 
72 
Appendix A 
Research Ethics Approval 
Brock University Research Ethics Board (REB) 
Application for Ethical Review of Research Involving Human Participants 
Please refer to the documents "Brock University Research Ethics Guidelines", which can be 
found at http://www.brocku.ca/rescarchservices/.prior to completion and submission ofthis 
application. 
If you have questions about or require assistance with the completion of this form, 
please contact the Research Ethics Office at (905) 688-5550 ext. 3035, or reb@brocku.ca. 
Return your completed application and all accompanying material in triplicate to the 
Research Ethics Office in MacKenzie Chown D250A. 
Please ensure all necessary items are attached prior to submission, 
otherwise your application will not be processed (see checklist below). 
No research with human participants shall commence prior to 
receivinJ( approvalfrom the research ethics board. 
Recruitment Materials 
• Letter of invitation 
• Verbal script 
• Telephone script 
• Advertisements (newspapers, posters, SONA) 
• Electronic 
Consent Materials 
• Consent form 
• Assent form for minors 
• Parental/3rd party consent 
• Transcriber 
Data Gathering Instruments 
• Questionnaires 
• Interview guides 
• Tests 
for research from cooperating organizations, 
or other institutions 
Office of Research Services 
Brock University· 500 Glenridge Ave· St. Catharines, ON· L2S 3AI • Fax: 905-688-0748 
Revised: August 2006 
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SIGNATURES 
Principal Investigator: 
Please indicate that you have read and fully understand all ethics obligations by checking the box beside 
each statement. 
[,(] I have read Section III:8 of Brock University's Faculty Handbook pertaining to Research Ethics 
and agree to comply with the policies and procedures outlined therein. 
[,(] I will report any serious adverse events (SAE) to the Research Ethics Board (REB). 
[ ,(] Any additions or changes in research procedures after approval has been granted will be submitted 
to the REB. 
[,(] I agree to request a renewal of approval for any project continuing beyond the expected date of 
completion or for more than one year. 
[,(] I will submit a fmal report to the Office of Research Services once the research has been 
completed. 
[ ,(] I take full responsibility for ensuring that all other investigators involved in this research follow 
the protocol as outlined in this application. 
Signamre ________________________________ ___ Date: _________ _ 
Co-Investigators: 
Signature ________________________ ___ Date: __________ ___ 
Signamre ________________________ ___ Date: __________ _ 
Signamre _______________________ ___ Date: _______ ---C 
Faculty Supervisor: 
Please indicate that you have read and fully understand the obligations as faculty supervisor listed below by 
checking the box beside each statement. 
[ ] I agree to provide the proper supervision of this smdy to ensure that the rights and welfare of all 
human participants are protected. 
[ ] I will ensure a request for renewal of a proposal is submitted if the smdy continues beyond the 
expected date of completion or for more than one year. 
[ ] I will ensure that a final report is submitted to the Office of Research Services. 
[ ] I have read and approved the application and proposal. 
Signature ________________________ _ Date: ___________ _ 
SECTION A - GENERAL INFORMATION 
I. Title of the Research Project: Social Determinants of Child Hypertension 
2. Investigator Information: 
Name Position Dept./Address I Phone No. E-Mail 
Principal Terrance J Wade Faculty CHSC/CYS 4146 twade(i7;'brocku.ca 
Investigator 
Co- Paul LeBlanc Faculty CHSC 4216 pleblanc(iVbrocku.ca 
Investigator(s) Deborah O'Leary Faculty CHSC 4339 dolearyY;ubrocku.ca 
Faculty 
Supervisor(s) 
3. Proposed Date (dd/mmlyyyy) (a) of commencement: 0111012007 (b) of completion: 30/06/2012 
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4. Indicate the location(s) where the research will be conducted: 
5. 
6. 
7. 
Brock University [,(] 
Community Site [ ] Specify 
School Board [ ] Specify 
Hospital [ J Specify 
Other [ J Specify 
Other Ethics ClearancelPermission: 
(a) Is this a multi-centered study? 
(b) Has any other University Research Ethics Board approved this research? 
[ ] Yes [,(] No 
[ ] Yes [,(] No 
If YES, there is no need to provide further details about the protocol at this time, provided that all 
of the following infonnation is provided: 
Title of the project approved elsewhere: 
Name of the Other Institution: 
Name ofthe Other Board: 
Date of the Decision: 
A contact name and phone number for the other Board: 
Please provide a copy of the application to the other institution together with all 
accompanving materials. as well as a copy of the clearance certificate / approval. 
If NO, will any other Research Ethics Board be asked for approval? 
Specify University/College Niagara Catholic District School Board 
[,(] Yes [) No 
(d) Has any other person(s) or institutions granted pennission to conduct this research? 
[ J Yes [,(] No 
Specify (e.g.,. school boards, community organizations, proprietors) 
Level of the Research: 
[ ] Undergraduate 
[ ] Post Doctorate 
[ ] Undergraduate Course Assignment 
(specify course) 
Funding of the Project: 
(a) Is this project currently being funded 
(b) If No, is funding being sought 
If Applicable: 
[ ] Masters ThesislProject [ ] Ph.D. 
[,(] Faculty Research [ ] Administration 
[ ] Graduate Course Assignment [] Other 
(specify course) (specify) 
[,(] Yes [] No 
[ ] Yes [] No 
(c) Period of Funding (dd/mm/yyyy): From: 01107/2007 To: 31106/2012 
(d) Agency or Sponsor (funded or applied for) 
[ J CIHR [] NSERC [ ] SSHRC [,(] Other (specify): HSFO 
(e) Funding 1 Agency File # (not your personal PIN) 
8. Conflict ofInterest: 
(a) Will the researcher(s), members of the research team, and/or their partners or 
immediate family members receive any personal benefits related to this study -
Examples include financial remuneration, patent and ownership, employment, 
consultancies, board membership, share ownership, stock options. Do not include 
conference and travel expense coverage, possible academic promotion, or 
other benefits which are integral to the general conduct of research. 
[ ] Yes [,(] No 
If Yes, please describe the benefits below. 
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I none 
(b) Describe any restrictions regarding access to or disclosure of infonnation (during 
or at the end of the study) that the sponsor has placed on the investigator(s). 
SECTION B - SUMMARY OF THE PROPOSED RESEARCH 
9. Rationale: 
Briefly describe the purpose and background rationale for the proposed project, as well as the 
hypothesis( es )/research question( s) to be examined. 
(A) Statement of the Health Problem: 
Child hypertension (high blood pressure) is on the rise in Canada and the rest of North America. Since 
hypertension is a risk factor for the development of heart disease and stroke, our concern is that children 
who exhibit high blood pressure now will be at much greater risk for heart disease and stroke as they 
become adults. Although biological and genetic factors are important causes of hypertension, social and 
behavioural factors are also important. For example, some research has shown that children living in 
poverty are more likely to have high blood pressure than other children. Yet, we know very little about 
how social detenninants affect hypertension in children and, more importantly, why these factors are 
linked to high blood pressure in childhood. 
(B) Objective of the project: 
Our study proposes to not only identify which social factors are related to hypertension, but also to 
explore why these factors are linked to high blood pressure in children. It is through this that we believe 
the clues for successful intervention will be found. For example, it is unlikely that much can be done to 
address poverty among families without considerable governmental intervention. But if we can show 
that children from disadvantaged families not only have higher blood pressure than other children, but 
also that they are less physically active, then we can intervene to change this lifestyle factor. However, it 
is only through identifying the social risk factors (e.g., family poverty) and the intervening factor that 
leads to child hypertension (e.g., inactivity), that we can truly begin to design programs to address this 
problem. . 
Once the most important social detenninants have been identified, and the factors that explain why these 
social conditions lead to hypertension in children revealed, we will engage parents, teachers and 
community representatives to help design programs to improve the health and well-being of children. 
Next, we will actually implement the programs that result from our consultations and test to see if they 
did indeed work (if they lowered blood pressure among children at risk). 
(C) How will this work be done? 
There are two phases to our study. In the Phase 1 lab component, tor which this REB application 
applies, a subsample of children and their parents across hypertensive, pre-hypertensive and nonnal 
blood pressure groups (~ 100 per group, from a 3,000 subject screen base which has already received 
approval REB # 06-315 to Terrance Wade) will complete detailed questionnaires and will undergo an 
extensive series of physiological tests including a full body and blood analysis, blood pressure, arterial 
distensibility, left ventricular mass and detailed nutrition analysis. This protocol submission is based on 
a previously approved protocol (REB 04-419 to Deborah O'Leary). 
10. Methods: 
Are any of the following procedures or methods involved in this study? Check all that apply. 
[ ] Questionnaire (mail) [ ] Focus Groups [,/] Non-invasive physical 
[ ] Questionnaire (email/web) [ ] Journals measurement (e.g., exercise, 
[,/] Questionnaire (in person) [ ] Audio/video taping (specify) heart rate, blood pressure) 
[ ] Interview(s) (telephone) [ ] Observations [,/] Analysis of human tissue, 
[ ] Interview(s) (in person) [ ] Invasive physiological body fluids, etc. (Request for 
[ ] Secondary Data measurements (e.g., Use of Human Tissue 
[ ] Computer-administered venipuncture, muscle Sample attached) 
tasks biopsies) [ ] Other: (specify) 
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Describe sequentially, and in detail, all of the methods involved in this study and all procedures in 
which the research participants will be involved (e.g., paper and pencil tasks, interviews, 
questionnaires, physical assessments, physiological tests, time requirements, etc.) 
Attach a copy o(all questionnaire(s}. interview guides. or other test instruments. 
Sample Frame: The Niagara Catholic District School Board (NCDSB) will provide a subject base, 
facilitating access to their 50 elementary schools in the Niagara region (~16,700 students from 
kindergarten to grade 8). Our focus will be on children in grades 6 to 8 (age ~ 11 to ~ 13), a population of 
about 5,800 students. 
Sampling Strategy: Using mapped community-level SES data based on average household income, 
education, and urbanicity, schools situated within neighbourhoods across different strata fonn the school 
sampling frame will be identified. Schools will be randomly selected across each community stratum. In 
September, 3,000 children in grades 6, 7 and 8 will be screened to assess blood pressure, body 
composition (waist and hip circumference, height, and weight), demographic infonnation and activity 
level. A subsample of children and their parents across hypertensive, pre-hypertensive and nonnal blood 
pressure groups (100 per group) will complete detailed questionnaires (REB 06-315 to Terrance Wade) 
and undergo an extensive series of physiological tests including a full body and blood analysis, blood 
pressure, arterial distensibility, left ventricular mass (using Doppler echocardiography) and detailed 
nutrition analysis. 
Lab Testing: After being recruited in the study, the child will participate in one, 1 ~ hour testing 
session. Before starting the testing session the child will be familiarized with the laboratory, in addition 
to the testing procedures being explained to them. The child and their parent will be asked to read an 
infonnation sheet on the study and sign a consent fonn (Appendix A). 
Some factors, such as food, exercise and temperature have been purported to affect 
perfonnance. To account for this, subjects will be asked to fast for 12 hours prior to the testing session; 
avoid caffeine the day of testing; refrain from exercise on the testing day (prior to the procedure) and 
testing will be conducted in a temperature controlled room. The child will be asked to wear athletic 
attire for the testing session. 
Upon arrival at the lab and after signing the infonned consent, each subject will then 
immediately have their blood taken for analysis. Following this, each child will be given a preset meal 
(allergy sensitive) consisting of approximately 350 kcal. They will also be instructed to void their 
bladder, as this has been shown to have an effect on sympathetic nerve activity and hence blood 
pressure. Each subject's weight, height, skinfold thickness, waist circumference, hip circumference and 
Tanner stage (Appendix B) will then be recorded. Next, after 15-minutes of acclimatization, six resting 
blood pressure measures will be obtained using the automated BPM-300. Following blood pressure 
measurement, 5 minutes of beat-by-beat heart mte will be collected. As well, the left ventricle, along 
with the right common carotid artery will be imaged using Doppler ultrasound and the left common 
carotid artery pulse pressure will be recorded using hand-held tonometry. 
Measurements: 
Blood analysis 
Body composition & Tanner stage 
Blood Pressure 
Baroreflex function 
Arterial Stiffness 
Left Ventricular Mass 
Blood Analvsis: After cleaning the middle finger of the non-dominant hand with an alcohol swab, two 
small drops of whole blood will be collected by finger pinprick utilizing disposable single use lancets. 
The site of the pinprick will once again be cleaned with a fresh alcohol swab and covered with an 
adhesive bandage. The subjects will feel a small prick but will not feel any pain or discomfort for the 
remainder of the sampling. The tip of that finger may feel sensitive and a little bit sore for about a day. 
Blood analysis will test for total cholesterol, high density (HDL), low density (LDL) and very-
low-density-lipoprotein cholesterol (VLDL), along with triglycerides (TG), glucose and glycosylated 
haemoglobin (HbAIC) to identify co-morbidities associated with hypertension (e.g., obesity, type 2 
diabetes). The blood anal sis will be done using the Cholestech GDX and LDX (Hayward, CA, USA), 
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small portable fmger pinprick analyzer. This unit is a valid and reliable instrument capable of obtaining 
results in 5 minutes from one drop of whole blood. The analyzer is a U.S. National Glycohemoglobin 
Standardization Program (NGSP)-certified instrument for the quantification of blood HbAI C (% of total 
haemoglobin), which is directly proportional to the concentration of glucose in the blood over the past 2-
3 months. The Cholestech LDX meets all U.S. National Cholesterol Education Program (NCEP) 
guidelines for precision and accuracy regarding measurements (in mg/dL) of total cholesterol (TC), 
HDL, TG, glucose, TCIHDL ratio, and estimates ofLDL and VLDL. 
Body Composition: Height will be measured without footwear and heels together. The subject will stand 
vertically erect with eyes forward, shoulders relaxed with arms downward. Height will be recorded to 
the nearest 0.2 cm from the highest point on the top of the head using a portable stadiometer. Weight will 
be measured and recorded to the nearest 0.1 kg using a calibrated electronic medical scale. The subject 
will be without footwear and wearing athletic attire. Waist and hip circumference will be measured with 
subjects standing upright, heels together, arms in resting position and breathing relaxed. Waist will be 
measured around the narrowest point (approx. belly button height); hip will be measured at the level of 
the greatest protrusion of the gluteal (buttock) muscles. Both waist and hip measurements will be taken 3 
times each with a flexible-inelastic tape measure to the nearest 0.2 cm and averaged. Skinfold thickness 
(mm) will be assessed at two sites (triceps and subscapular) using a Harpenden calliper (British 
Indicators, Herts, England). Percentage of body fat (%BF) will be calculated using the two-site 
prediction equations developed for children (age and gender specific) :S18 years of age. All body 
composition measures will take place behind a portable curtain for privacy. The parent can be present at 
all tim~s during this testing. 
Tanner Stage: Pubertal maturation will be determined by self-report using the pictures from the Sexual 
Maturation Scale by Tanner (Appendix B). 
Blood Pressure: To verify the values collected in the field (REB 06-315 to Terrance Wade), as well as 
record current and precise readings, blood pressure will additionally be measured in the lab setting 
following the same protocol as the field testing (school data collection) using the BPM-300. Blood 
pressure levels that are:::: 90th percentile but <95th percentile on an age/sex/height standardized normal 
curve will be categorized as pre-hypertensive, while those above the 95th percentile will be classified as 
hypertensive. 
Baroretlex Function: Baroreflex sensitivity will be measured by determining the relationship between 
beat-by-beat heart rate (beats/minute) and blood pressure collected during supine rest. Blood pressure 
will be obtained non-invasively using the finger cuffphotoplethysmograph system known as the 
Finometer (Finapres Medical Systems, Arnhem, Netherlands). This system calibrates finger blood 
pressure to brachial blood pressure by automated sphygmomanometer measures taken at preset times. As 
for heart rate, it will be recorded using 2 sets of3-lead electrocardiogram (ECG). Baroreflex sensitivity 
is calculated as the change in heart rate (beats/minute) in response to a given change in blood pressure 
(mmHg). 
Arterial Stiffuess: Distensibility is an index of arterial stiffness and will be measured in the common 
carotid artery (CCA) using the Doppler ultrasound method. The right CCA will be visually assessed in 
the supine position with B-mode ultrasound video clips using a Doppler ultrasound (Vivid I, GE Medical 
Systems, Horten, Norway) and EchoPAC software (GE Medical Systems). Measurements will be taken 
2-3 cm proximal from where the right CCA bifurcates into the external and internal carotid arteries. 
Diameters corresponding to systole and diastole will be measured, and pulsatile pressure of the left CCA 
will be measured simultaneously by hand-held tonometry (Millar SPT -301, Millar Instruments, Houston, 
TX, USA). Pulsatile cross sectional area and the corresponding pulsatile pressure will be used to 
determine vessel distensibility 
Left Ventricular Mass (L VM!: Numerous studies report that L VM is influenced by blood pressure. 
Therefore, LVM will be measured using non-invasive Doppler Echocardiography (Vivid I). Specifically, 
LV dimensions will be measured in the short-axis view with a 2-dimensional guided M-mode 
echocardiogram according to standard criteria. Three cycles will be obtained and averaged for L VM 
determination. 
NOTE: The above procedures and measurements have been previously approved in REB #04-419 
to Deborah O'Lea 
11. Professional Expertise/Qualifications: 
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Does this procedure require professional expertise/recognized qualifications (e.g., registration as a 
clinical psychologist, first aid certification)? 
[~] Yes [] No 
specify: ECG and ultrasound techniques and methods 
***Blood analysis via pinprick does not require any specific qualifications, 
other than attending a Health and Safety workshop in which all lab personnel 
will be introduced to proper procedures required when handling blood products 
(i.e. protective apparel, disposal of blood products etc.). 
If YES, indicate whether you, your supervisor, or any members of your research team have the 
professional expertise/recognized qualifications required? 
[,/] Yes [] No 
12. Participants: 
Describe the number of participants and any required demographic characteristics (e.g., age, 
gender). 
300 students of hypertensive, pre-hypertensive and normotensive status in grades 6, 7, and 8 from the 
Niagara Catholic District School Board. 
13. Recruitment: 
Describe how an4 from what sources the participants will be recruited, including any relationship 
between the investigator(s), sponsor(s) and participant(s) (e.g., family member, instructor-student; 
manager-employee). 
Attach a COPy of any poster(s). advertisementM and/or letterM to be used for recruitment. 
Students will be recruited from grade 6, 7 and 8 classes in randomly selected schools from the Niagara 
Catholic District School Board stratified across blood pressure group, aggregate community-level SES 
and urbanicity using aggregate socioeconomic census data. 
14. Compensation: 
(a) Will participants receive compensation for participation? 
(b) If yes, please provide details. 
Yes 
[,/] 
I Twenty dollars will be given to each participant as a token of appreciation for participation. 
SECTION C - DESCRIPTION OF THE RISKS AND BENEFITS OF THE PROPOSED 
RESEARCH 
15. Possible Risks: 
1. Indicate if the participants might experience any of the following risks: 
a) Physical risks (including any bodily contact, physical stress, or 
administration of any substance)? 
b) Psychological risks (including feeling demeaned, embarrassed 
worried or upset, emotional stress)? 
c) Social risks (including possible loss of status, privacy, and / or 
reputation)? 
d) Are any possible risks to participants greater than those that the 
participants might encounter in their everyday life? 
[,/] Yes [ ] No 
[ ] Yes [,/] No 
[ ] Yes [,/] No 
[ ] Yes [,/] No 
e) Is there any deception involved? [ ] Yes [,/] No 
f) Is there potential for participants to feel coerced into contributing to [] Yes [,/] No 
this research (e.g., because of regular contact between them and 
the researcher)? 
No 
[ ] 
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2. If you answered Yes to any of la - If above, please explain the risk. 
Physical Risks - Finger pinprick for blood analyses is associated with minor discomfort in the fingertip 
for up to 24 hours. When the surface of the skin is broken, there is always a risk of infection. However, 
with proper precautions taken in the laboratory during (proper cleaning before and after sampling, using 
sterile equipment) and after (adhesive bandage) testing, there is an extremely low risk of infection. 
All Doppler Ultrasound procedures are non-invasive and offer minimal risk to participants. In rare 
instances, participants may experience numbness and/or tingling in the area and/or a minor rash from 
electrode adhesive and/or gel. 
3. Describe how the risks will be managed and include the availability of appropriate medical or 
clinical expertise, qualified persons. Explain why less risky alternative approaches could not be used. 
Participants will be informed prior to the study that they DO NOT have to take part in any procedure of 
the investigation that causes them discomfort. In accordance, participants know that they are able to 
withdraw from the study at any time, and all of their data collected to date will be destroyed. 
Additionally, participants will be instructed to contact the study coordinator if they feel any adverse 
effects from completing any portion of the investigation, and/or if they have any questions or concerns. 
In addition, all laboratory personnel will be sufficiently trained in the testing procedures, as well as being 
trained in the proper, tactful and professional manner of dealing with children of this age. 
16. Possible Benefits: 
Discuss any potential direct benefits to the participants from their involvement in the project. 
Comment on the (potential) benefits to the scientific community/society that would justify 
involvement of participants in this study. 
A potential benefit to the participants includes the identification of any possible serious blood 
pressure/heart anomalies for the child that should be followed up by a general practitioner, as well as any 
underlying cardiovascular disease risk factors. 
Potential benefits to the scientific community and society include the identification of social factors that 
are related to hypertension among children. This should assist in reducing the future incidence of heart 
disease, thus being a potential benefactor to the children themselves, parents, teachers, health care 
providers, along with health programming and policy experts. Heart disease is the number one cause of 
death in Canada and by early identification of the issue, the future health of our nation can hopefully be 
protected. 
SECTION D - THE INFORMED CONSENT PROCESS 
17. The Consent Process: 
Describe the process that the investigator(s) will be using to obtain informed consent. Include a 
description of who will be obtaining the informed consent. If there will be no written consent 
form, explain why not. 
For information about the required elements in the letter of invitation and the consent form, as 
well as samples, please refer to: 
http://www.brocku.calresearchservices/Certification&Polices/Certification&Polices_ APR _Guideli 
nes.html 
Ifapplicable. attach a copy ofthe Letter of Invitation. the Consent Form. the content of any 
telephone script. and any other material that will be utilized in the informed consent process. 
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An initial letter of introduction and infonned consent will be sent home with all children in grades 6, 7 
and 8 at the beginning of the study, from all selected schools, to be signed by the parent or legal guardian 
and the child him/herself and returned to the school (already approved - REB # 06-315 to Terrance 
Wade). For the lab component, randomly selected families stratified across blood pressure group, 
aggregate community-level SES and urbanicity will be mailed a package providing a letter of 
introduction inviting them to participate in the lab component of the study. We will follow up the letter 
with a telephone call to answer any questions, ask for their approval, and arrange a time to come to the 
lab. Upon coming to the lab, the child and their parent will be asked to read an infonnation sheet on the 
study and sign a consent fonn (Appendix A). 
18. Consent by an authorized party: 
If the participants are minors or for other reasons are not competent to consent, describe the 
proposed alternative source of consent, including any pennission fonn to be provided to the 
person(s) providing the alternative consent. 
The parent and child will sign the consent fonn, and the student will be asked to give verbal assent at the 
time of the actual data collection. 
19. Alternatives to prior individual consent: 
If obtaining individual participant consent prior to commencement of the research project is not 
appropriate for this research, please explain and provide details for a proposed alternative consent 
process. 
20. Feedback to Participants: 
Explain what feedback! infonnation will be provided to the participants after participation in the 
project. Include, for example, a more complete description of the purpose of the research, and 
access to the results of the research. Also, describe the method and timing for delivering the 
feedback. 
Participants and their parents will have access to their own data if they are interested by contacting the 
researchers. They will also have access to group data when it becomes available through a feedback 
report sent to participating schools descnbing the main findings of the research. 
21. Participant withdrawal: 
a) Describe how the participants will be infonned of their right to withdraw from the project. 
Outline the procedures that will be followed to allow the participants to exercise this right. 
The letter of introduction and infonned consent will make it known to both the parent and child that they 
can opt not to participate at no risk, cost, or negative impact. As well, it will be made known at the time 
of measurement that each child can choose not to participate in any or all tests if they so choose. 
b) Indicate what will be done with the participant's data and any consequences that withdrawal 
might have on the participant, including any effect that withdrawal may have on participant 
compensation. 
If a parent or child refuses to participate in any specific test, the research assistant will proceed to the 
next test. If a parent or student chooses to withdraw completely from the study at any time, their 
complete data will be removed and deleted from the electronic database. We will keep their consent fonn 
on file. If they visit the lab at Brock and, after signing the consent fonn, begin the testing, they will 
receive the promised honorarium regardless of whether they choose to complete any or all testing 
protocols. 
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SECTION E - CONFIDENTIALITY & ANONYMITY 
Confidentiality: information revealed by participants that holds the expectation of privacy. This 
means that all data collected will not be shared with anyone except the researchers listed on this 
application. 
Anonymity of data: information revealed by participants will not have any distinctive character or 
recognition factor, such that information can be matched (even by the researcher) to individual 
participants. Any information collected using audio-taping, video recording, or interview cannot 
be considered anonymous. Please note that this refers to the anonymity of the data itself and 
not the reporting of results. 
22. Given the definitions above, in the student project(s): 
a) Will the data be treated as confidential? [J Yes [,(] No 
b) Are the data anonymous? [ ] Yes ['(J No 
c) Describe any personal identifiers that will be collected during the course of the research 
(e.g., participant names, initials, addresses, birth dates, student numbers, organizational names 
and titles etc.). Indicate how personal identifiers will be secured and if they will be retained 
once data collection is complete. 
We will have parent/guardian name, address, and phone number and child name and school name on file. 
This information will be separated from the data file and linked by an identifying variable only_ The 
identifying information and linking variable will be retained once data collection is complete to facilitate 
subsequent components of this study, but will be kept separated from the data file by the principal 
investigator and/or his representative(s). 
d) If any personal identifiers will be retained once data collection is complete, provide a 
comprehensive rationale explaining why it is necessary to retain this information, including the 
reteution of master lists that link participant identifiers with unique study codes and de-
identified data. 
This study will be conducted in a series of phases including a population screen, a detailed laboratory 
component, and the development, implementation, and evaluation of interventions. In this REB 
application, we are asking for approval for the laboratory component of the study only. At the time in 
which the protocol for each subsequent phase is finalized, we will seek REB consent at that time. As such, 
we will keep the personal identifying information that we collect from the lab component to facilitate 
direct contact with participants for future involvement in subsequent aspects of this study and for linking 
with subsequent data collection efforts. 
e) State who will have access to the data. 
The de-identified data will be available to all researchers named in the project and their representatives 
including employees hired for the project, along with graduate and undergraduate research assistants. All 
persons who access to identifiable data other than the named researchers will sign a confidentiality 
agreement with the Principal Investigator. Other students may be given access to the de-identified data 
for research and thesis projects as approved by the investigative team. Community service partners will 
have access to aggregate results of the de-identified data but not to the individual level data itself. 
Participants and their parents will have access to their own data if they are interested by contacting the 
researchers. 
f) Describe the procedures to be used to ensure anonymity of participants and/or confidentiality of 
data both during the conduct of the research and in the release of its findings. 
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All results that are to be publicly released will be done so only in aggregate fonn and will not identify 
specific individuals or families. 
g) Ifparticipant anonymity and/or confidentiality is not appropriate to this research project, 
explain, in detail, how all participants will be advised that data will not be anonymous or 
confidential. 
h) Explain how written records, video/audio tapes, and questionnaires will be secured, and provide 
details of their final disposal or storage, including how long they will be secured and the disposal 
method to be used. 
All paper data will be stored in a locked filing cabinet in a secure research lab that is alanned. Access to 
the lab is monitored and restricted to approved personnel only. All data will be secured and stored for 7 
years after the study. After this time, documents will be destroyed using a shredding machine/service. 
SECTION F -- SECONDARY USE OF DATA 
23. a) Is it your intention to reanalyze the data for purposes other than described in this application? 
[,(] Yes [] No 
b) Is it your intention to allow the study and data to be reanalyzed by colleagues, students, or 
other researchers outside of the original research purposes? If this is the case, explain how 
you will allow your participants the opportunity to choose to participate in a study where their 
data would be distributed to others (state how you will contact participants to obtain their re-
consent) 
Participants will be infonned on the consent fonn that their electronic data will be kept for further 
analysis beyond the original purposes of the study. They will be asked to provide infonned signed 
consent of this to approve or deny the future use of their data beyond this study. They will also be 
infonned that they have the option at any time to request that their individual data be removed from any 
and all subsequent analyses beyond the date in which they make this request. 
If there are no plans to reanalyze the data for secondary purposes and, yet, you wish to keep the 
data indefinitely, please explain why. 
SECTION G -- MONITORING ONGOING RESEARCH 
24. Annual Review and Serious Adverse Events (SAE): 
a) Minimum review requires the completion of a "Renewal/Project Completed" fonn at least 
annually. Indicate whether any additional monitoring or review would be appropriate for this 
project. 
It is the investigator's responsibility to notify the REB using the "RenewallProject 
Completed" form, when the project is completed or if it is cancelled~ 
http://www.brocku.ca/researchservicesiFonnsiForms.htmi 
Additional review of the overall project and the subsequent data collection phases will be submitted to 
the REB as appropriate as indicated above. 
*Serious adverse events (unanticipated negative consequences or results affecting 
participants) must be reported to the Research Ethics Officer and the REB Chair, 
as soon as possible and, in any event, no more than 3 days subsequent to their occurrence. 
25. COMMENTS 
If you experience any problems or have any questions about the Ethics Review Process at Brock 
University, please feel free to contact the Research Ethics Office at (905) 688-5550 ext 3035, or 
reb@brocku.ca 
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FROM: 
TO: 
Linda Rose-Krasnor, Acting Chair 
Research Ethics Board (REB) 
Terrance Wade, Community Health Sciences 
Paul Leblanc, Deborah O'Leary 
",-,FI=L=E::.--: ___ 07-060 - WADE 
DATE: October 1, 2007 
The Brock University Research Ethics Board has reviewed the research proposal: 
Social Determinants of Child Hypertension -
The Research Ethics Board finds that your proposal requires clarification: The researcher 
may proceed with the work as soon as the following issue(s) have been addressed and 
received clearance by the Board: 
Section A - General Information 
5 - Other Ethics Approval/Permission 
Please forward approval from the NCDSB once ithas been obtained. 
**Thi~'approvalwill besought upon receiving Brock University Ethics approval 
Section D - The Informed Consent Process 
Consent form 
Please explain the Tanner stage instrument and how it will be administered. Will 
parents be present? 
*,*The;1l;~niJerSt~ge in~!rurr{e~thasjjeen rrmoviJ4,. I'!Jtsplace,s)5eletait;n4~trrlfy 
asses:mi~flthaslJeen(laded ...•. Tl1rsis4ng1J~~iJ~(Jsive.proced~reus,ing t~f Sunlight 
B()1Jij.geT~Systern.($unlightM.e(Jj~{llj/Lfd,tel)1xiv, ·lsrael).to4eterw:lne..~kel(!tarage; 
i'hisprotoc()[ haspn~vFduslyb~¢flapproyedin:REB04-419 to.lfelJOrahO'Leary 
* *p}c,{jse'see{lttach11)Jmt e.ntitl~4.;'()yerYiewojlab Vjsitand r~~tingJ?;r()ce¢uresJ; body 
cp:iijiositi()11;paragraph .. ". .'. .. . 
F'arentsWfll be Hdvitedto bep~esentfdfi'altie'sting during {heiah yisit 
18 - Consent by an authorized party 
Please clarify the verbal assent process and provide a script or guideline for 
obtaining verbal assent. 
**pl~d~f!sJliaitaC0n1entent#led 'ErSeat, Verbal /l$senfGuidelfljes'jor a deiailecl\()utlin~ 
of the t~ifphone scrip(joy obtaining verbalassent' 
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* *As. well: pleaseseeatiachmententitled . '}{/JeatConsmt}'orm ,!ortne comentfar,m 
that parentsGlJd childrerf~ill read and SIgn in thelab pr,ior> to testing (hat will again 
detail the lab tests and testing protocoL 
Please add a statement to all participant materials that advises parents to keep a 
copy for their own records. 
* *pleasesee'attacfiment entitled 'InfornwtiCm Leiter tol?:drent$J,paragrapn' three. 
**As well, wewili}xrovidethem with a c:opyoftneconse~if6rmat their lab visit. 
20 - Feedback to Participants 
In your application, you state that parents may access their individual child's 
results by contacting the researchers. This information should appear in the consent -
form. What explanation would accompany these results? Please make it clear to parents 
that results are not diagnostic. 
* *please see attachnJe'htel1titl~d 'Information and>Cons(;nt; fQi':;this. information. 
For each point of clarification, please highlight the changes you have made on the 
corresponding documents. 
If you would like further information or assistance in responding to these clarification 
requests, please contact Lori Walker (ext. 4876) in the Research Services Office. 
No research with Human Participants will commence prior to receiving ethics 
clearance from this board. 
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AppendixB 
Parental Information form 
Dr T_ Wade. m 4146. twade®brodw.Q 
Dr. OeOOi'ali Cl'lJlalY • ext 4339. dll!~.Q 
Dr; PaulleBlam: « m 4116 • pleblanc@brodw.G! 
ROO!lltly you W'efe contacted by HBeat (Heart Booavloural Envirollmootal AssMlimellt Team) regarding your child beIng randomly (!men to 
partldpate III the sIDllnd phase aHhe mSllardlstudy to examIne high blood pressure {hypertooskm}. Thank youfm' volunteering to participate In the 
second phase of the study! As W'e discussed, you am! your chUd I!kely already completed some questionnaires that were sent home from school for 
the fll'lit phase of the study. At school your chUd also had their blood pressure, height" W'e1g1Jt, hlp and waist circumference measured and completed 
some questkmnalres about their physical actMty: 
For Ihls pha>!! of Ihe study, the testing wUI ~ place at Brock Ulllverslty. The total testing mould take about 1'h hool'li. We ask that the parootl 
guardian Is presl!l1t for at least the first half-hour. Your child wlll reali'll! $2Q as a tokl!l1 of our 3ppredatkm for you and your child's pal1lc!patlon In 
thts phase oHhe study. 
Although WI! already dlscu5S'ed some of this Informal1on owrthe pOOIl!!, WI! ask that you mad the attachi!d Informatkm fOl"m detailing the vlslt am:! 
testing procedures Ihat will be dOlle (OWrvtew of lab VIsit and Testing Procedures}, ;!flO keep the Illmnnation for your records. 
Some factm sudl as mod, ex@rcls@ and temperature, may affect the lab tests. TherefOl"e, WI! ask that your child does not eat or drink anything extept 
water OIK1! they go to bed the night before testing. We will provid!! your child with an allergy-sensitive meal that morning. We aiso ask that your 
chIld avoids caffeine (f0l" example, roifee, tea, mla) and ri!fralns from eXNdse til!! morlling of testlng.FlIlally, your chIld should either be dressed III 
alhlet!c at!!re (shorts, t·shlrt; or tank top and running shoos) or bring these dothes to the testing sessloo. 
At the beginning of yoor \IIslt to Brodt Un!wrslty, we wll! go OWf the lab procedure and you will have an o(lf.lOl"tunlty to ask any questions filiated 
to the tests. Once you are 5atlsfted, WI! win have you and your child sign a (onsl!l1t form to allow your child to partfclpate In this phase of the H!leat 
research study. 
This study has been fl!1llewed and apprrnted by the Research Ethk:s Boards from both Brodt UnlV!!r5lty and the Niagara catholic District School 
Board. If you have any questloos about the study 01" lab testing pmcedur~ please contact Dr. DebOl"ah O'Leary at 905·688·5550 (;.:4339), Dr. Paul 
leBlanc at 9Q5-6S8-5550 {x4216}, or Dr. Terrance W<KIe at 905-688·5550 (;.:4t46). If you have any further qu!!Stlons rngardlng your rIghts as a 
research partlt:fpant contact the Research Ethics OOker !nthe Office of R!!>earm SerVices at (g(5) 683-5550 (x3035) or I!l1I3I1 at fIlb@brocku.ca. 
Terrance 1. wade, Ph. D. Paullel:!lallc. Ph.D. 
, Principal Investigators: Dr. Terrance J. Wade • Dr. Deborl!h IYI.e1!ly" Dr. 101m Calmey 
Co-Investigators: Dr; !'au! LeBIaru: • Ill: JillnlJll • Dr. Colleen Hood. 01. Joim Hay • Dr. PanayiDla ~entrOll • Dr. Brian lilly. Dr. !}awn Zinga • Dr. Kevin Sh!lll'lllllker 
• File 06-315 WADE: lI£seartb SeMces • Brode UlrivIlrsllv • Room (315 • 005.688.5550 ext 4315 
Brock University 5 1. CAT K A II ! N fi S • 0 N T A II I 0 (A III A n A • W W W • B it 0 C Ie. U • C A 
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Appendix C 
Informed Consent and Data Package 
SOCIAL DETERMINANTS OF CHILD HYPERTENSION 
Your mlkl _________________ Is illVited to partlclpaU! In a researdl stut:!y befng (ooductMI by the 
Investigators listed belO'lM Prior to participating In this stut:!y you are asl:ed to read and slgn this form, which ooIilnes the purpose and gives a detailed 
description of the ti!!st1ng procedures used in full study, The testing procedures wUl be conducted at Brock university. 
Primary fnvestmatm Department Pllone EITIail 
Dr.li1fr.mce 1 Wade 
Dr. Deborah O'leal)' 
Dr. !'aulleBlanc 
PURPOSE 
Community Health Sdem:es 
Community Health SdOOCllS 
Community Health SdOOC9S 
(905) 688-5550 )(4146 
{90S} 688-5550 x4339 
(905)688-5550 x42.16 
tvIIadM:llbrod!:u.ca 
do!eary@brod:u.Gl 
pleb!aoc@brod!:u.G 
Adults ill canada and the United States have a 900/n lifetime risk of dellllloplng high blood pressure, afro lmown as hypertllllsioo. High blood 
pressure (HSP) Is 000 of the strongest predictors of heart disease. some sc!llIlttsts 5uwe>l: tltat HSP may start In childhood, but we do nol: know 
what factors may be 1I1\10l\1m This >l:udy will help us I!'arn what factors may contribute to childhood hypertension. If W!! can learn what these 
factors an?, we might be able to offer suggestions to families, schools, and mmmunHies to Improvll the heart health of children. Th!s knowledge 
muld help al! children In Canada l!llld healthIer livlls llnd reduce thillr chanm of havIng heart disease as adUlts. 
OVERVIEW OF tAB VISIT 
Upon arrlllal at Boo. University, you and your mild will be famlliarized with the laboratory and the tllStlng procedures will be llJ(plalned. Once 
you <Ire satisfied with thl! (>xpianatlon of the testing procedures, you and your child win then be asKed to read the Information sheet about the 
study and slgn the mnsllllt form. If your child is not <llready wearing athle1!c attire, sllt!!Ite will be asKed to change In the washroom. 
The testing will begin with the child's blood test using a finger prick to obtain WID Of three tfmps of blood for analysis. RlllowIng this, your mlld 
will 00 givlll1 an allergy sllns!tille bi'l!akfast btlfOrl! any further testing. 
Am they haw ilnl5hed breakl'ast,they wI!! also be asked to empty th!!lr bladder; as this has been mOWll to have an effect 00 blooo pressure. 
Before testlllg blood pressure. :your chlkl wi n be til <I sitting position fur t 5 minutes. Then their blooo prllSsure will be tal:en uslng an automatic 
blood pressurl! monitor {tim same unit that was PnMously used In school to measure your child's blood pressure}. 
Next, your chlld's weight, height, sklnfold thickness. waist cfrruffiferooce, hlp orrumferencl!, and skeletal maturity wm be rocorded. Finally. the 
child will lie demn and have herihls heart rate monftorl!d amI hall!! their heart and right carmld artery (artery In the neck) Imaged uslng Doppmr 
ullrasound (the same type of ultrasound seooln a hospltJl). At the end (If testing. your child wi" rl!Cllllie $20 as a tol:en of our appredatlon for 
your In\lOh/ement In the ~tudy. 
l'arem, are more than welrome to be presem for testing. 
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OVERVIEW Of TESTING PIHl€EDURES 
The fullowlng procedures <Ire described In furlh!!!' limn below: 
Blood Analysfs 
Blood Pre~sure Measurement 
Body COOIposltlon 
Hllan Rate 
Clrotld Artmy and Heart Ultrasound 
TESTING PROCEDtI RES 
Blood Analysis 
OVERVIEW OF LAB VISIT AND TESTING PROCEDURES 
ring!!!' pinprick blood sampling· The mMdle fing!!!' of '!he non·domlnant hand (e.g. If rf!#lt haru:l!!d. the mkld!e finger of till! left hand wUl bl! used) 
wUl be prrdmd 50 two drupe; of blood GI!1 be sampled. They wiH fee! too small prki but wfll not fee! any pain or dlsrornfurt for the remalnd!!!' of 
the sampling. The tip of that finger may feel sensitllie and a llttle bit sore ior about a day. It is Important to ke!!p the site dean and covered with 
an adheSive bandage until It 15 healed (up to 24 hours) to mlnlmlz@ any risk of Inf@ctlon. 
Blood Pressure 
Blood pr~5urllls monitored ~jng a non-invaslve metllod. The method IfllI()wes an automated arm cuff system tIlat Is slmllar to '!he me'!hod ~ed 
In a dorll:i!'s offJce. A (Uff Is wrapp~ around '!he upj:l!!!' arm and ts Inflatoo tIl!!ll deflated. After sitting In a msting posfUon for 15 minutes, '!he 
mild will nave their blood pressure tak!!ll automatically, j) tlmes In 1 minute lllt!!fvais. No lisl< Is Involved. 
Body Composition 
All 00dy composltloo measures wll! take place b!!hlnd a portable curtain for pr!ll:acy witll the parent pmsent If desired. Height, weight, hip and 
waist OfUlmfe!!!Ilce wll! be meii~ured. Skjufokl thickness wll! 00 as5!!5:sed uslng a non-Invasive me'!hod that measures skin thickness. TOO test!!!' 
plnrnes the skin at tile appropriate site to raIse a double lay!!!' of skin and '!h! underlying :adlpow tissue, but not tIl@ muscle. TIl! calipers afe 
tIlen appf!!ld at rt9ht angles to the plnm ami a reading is tal<!!ll. Sklnfold measures win be taken 111 two sltes lIldudlllg too subscapular UOWf!f 
shoulder blade} and trla!p5 {back of the upper arm). No risk Is, Invu!lIIld. Next, your child's forearm, Iow!!f leg and wrts[ will bl! measured using 
Doppier ultrasound to gauge skeletal maturlty. Th@ ultril50Und tedJnlque used Is completely mill-Invasive and srmnar to that used to vlsua!!z@ til! 
dilvmopment cqf a baby diJrlllg prllg!1at1l.1'. Again, no risk Is lIlvoIved. 
lfeartRate 
Heart rate will be J!l!!il5ured uslng sensors placed 00 too skin of your child's upper mest. These sensors are electr"Ooos used to detect the electrical 
actMtll generated by the heart ami do not transmit electrical signals Into the body from too heart rate monitor. No risk Is fnvolved. 
Carotid Artery and Heart Ultrasound 
All carotid ilrtmy and heart ultrasound measures will be taken In a lylng posmon In a prIVati! room. In addition to the ultrasound pffilllOllsly men-
11oned, two more ultrasound measures Will be performed. Am, the (amfki artelY ultrasound will be performed using 1I small transducer to Visual-
Ize '!he carotid art!!!'y. As we!!, G1mtki artery blood pressure will bl! s!mll!taooousfy obtained us!ng a thin pen-Uke deVIce that is Ug!Jt!y pressoo 
against the neck. Both tIl@ probe and pen IIke-aeVlG! willl:le pffiS5ie!! against too nocK on opposlm slde!;. It Is a non-invaslve plUCl!dur!!. Second, 
tile ultrasound of the heart will be performed with a small prob!! placed between your child's ribs: on the !eft side of '!helr cheM.ThIs procedure Is 
also non·lIlvaswe and no rlsk 15 Invowe!!. 
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'OVERVIEW OF LAB VISIT AND TESTING PROCEDURES 
POTENTIAl.. RISKS AND DISC:OM FORU 
Please refer to the "Testing Procedures n Prl!Viooily mentioned for a mmpkltl! dllSQ'fptkm of the proclldures to be performed dunng the study 
and the potentia! !ish assoclatoo with these procedures, If an injury occurs at an}' time during the Investigation, approp!iatei'lrst aidlCPR will 00 
admfllistered ami you wllfbe advised tr> seek nocessary medica! help. 
BENEfiTS AND REMUNERATION 
A potential benefit fur your child's partldpatlon In this project Is the knowledge of their blood pressure, heart and artery asse5Sment, as wen 
as an}' umienylng cardiovascular disease risk factoo. Your d'llkl will also be reimbursed $20 as a token of oor appreciation fur yoUiyour ,Md's 
Involvement In the study. 
CON f I D EN 'HAlITV 
All data ml!ected during tMs study",,'IlI remain confidential and stored in offims and on 500lred computers to whld'l only the princlpallnves· 
tlgators, CO·IIlV!!5tlgatOrs, project coomlnatDr, and researm asslstants wi II haw access. 1he electronic fjie containing your answl!rs and bOOy 
measurements will enly contain a unique ldentlTlcatkm number and no other Identifying Information te ensure your Information Is completely 
anonymous. You should be aware that the results of this stucly Mil be made available to the sdentlflc community. through publication In sdentiflc 
jouma!5; how~ver. we wll! only use the clllllblned data from famllies solhat no single mild or family carl be kient!fled. )'00 will have acmss to 
your mUd's dati, as weI.! as the group data when It becomes available ami if you are Interested. Please contact the researchers directly if you 
wish to obtain this Information. 
RARTICIPATION AND WITHDRAWAL 
You can choose whether your mild partlctpates fn th!, study Dr oot. You may exercise the optlon of removing your mild's data from the study If 
you wish. You may also rofuse to answer any question. posed to you oodlor yoor dlild durtn!} the study and stm remain as a partldparrt In the 
study.1he illVestlgators resewe the right to wtthdraw your mild from the study If they believe that cirrumstmces have a!isen which warrant 
doing so. 
RIGHTS OF RESEARCH PARTICIPANTS 
Yoll may withdraw your consent to parncipate In this study at any tlme, and you may also dlsmntfnue the partiCIpation of YOW' child at any tlmll 
without penalt}t In slgnlng this mns!!ntform Dr In participating In this study you ar!! not waiving any legal dalms or remedies. litiS stucIy has 
been fl!'llewed and received clearance from the llI'ock University Researm Ethks Board {Ale 014160 -WADE}. if you have any further qU!!5t!0n5 
regarding your rights as a research partlcfp.lflt contact the Research Ethics Officer In the Office of Research Services at (90S) 6811-5556 x3035 or 
emall at reb@brodru.ca. 
IN FOR M AT! 0 N 
Please contact Dr. Deoorah o'teary at 905-68&.5550 {x4339l. Dr. Paul LeBkmc at 90%88·5550 {x4216} Of Dr. Terrance wade at 905-68!l·555(J 
(x4146) 1f}'Oil have any questions about the study. 
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INfORMED CONSENT 
I have read and understand the above explanation of the purpose and procedures of the project and j am aware of 
the potential risks and my rights as a research participant. I understand that I can gain access to my child's individual 
results by contacting the researchers, and I understand that these results are oot a dinkat diagoosis. My questions 
have been answered to my satisfaction and I agree to allow my child to participate in this study. 
CONSENT FORM 
0 ! ~ pemli>5lon ffrf my mild to partidpate ill the BnJci: Unhr1!fslty HS€at lBD component conducted by Dr. !!!france L WadE; Dr. DeOOr.ll O'Leary and 
Dr l'aullef!1aoc 
0 ! liil oot 11M: perrntssloo Tfrf my {nlhl til participate In tlle Bn:Kk Unwersily H!:leat lab {ornpollent cooom:tro by Df. maw.e 1 Wade. Dr. DeOOrnh O'leary and 
Dtl'aulleBlaoc 
SIgnature of Paroo!1Guardlan: Date: 
Printed Name of ParnntfGuan:!iall: 
Signature of S~l'lt !}aw: 
Prlllted Name of Student 
in additioo to the current study, data collectw may be used later to answer other research questioos that may arise from this study. We 
woo!dJike your permission to keep the information that you and your child pmvidw on file after this f5earch study is over. All storw 
personal data will be kept strictly wnfidential and all i nformalion will be mdw so that no one will Ire able to Identify you or your child. 
At any tIme, you can ask to have your information removed and not indudw !n any fl.ll:tlre projects by contacting Dr. Terrance 1. Wade 
{905·688-5SS0 ext 4146) or Dr. Deborah O'Leary (9fl!i-68&-555Q ext 4339). 
!Il my judgment !he partlclpant Is lIo!untartly and koowlllgly gMng Infooned (OOseRt and possesses the lega! Gljkllfiy to give iofulfl'lJ!d ronsent 
and participate in tlll£ researrn study. 
SIgnature of Investigator: Date: 
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AppendixD 
Participant Information 
LABORATORY INFORMATION SHEET 
Date: __________________________ __ Time (am/pm): _____ _ 
Student ID#: 
Gender: 
Allergies: 
Medical Concerns: 
Height: 
____ cm 
Name: 
DOB(mmddyyyy): 
Medications: 
Sitting Height: ____ (-74) = Weight: 
_____ cm ____ kg 
Age: 
BMI: 
(kg/m2) 
SECTION 2: QUESTIONNAIRES and CONSENTS 
STUDENT PARENT 
1. Consent (signed): Y N 1. Consent (signed): Y N 
2. Current Med History: Y N 2. Missing Data (PQ & CQ), Sleep Questionnaire: Y N 
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Examiner: 
SITE TRIAL 1 (mm) 
SUBSCAPULAR 
TRICEPS 
SUM OF SKIN FOLDS: _____ (mm) 
1. Have you had your period?: Y 
3. How often do you get periods?: 
__________ days 
N 
TRIAL 2 (mm) TRIAL 3 (> Imm) MEDIAN (mm) 
PERCENT BODY FAT: _____ (%) 
2. How old were you when you first had your period?: 
_____ yrs 
4. How long does your period last for?: 
__________ day~ 
SECTION 6: ARTERIAL MEASUREMENTS 
Examiner: 
Frequency: 10.0 mHz Power: 0 dB Persistence: turn to minimum 
Pre 1 Post 1 
2 2 
3 3 
92 
Systolic Diameter: mm Compliance: 
Diastolic Diameter: mm Distensibility: 
Diameter Change: mm CaPP: mmHg 
Baroreflex Sensitivity: MeanHR: 
SECTION 7: LEFT VENTRICULAR MASS MEASUREMENTS 
Examiner: 
Probe: _____ _ Depth: _____ cm 
B-Mode Images: M-Mode Images: 
Interventricular Septum (end-distole): cm Ejection Fraction: 0/0 
Left Ventricular Diameter (end-diastole): cm Circumferential Fiber Shortening: % 
Left Posterior Wall (end-diastole): cm Stroke Volume: mI 
End Diastole Volume: ml Left Ventricular Mass: g 
End Systole Volume: mI Left Ventricle Mass Indexed by BSA: g/m2 
Left Ventricle Mass Indexed by HT: 
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AppendixE 
Years from Peak Height Velocity Equations 
Peak Height Velocity Equations 
Boys predictive equation: (Eq. 3) Maturity Offset = -9.236 + 0.0002708· Leg Length and 
Sitting Height interaction -0.001663· Age and Leg Length interaction + 0.007216· Age 
and Sitting Height interaction + 0.02292· Weight by Height ratio 
Where R = 0.94, R2 = 0.891, and SEE = 0.592 
Girls predictive equation: (Eq. 4) Maturity Offset = -9.376 + 0.0001882· Leg Length and 
Sitting Height interaction + 0.0022· Age and Leg Length interaction + 0.005841· Age and 
Sitting Height interaction -=-0.002658· Age and Weight interaction + 0.07693·Weight by 
Height ratio 
Where R=0.94, R2=0.890, and SEE = 0.569. 
Mirwald RL, Baxter-Jones ADG, Bailey DA, Beunen GP. (2002). An assessment of 
maturity from anthropometric measurements. Medicine & Science in Sports & 
Exercise, 34(4), 689-694 
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AppendixF 
BP Levels for Boys and Girls by Age and Height Percentile 
BP Levels for Boys by Age and Height Percentile 
Age BP SBP !mmH~~ 
(years) Percentile Percentile of Hei~ht 
5th 10th 25th 50th 75th 90th 95th 
11 50th 99 100 102 104 105 107 107 
90th 113 114 115 117 119 120 121 
95th 117 118 119 121 123 124 125 
99th 124 125 127 129 130 132 132 
12 50th 101 102 - 104 106 108 108 110 
90th 115 116 118 120 121 123 123 
95th 119 120 122 123 125 127 127 
99th 126 127 129 131 133 134 135 
13 50th 104 105 106 108 110 111 112 
90th 117 118 120 122 124 125 126 
95th 121 122 124 126 128 129 130 
99th 128 130 131 133 135 136 137 
14 50th 106 107 109 111 113 114 115 
90th 120 121 123 125 126 128 128 
95th 124 125 127 128 130 132 132 
99th 131 132 134 136 138 139 140 
Age BP DBP (mmHg) 
(years) Percentile Percentile of Height 
5th 10th 25th 50th 75th 90th 95th 
11 50th 59 59 60 61 62 63 63 
90th 74 74 75 76 77 78 78 
95th 78 78 79 80 81 82 82 
99th 86 86 87 88 89 90 90 
12 50th 59 60 61 62 63 63 64 
90th 74 75 75 76 77 78 79 
95th 78 79 80 81 82 82 83 
99th 86 87 88 89 90 90 91 
13 50th 60 60 61 62 63 64 64 
90th 75 75 76 77 78 79 79 
95th 79 79 80 81 82 83 83 
99th 87 87 88 89 90 91 91 
14 50th 60 61 62 63 64 65 65 
90th 75 76 77 78 79 79 80 
95th 80 80 81 82 83 84 84 
99th 87 88 89 90 91 92 92 
* The 90th percentile is 1.28 SD, the 95th percentile is 1.645 SD, and the 99th percentile is 2.326 SD over the mean. 
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BP Levels for Girlss by Age and Height Percentile 
Age BP SBP (mmHg) 
(years) Percentile Percentile of Hei!ilht 
5th 10th 25th 50th 75th 90th 95th 
11 50th 100 101 102 103 105 106 107 
90th 114 114 116 117 118 119 120 
95th 118 118 119 121 122 123 124 
99th 125 125 126 128 129 130 131 
12 50th 102 103 104 105 107 108 109 
90th 116 116 117 119 120 121 122 
95th 119 120 121 123 124 125 126 
99th 127 127 128 130 131 132 133 
13 50th 104 105 106 107 109 110 110 
90th 117 118 119 121 122 123 124 
95th 121 122 123 124 126 127 128 
99th 128 129 130 132 133 134 135 
14 50th 106 106 107 109 110 111 112 
90th 119 120 121 122 124 125 125 -
95th 123 123 125 126 127 129 129 
99th 130 131 132 133 135 136 136 
Age BP DBP ~mmH!il~ 
(years) Percentile Percentile of Hei!ilht 
5th 10th 25th 50th 75th 90th 95th 
11 50th 60 60 60 61 62 63 63 
90th 74 74 74 75 76 77 77 
95th 78 78 78 79 80 81 81 
99th 85 85 86 87 87 88 89 
12 50th 61 61 61 62 63 64 64 
90th 75 75 75 76 77 78 78 
95th 79 79 79 80 81 82 82 
99th 86 86 87 88 88 89 90 
13 50th 62 62 62 63 64 65 65 
90th 76 76 76 77 78 79 79 
95th 80 80 80 81 82 83 83 
99th 87 87 88 89 89 90 91 
14 50th 63 63 63 64 65 66 66 
90th 77 77 77 78 79 80 80 
95th 81 81 81 82 83 84 84 
99th 88 88 89 90 90 91 92 
* The 90th percentile is 1.28 SD, the 95th percentile is 1.645 SD, and the 99th percentile is 2.326 SD over the mean. 
National High Blood Pressure Education Program Working Group on High Blood 
Pressure in Children and Adolescents. The fourth report on the diagnosis, 
evaluation, and treatment of high blood pressure in children and adolescents. 
Pediatrics 2004;114(2):555-76. 
96 
AppendixG 
Statistical Output 
Descriptives of Children Within Each BP Category 
o = high BP 
Std. 
N Mean Std. Error 
l=nonnal Deviation 
BP 
0 85 .3412 .47692 .05173 
Sex (M/F) 1 21 .4762 .51177 .11168 
Total 106 .3679 .48453 .04706 
0 85 12.7637 .81889 .08882 
Age (years) 1 21 13.0564 .91345 .19933 
Total 106 12.8217 .84210 .08179 
0 85 157.9812 9.28567 1.00717 
Height (cm) 1 21 160.5524 9.42595 2.05691 
Total 106 158.4906 9.32538 .90576 
0 85 49.7035 11.93021 1.29401 
Weight (kg) 1 21 68.6048 21.53250 4.69878 
Total 106 53.4481 16.10819 1.56457 
0 85 19.7531 3.57676 .38795 
BMI (kg/m2) 1 21 26.3871 7.1362 1.55725 
Total 106 21.0674 5.19548 .50463 
0 85 -1.7080 .80756 .08759 
PHV (years) 1 21 -1.6800 1.04358 .22773 
Total 106 -1.7025 .85399 .08295 
0 85 90.7725 5.00845 .54324 
SBP (mmHg) 1 21 110.1429 6.11198 1.33374 
Total 106 94.6101 9.34656 .90782 
0 85 55.1431 4.77857 .51831 
DBP (mmHg) 1 21 70.8810 5.38443 1.17498 
Total 106 58.2610 7.96945 .77406 
95% Confidence 
Interval for Mean 
Minimum Maximum 
Lower Upper 
Bound Bound 
.2383 .4440 .00 1.00 
.2432 .7091 .00 1.00 
.2746 .4612 .00 1.00 
12.5871 12.9404 11.21 14.34 
12.6406 13.4722 11.58 14.49 
12.6595 12.9839 11.21 14.49 
155.9783 159.9840 134.00 174.50 
156.2617 164.8430 142.30 177.10 
156.6946 160.2865 134.00 177.10 
47.1302 52.2768 28.50 94.00 
58.8033 78.4062 38.50 124.60 
50.3459 56.5504 28.50 124.60 
18.9816 20.5245 14.01 32 
23.1388 29.6355 17.11 41.92 
20.0668 22.0679 14.01 41.92 
-1.8822 -1.5338 -4.19 -.01 
-2.1551 -1.2050 -3.18 .65 
-1.8669 -1.5380 -4.19 .65 
89.6923 91.8528 81.67 106.00 
107.3607 112.9250 98.83 125.33 
92.8100 96.4101 81.67 125.33 
54.1124 56.1739 46.00 64.50 
68.4300 73.3319 58.17 81.67 
56.7262 59.7958 46.00 81.67 
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0 85 67.0196 4.38267 .47537 66.0743 67.9649 59.22 77.67 
MAP (mmHg) 1 21 83.9683 4.84973 1.05830 81.7607 86.1758 74.33 94.17 
Total 106 70.3774 8.11885 .78857 68.8138 71.9410 59.22 94.17 
0 85 807.6956 96.96434 10.51726 786.7809 828.6104 554.41 1059.45 
RRI 1 21 715.1654 93.42623 20.38727 672.6382 757.6925 583.12 978.40 
Total 106 789.3642 102.74900 9.97987 769.5759 809.1524 554.41 1059.45 
0 85 34.6705 5.04592 .54731 33.5821 35.7589 21.33 48.33 
Pulse Pressure 1 21 39.8814 8.13981 1.77625 36.1762 43.5866 24.67 56.33 
Total 106 35.7028 6.11099 .59355 34.5259 36.8797 21.33 56.33 
0 85 730.4086 520.07809 56.41039 618.2303 842.5868 1.78 2650.48 
LF RRI 1 21 448.9332 329.74437 71.95612 298.8353 599.0310 85.25 1220.19 
Total 106 674.6446 499.80211 48.54507 578.3887 770.9005 1.78 2650.48 
0 85 908.7187 959.86239 104.11169 701.6812 1115.7562 7.48 7215.56 
HFRRI 1 21 455.2583 580.88155 126.75875 190.8442 719.6724 29.32 2495.86 
Total 106 818.8822 913.40987 88.71821 642.9704 994.7940 7.48 7215.56 
0 85 1612.1574 1343.17525 145.68781 1322.4412 1901.8736 9.26 9008.47 
Total Power 
1 21 904.1915 787.30525 171.80409 545.8144 1262.5685 124.65 3101.76 
RRI 
Total 106 1471.9000 1281.30638 124.45148 1225.1357 1718.6643 9.26 9008.47 
0 85 1.0736 .74294 .08058 .9134 1.2339 .21 3.94 
LF/HF RRI 1 21 1.6431 .99718 .21760 1.1891 2.0970 .24 3.90 
Total 106 1.1865 .82642 .08027 1.0273 1.3456 .21 3.94 
0 85 .4712 .14358 .01557 .4402 .5021 .17 .80 
LFITP RRI 1 21 .5684 .16198 .03535 .4947 .6421 .20 .80 
Total 106 .4904 .15168 .01473 .4612 .5196 .17 .80 
0 85 .5288 .14358 .01557 .4979 .5598 .20 .83 
HFITP RRI 1 21 .4316 .16198 .03535 .3579 .5053 .20 .80 
Total 106 .5096 .15168 .01473 .4804 .5388 .20 .83 
0 85 5.0979 4.25177 .46117 4.1808 6.0150 .69 22.83 
LF SBP 1 21 7.5945 4.85814 1.06013 5.3831 9.8059 .25 21.39 
Total 106 5.5925 4.46734 .43391 4.7322 6.4529 .25 22.83 
HFSBP 0 85 1.5351 1.28327 .13919 1.2583 1.8119 .13 8.53 
98 
1 21 1.3450 .91689 .20008 .9277 1.7624 .08 4.55 
Total 106 1.4974 1.21793 .11830 1.2629 1.7320 .08 8.53 
0 85 6.6330 5.10344 .55355 5.5322 7.7338 1.00 28.25 
iT otal Power 
1 21 8.9395 5.34582 1.16655 6.5061 11.3729 .33 23.36 
SBP 
Total 106 7.0900 5.20891 .50593 6.0868 8.0931 .33 28.25 
0 85 3.9613 2.60284 .28232 3.3999 4.5227 .65 13.47 
LF/HF SBP 1 21 6.4974 3.90718 .85262 4.7189 8.2759 2.43 15.06 
Total 106 4.4637 3.05927 .29714 3.8746 5.0529 .65 15.06 
0 85 .7397 .13094 .01420 .7114 .7679 .39 .93 
LF/TP SBP 1 21 .8322 .07466 .01629 .7982 .8662 .71 .94 
Total 106 .7580 .12709 .01234 .7335 .7825 .39 .94 
0 85 .2603 .13094 .01420 .2321 .2886 .07 .61 
HF/TP SBP 1 21 .1678 .07466 .01629 .1338 .2018 .06 .29 
Total 106 .2420 .12709 .01234 .2175 .2665 .06 .61 
0 85 15.1245 6.78911 .73638 13.6601 16.5888 1.51 35.71 
LF Gain SBP 1 21 10.5212 6.81796 1.48780 7.4177 13.6247 1.88 31.64 
Total 106 14.2125 7.00901 .68077 12.8626 15.5623 1.51 35.71 
0 85 22.7787 11.44342 1.24121 20.3104 25.2470 3.25 61.68 
HF GainSBP 1 21 15.9607 9.43837 2.05962 . 11.6644 20.2570 5.05 37.83 
Total 106 21.4280 11.36594 1.10396 19.2390 23.6169 3.25 61.68 
ANOV A for Children Within BP Categories 
Sum of 
Squares df Mean Square F Sig. 
Sex (M/F) Between Groups .307 1 .307 1.311 .255 
Within Groups 24.344 104 .234 
Total 24.651 105 
Age (years) Between Groups 1.442 1 1.442 2.054 .155 
Within Groups 73.017 104 .702 
Total 74.459 105 
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Height (em) Between Groups 111.328 1 111.328 1.284 .260 
Within Groups 9019.762 104 86.728 
Total 9131.091 105 
Weight (kg) Between Groups 6016.066 1 6016.066 29.473 .000 
Within Groups 21228.678 104 204.122 
Total 27244.745 105 
BMI (kgfm2 ) Between Groups 741.130 1 741.130 36.824 .000 
Within Groups 2093.137 104 20.126 
Total 2834.267 105 
PHV (years) Between Groups .013 1 .013 .018 .894 
Within Groups 76.563 104 .736 
Total 76.576 105 
SBP (mmHg) Between Groups 6318.375 1 6318.375 230.224 .000 
Within Groups 2854.230 104 27.445 
Total 9172.605 105 
DBP (mmHg) Between Groups 4170.818 1 4170.818 173.648 .000 
Within Groups 2497.961 104 24.019 
Total 6668.779 105 
MAP (mmHg) Between Groups 4837.293 1 4837.293 241.417 .000 
Within Groups 2083.854 104 20.037 
Total 6921.146 105 
RRI Between Groups 144178.357 1 144178.357 15.549 .000 
Within Groups 964344.222 104 9272.541 
Total 1108522.579 105 
Pulse Pressure Between Groups 457.265 1 457.265 13.729 0.000 
Within Groups 3463.881 104 33.307 
Total 3921.145 105 
LF RRI Between Groups 1334176.174 1 1334176.174 5.574 .020 
Within Groups 2.490E7 104 239375.475 
Total 2.623E7 105 
HFRRI Between Groups 3462670.179 1 3462670.179 4.280 .041 
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Within Groups 8.414E7 104 809044.962 
Total 8.760E7 105 
Total Power RRI Between Groups 8440284.622 1 8440284.622 5.354 .023 
Within Groups 1.639E8 104 1576375.479 
Total 1.724E8 105 
LF/HF RRI Between Groups 5.460 1 5.460 8.571 .004 
Within Groups 66.252 104 .637 
Total 71.712 105 
LFITP RRI Between Groups .159 1 .159 7.339 .008 
Within Groups 2.257 104 .022 
Total 2.416 105 
HFITP RRI Between Groups .159 1 .159 7.339 .008 
Within Groups 2.257 104 .022 
Total 2.416 105 
LFSBP Between Groups 104.958 1 104.958 5.484 .021 
Within Groups 1990.543 104 19.140 
Total 2095.502 105 
HFSBP Between Groups .608 1 .608 .408 .525 
Within Groups 155.144 104 1.492 
Total 155.753 105 
Total Power SBP Between Groups 89.587 1 89.587 3.377 .069 
Within Groups 2759.347 104 26.532 
Total 2848.934 105 
LF/HF SBP Between Groups 108.309 1 108.309 12.882 .001 
Within Groups 874.401 104 8.408 
Total 982.710 105 
LFITP SBP Between Groups .144 1 .144 9.663 .002 
Within Groups 1.552 104 .015 
Total 1.696 105 
HFITP SBP Between Groups .144 1 .144 9.663 .002 
Within Groups 1.552 104 .015 
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Total 1.696 105 
LF Gain SBP Between Groups 356.831 1 356.831 7.729 .006 
Within Groups 4801.418 104 46.167 
Total 5158.249 105 
HF GainSBP Between Groups 782.787 1 782.787 6.369 .013 
Within Groups 12781.607 104 122.900 
Total 13564.394 105 
ANCOVA Tests of Between Subject Effects, Controlling for PHV, Age, BMI, & Sex 
Between-Subjects Factors 
N 
TwoCatDiag 0 85 
1 21 
Tests of Between-Subjects Effects 
Dependent Variable: LF RRI 
Type III Sum of 
Source Squares df Mean Square 
Corrected Model 3.573E6 5 714616.757 
Intercept 613513.260 1 613513.260 
phv 36982.586 1 36982.586 
trueage 957180.652 1 957180.652 
bmi 163562.055 1 163562.055 
gender 108408.358 1 108408.358 
hype 1961325.043 1 1961325.043 
Error 2.266E7 100 226561.418 
Total 7.447E7 106 
Corrected Total 2.623E7 105 
a. R Squared = .136 (Adjusted R Squared = .093) 
Tests of Between-Subjects Effects 
Dependent Variable: HF RRI 
F Sig. 
3.154 .011 
2.708 .103 
.163 .687 
4.225 .042 
.722 .398 
.478 .491 
8.657 .004 
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Type III Sum of 
Source Squares df Mean Square 
Corrected Model 8.809E6 5 1761856.523 
Intercept 2554054.790 1 2554054.790 
phv 442032.155 1 442032.155 
trueage 2981573.438 1 2981573.438 
bmi 1081589.566 1 1081589.566 
gender 88971.691 1 88971.691 
hype 5739561.400 1 5739561.400 
Error 7.879E7 100 787940.636 
Total 1.587E8 106 
Corrected Total 8.760E7 105 
- a. R Squared = .101 (Adjusted R Squared = .056) 
Tests of Between-Subjects Effects 
Dependent Variable: TP RRI 
Type III Sum of 
Source Squares df Mean Square 
Corrected Model 2.166E7 5 4332735.466 
Intercept 5590143.394 1 5590143.394 
phv 963912.154 1 963912.154 
trueage 6954761.806 1 6954761.B06 
bmi 2362404.574 1 2362404.574 
gender 56655.673 1 56655.673 
hype 1.410E7 1 1.410E7 
Error 1.507EB 100 1507196.571 
Total 4.020E8 106 
Corrected Total 1.724EB 105 
a. R Squared = .126 (Adjusted R Squared = .OB2) 
Tests of Between-Subjects Effects 
Dependent Variable: LF/HF RRI 
F Sig. 
2.236 .056 
3.241 .075 
.561 .456 
3.784 .055 
1.373 .244 
.113 .738 
7.284 .008 
F Sig. 
2.875 .018 
3.709 .057 
.640 .426 
4.614 .034 
1.567 .214 
.038 .847 
9.356 .003 
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Type III Sum of 
Source Squares df Mean Square 
Corrected Model 8.176a 5 1.635 
Intercept .225 1 .225 
phv .200 1 .200 
Itrueage .046 1 .046 
bmi 2.549 1 2.549 
gender .081 1 .081 
hype 1.515 1 1.515 
Error 63.536 100 .635 
Total 220.926 106 
Corrected Total 71.712 105 
a. R Squared = .114 (Adjusted R Squared = .070) 
Tests of Between-Subjects Effects 
Dependent Variable: LF/TP RRI 
Type III Sum of 
Source Squares df Mean Square 
Corrected Model .190a 5 .038 
Intercept .045 1 .045 
phv .005 1 .005 
trueage .001 1 .001 
bmi .028 1 .028 
gender .000 1 .000 
hype .067 1 .067 
Error 2.226 100 .022 
Total 27.912 106 
Corrected Total 2.416 105 
a. R Squared = .079 (Adjusted R Squared = .033) 
Tests of Between-Subjects Effects 
Dependent Variable: HF/TP RRI 
F Sig. 
2.574 .031 
.354 .553 
.314 .576 
.073 .788 
4.013 .048 
.127 .722 
2.384 .126 
F Sig. 
1.707 .140 
2.031 .157 
.211 .647 
.060 .808 
1.247 .267 
.008 .930 
3.003 .086 
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Type III Sum of 
Source Squares df Mean Square 
Corrected Model .190a 5 .038 
Intercept .033 1 .033 
phv .005 1 .005 
trueage .001 1 .001 
bmi .028 1 .028 
gender .000 1 .000 
hype .067 1 .067 
E-rror 2.226 100 .022 
Total 29.939 106 
Corrected Total 2.416 105 
a. R Squared = .079 (Adjusted R Squared = .033) . 
Tests of Between-Subjects Effects 
Dependent Variable: LF SBP 
Type III Sum of 
Source Squares df Mean Square 
Corrected Model 323.851 a 5 64.770 
Intercept .502 1 .502 
phv .000 1 .000 
trueage .103 1 .103 
bmi 212.845 1 212.845 
gender .314 1 .314 
hype 1.533 1 1.533 
Error 1771.651 100 17.717 
Irotal 5410.788 106 
Corrected Total 2095.502 105 
a. R Squared = .155 (Adjusted R Squared = .112) 
Tests of Between-Subjects Effects 
Dependent Variable: HF SBP 
F Sig. 
1.707 .140 
1.488 .225 
.211 .647 
.060 .808 
1.247 .267 
.008 .930 
3.003 .086 
F Sig. 
3.656 .004 
.028 .867 
.000 .998 
.006 .939 
12.014 .001 
.018 .894 
.087 .769 
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Type III Sum of 
Source Squares df Mean Square 
Corrected Model 5.610a 5 1.122 
Intercept .357 1 .357 
phv .419 1 .419 
trueage .110 1 .110 
bmi 3.699 1 3.699 
gender 1.093 1 1.093 
hype 2.241 1 2.241 
Error 150.142 100 1.501 
Total 393.436 106 
Corrected Total 155.753 105 
a. R Squared = .036 (Adjusted R Squared = -.012) 
Tests of Between-Subjects Effects 
Dependent Variable: TP SBP 
Type III Sum of 
Source Squares df Mean Square 
Corrected Model 369.664a 5 73.933 
Intercept .012 1 .012 
phv .436 1 .436 
trueage .000 1 .000 
bmi 272.664 1 272.664 
gender 2.578 1 2.578 
hype .067 1 .067 
Error 2479.270 100 24.793 
Total 8177.280 106 
Corrected Total 2848.934 105 
a. R Squared = .130 (Adjusted R Squared = .086) 
Tests of Between-Subjects Effects 
Dependent Variable: LF/HF SBP 
F Sig. 
.747 .590 
.238 .627 
.279 .598 
.073 .787 
2.464 .120 
.728 .396 
1.493 .225 
F Sig. 
2.982 .015 
.000 .982 
.018 .895 
.000 .998 
10.998 .001 
.104 .748 
.003 .959 
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Type III Sum of 
Source Squares df Mean Square 
Corrected Model 129.653a 5 25.931 
Intercept .338 1 .338 
phv .534 1 .534 
trueage .294 1 .294 
bmi 18.690 1 18.690 
gender .667 1 .667 
hype 41.934 1 41.934 
Error 853.057 - 100 8.531 
Total 3094.749 106 
Corrected Total 982.710 105 
a. R Squared = .132 (Adjusted R Squared = .089) 
Tests of Between-Subjects Effects 
Dependent Variable: LFITP SBP 
Type III Sum of 
Source Squares df Mean Square 
Corrected Model .198a 5 .040 
Intercept .063 1 .063 
phv .001 1 .001 
trueage .000 1 .000 
bmi .050 1 .050 
gender 3.753E-5 1 3.753E-5 
hype .043 1 .043 
Error 1.498 100 .015 
Total 62.601 106 
Corrected Total 1.696 105 
a. R Squared = .117 (Adjusted R Squared = .073) 
Tests of Between-Subjects Effects 
Dependent Variable: HFITP SBP 
F Sig. 
3.040 .013 
.040 .843 
.063 .803 
.034 .853 
2.191 .142 
.078 .780 
4.916 .029 
F Sig. 
2.649 .027 
4.235 .042 
.063 .802 
.008 .929 
3.320 .071 
.003 .960 
2.891 .092 
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Type III Sum of 
Source Squares df Mean Square 
Corrected Model .198a 5 .040 
Intercept .020 1 .020 
phv .001 1 .001 
trueage .000 1 .000 
bmi .050 1 .050 
gender 3.753E-5 1 3.753E-5 
hype .043 1 .043 
Error 1.498 100 - .015 
Total 7.903 106 
Corrected Total 1.696 105 
a. R Squared = .117 (Adjusted R Squared = .073) 
Tests of Between-Subjects Effects 
Dependent Variable: LF Gain 
Type III Sum of 
Source Squares df Mean Square 
Corrected Model 751.565a 5 150.313 
Intercept .745 1 .745 
phv .667 1 .667 
trueage 65.171 1 65.171 
bmi 73.019 1 73.019 
gender 82.542 1 82.542 
hype 198.760 1 198.760 
Error 4406.684 100 44.067 
Total 26569.706 106 
Corrected Total 5158.249 105 
a. R Squared = .146 (Adjusted R Squared = .103) 
Tests of Between-Subjects Effects 
Dependent Variable: HF Gain 
F Sig. 
2.649 .027 
1.362 .246 
.063 .802 
.008 .929 
3.320 .071 
.003 .960 
2.891 .092 
F Sig. 
3.411 .007 
.017 .897 
.015 .902 
1.479 .227 
1.657 .201 
1.873 .174 
4.510 .036 
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Type III Sum of 
Source Squares df Mean Square 
Corrected Model 1551.917a 5 310.383 
Intercept 61.921 1 61.921 
phv 48.400 1 48.400 
trueage 336.899 1 336.899 
bmi 156.354 1 156.354 
gender 87.971 1 87.971 
hype 466.647 1 466.647 
Error 12012.477 100 120.125 
Total 62235.053 106 
Corrected Total 13564.394 105 
a. R Squared = .114 (Adjusted R Squared = .070) 
Regression 
BP Group: LF Gain 
Variables Entered/Removedb 
Variables Variables 
Model Entered Removed Method 
1 student gender 
(M/F), Body 
. Enter 
Mass Index, phv, 
hyper, trueagea 
a. All requested variables entered. 
b. Dependent Variable: gainlfsb 
Model Summary 
Adjusted R Std. Error of the 
Model R R Square Square Estimate 
1 .382a .146 .103 6.63829 
a. Predictors: (Constant), student gender (M/F), Body Mass Index, 
phv, hyper, trueage 
F Sig. 
2.584 .031 
.515 .474 
.403 .527 
2.805 .097 
1.302 .257 
.732 .394 
3.885 .051 
-
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Model Sum of Squares df Mean Square F Sig. 
1 Regression 751.565 5 150.313 3.411 .007a 
Residual 4406.684 100 44.067 
Total 5158.249 105 
a. Predictors: (Constant), student gender (M/F), Body Mass Index, phv, hyper, trueage 
b. Dependent Variable: gainlfsb 
Coefficientsa 
Standardized -
Unstandardized Coefficients Coefficients 
Model B Std. Error Beta t Sig. 
1 (Constant) -.170 16.646 -.010 .992 
hyper -4.036 1.900 -.231 -2.124 .036 
Body Mass Index -.189 .147 -.140 -1.287 .201 
Student gender (M/F) 1.891 1.382 .131 1.369 .174 
trueage 1.459 1.200 .175 1.216 .227 
phv .143 1.159 .017 .123 .902 
a. Dependent Variable: gainlfsb 
BP Group: HF Gain 
Variables Entered/Removedb 
Variables Variables 
Model Entered Removed Method 
1 student gender 
(M/F), Body 
. Enter 
Mass Index, phv, 
hyper, trueagea 
a. All requested variables entered. 
b. Dependent Variable: gainhfsb 
Model Summary 
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Adjusted R Std. Error of the 
Model R R Square Square Estimate 
1 .338a .114 .070 10.96014 
a. Predictors: (Constant), student gender (M/F), Body Mass Index, 
phv, hyper, trueage 
Model Sum of Squares df Mean Square 
1 Regression 1551.917 5 310.383 
Residual 12012.477 100 120.125 
Total 13564.394 105 
F 
2.584 
a. Predictors: (Constant), student gender (M/F), Body Mass Index, phv, hyper, trueage 
b. Dependent Variable: gainhfsb 
Coefficientsa 
Unstandardized Coefficients 
Model 
1 (Constant) 
hyper 
Body Mass Index 
student gender (M/F 
trueage 
phv 
a. Dependent Variable: gainhfsb 
SBP: LFGain 
B Std. Error 
-16.848 27.483 
-6.184 3.137 
-.277 .242 
1.952 2.281 
3.318 1.981 
-1.215 1.913 
Variables Entered/Removedb 
Variables Variables 
Model Entered Removed Method 
Standardized 
Coefficients 
Beta 
-.218 
-.126 
.083 
.246 
-.091 
Sig. 
.031a 
t Sig. 
-.613 .541 
-1.971 .051 
-1.141 .257 
.856 .394 
1.675 .097 
-.635 .527 
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1 phv, bmi, 
student gender 
(M/F), . Enter 
LabFieldAveS, 
trueagea 
a. All requested variables entered. 
b. Dependent Variable: gainlfsb 
Model Summary 
Adjusted R Std. Error ofthe 
Model R R Square Square Estimate 
1 .362a .131 .087 6.69587 
a. Predictors: (Constant), phv, bmi, student gender (M/F), 
LabFieldAveS, trueage 
Model Sum of Squares df Mean Square 
1 Regression 674.785 5 134.957 
Residual 4483.464 . 100 44.835 
Total 5158.249 105 
F 
3.010 
a. Predictors: (Constant), phv, bmi, student gender (M/F), LabFieldAveS, trueage 
b. Dependent Variable: gainlfsb 
Coefficientsa 
Standardized 
Unstandardized Coefficients Coefficients 
Model B Std. Error Beta 
1 (Constant) 15.698 17.718 
LabFieldAveS -.156 .094 -.208 
bmi -.160 .170 -.119 
student gender (M/F) 1.879 1.395 .130 
trueage 1.301 1.206 .156 
Sig. 
.014a 
t Sig. 
.886 .378 
-1.649 .102 
-.944 .348 
1.347 .181 
1.079 .283 
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bmi -.160 .170 
student gender (M/F) 1.879 1.395 
trueage 1.301 1.206 
phv .437 1.174 
a. Dependent Variable: gainlfsb 
SBP: HF Gain SBP 
Variables Entered/Removedb 
Variables Variables 
Model Entered Removed Method 
1 phv, bmi, 
student gender 
(M/F), . Enter 
LabFieldAveS, 
trueagea 
a. All requested variables entered. 
b. Dependent Variable: gainhfsb 
Model Summary 
Adjusted R Std. Error of the 
Model R R Square Square Estimate 
1 .338a .114 .070 10.96241 
a. Predictors: (Constant), phv, bmi, student gender (M/F), 
LabFieldAveS, trueage 
Model Sum of Squares df Mean Square 
1 Regression 1546.944 5 309.389 
Residual 12017.450 100 120.174 
Total 13564.394 105 
-.119 
.130 
.156 
.053 
F 
2.574 
a. Predictors: (Constant), trueage, bmi, student gender (M/F), LabFieldAveS, phv 
b. Dependent Variable: gainhfsb 
Coefficientsa 
Standardized 
Model Unstandardized Coefficients Coefficients 
-.944 .348 
1.347 .181 
1.079 .283 
.372 .711 
Sig. 
.031 a 
t Sig. 
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B Std. Error Beta 
1 (Constant) 11.723 29.009 .404 .687 
LabFieldAveS -.303 .155 -.249 -1.960 .053 
bmi -.157 .278 -.072 -.565 .573 
student gender (M/F) 2.021 2.284 .086 .885 .378 
trueage 3.103 1.975 .230 1.571 .119 
phv -.685 1.922 -.051 -.357 .722 
a. Dependent Variable: gainhfsb 
Correlations 
HF 
hype SBP DBP RRI PP Age Sex BMI PHV LFRRI RRI 
hype PC 1.000 .830- .791"' -.361 "" .341 "" .139 .112 .511 "" .013 -.226" -.199" 
Sig.2T .000 .000 .000 .000 .155 .255 .000 .894 .020 .041 
N 106.000 106 106 106 106 106 106 106 106 106 106 
SBP PC .830 "" 1.000 .845 - -.256 "" .528"" .200" .131 .651 - .112 -.193" -.174 
Sig.2T .000 .000 .008 .000 .040 .181 .000 .252 .047 .074 
N 106 106.00 106 106 106 106 106 106 106 106 106 
DBP PC .791 "" .845 "" 1.000 -.317 "" .123 .081 .042 .496"" .026 -.277 " . -.201 
Sig.2T .000 .000 .001 .207 .411 .667 .000 .792 .004 .039 
N 106 106 106.00 106 106 106 106 106 106 106 106 
RRI PC -.361 "' -.256 - -.317 '" 1.000 .049 .180 .241 
, 
-.091 .147 .361- .328 " 
Sig.2T .000 .008 .001 .618 .065 .013 .354 .132 .000 .001 
N 106 106 106 106.00 106 106 106 106 106 106 106 
PP PC .341 " .528"' .123 .049 1.000 .139 .098 .404" .094 -.057 -.068 
Sig.2T .000 .000 .207 .618 .156 .316 .000 .339 .563 .491 
N 106 106 106 106 106.00 106 106 106 106 106 106 
Age PC .139 .200 
, 
.081 .180 .139 1.000 .238' .095 .7M' .235" .170 
Sig.2T .155 .040 .411 .065 .156 .014 .330 .000 .015 .082 
N 106 106 106 106 106 106.00 106 106 106 106 106 
Sex PC .112 .131 " .042 .241 .098 .238' 1.000 .053 .158 .097 -.008 
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Sig.2T .255 .181 .667 .013 .316 .014 .592 .107 .321 .933 
N 106 106 106 106 106 106 106.00 106 106 106 106 
BMI PC .511- .651 - .496- -.091 .404 
., 
.095 .053 1.000 -.060 -.036 .009 
Sig.2T .000 .000 .000 .354 .000 .330 .592 .540 ,715 .924 
N 106 106 106 106 106 106 106 106.00 106 106 106 
PHV PC .013 .112 .026 .147 .094 " .744 ,158 -.060 1.000 .165 .088 
Sig.2T .894 .252 .792 .132 .339 .000 .107 .540 .091 .367 
N 106 106 106 106 106 106 106 106 106.00 106 106 
LFRRI PC -.226 -.193' -.277- .361 " -.057 .235 .097 -.036 .165 1.000 .611 -
Sig.2T .020 .047 .004 .000 .563 .015 .321 .715 .091 .000 
N 106 106 106 106 106 106 106 106 106 106.00 106 
HFRRI PC -.199' -.174 -.201 
, 
.328-
-.068 .170 -.008 .009 .088 .611 - 1.000 
Sig.2T .041 .074 .039 .001 .491 .082 .933 .924 .367 .000 
N 106 106 106 106 106 106 106 106 106 106 106.00 
TPRRI PC -.221 
, 
-.195 -.248 .361 " -.066 .199' .045 .004 .109 .807 " .954 " 
Sig.2T .023 .045 .010 .000 .502 .041 .647 .969 .266 .000 .000 
N 106 106 106 106 106 106 106 106 106 106 106 
LF/HF RRI PC .276" .327 - .254- -.286- .150 .057 .000 .299- .035 -.017 -.426" 
Sig.2T .004 .001 .009 .003 .124 .561 .995 .002 .725 .864 .000 
N 106 106 106 106 106 106 106 106 106 106 106 
LFITP RRI PC .257 - .296" -.221 -.271 - .160 .055 .039 .219' .037 .020 -.521 -
Sig.2T .008 .002 .023 .005 .102 .576 .690 .024 .710 .836 .000 
N 106 106 106 106 106 106 106 106 106 106 106 
HFITP RRI PC -.257- -.296- -.221 
, 
.271 - -.160 -.055 -.039 -.219' -.037 -.020 .521 " 
Sig.2T .008 .002 .023 .005 .102 .576 .690 .024 .710 .836 .000 
N 106 106 106 106 106 106 106 106 106 106 106 
LFSBP PC .224' .273- .107 -.104 .180 .048 .013 .392- -.016 .215' .100 
Sig.2T .021 .005 .274 .289 .064 .622 .892 .000 .874 .027 .308 
N 106 106 106 106 106 106 106 106 106 106 106 
HF SBP PC -.062 -.002 -.075 -.023 .052 -.005 -.090 .096 .022 .157 .297-
Sig.2T .525 .985 .445 .813 .600 .956 .358 .327 .823 .107 .002 
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N 
TPSSP PC 
Sig.2T 
N 
LF/HFSSP PC 
Sig.2T 
N 
LFITP SSP PC 
Sig.2T 
N 
HFITP SSP PC 
Sig.2T 
-
N 
LF Gain PC 
Sig.2T 
N 
HF Gain PC 
Sig.2T 
N 
PC = Pearson correlation 
2T = 2-Tailed 
106 106 
.177 .234' 
.069 .016 
106 106 
.332-
.301 -
.001 .002 
106 106 
.292 " .278" 
.002 .004 
106 106 
-.292-
-.278 -
.002 .004 
106 106 
-.263 
., 
-.231 
, 
.006 .017 
106 106 
-.240 
, 
-.245' 
.013 .012 
106 106 
**. Correlation is significant at the 0.01 level 
(2T) 
*. Correlation is significant at the 0.05 level 
(2T) 
TP LF/HF LFITP 
RRI RRI RRI 
hype PC -.221 
, 
.276" .257 
,. 
Sig.2T .023 .004 .008 
N 10.6 106 106 
SSP PC -.195 
. 
.327- .296-
106 106 
.074 -.094 
.448 .335 
106 106 
, 
.203 -.128 
.037 .192 
106 106 
.187 -.097 
.055 .325 
106 106 
-.187 .097 
.055 .325 
106 106 
, 
" 
-.201 .449 
.039 .000 
106 106 
-.234' .551 -
.016 .000 
106 106 
HFITP LF 
RRI SSP 
-.257- .224' 
.008 .021 
106 106 
-.296-
.273 -
106 106 106 106 106 106 106 
.167 .040 -.010 .359- -.008 .221 
, 
.155 
.088 .682 .922 .000 .933 .023 .112 
106 106 106 106 106 106 106 
.156 .056 .063 .293 " -.018 .030 -.230' 
.110 .567 .519 .002 .856 .762 .018 
106 106 106 106 106 106 106 
.120 .030 .024 .301 
., 
-.037 .042 -.223' 
.220 .757 .806 .002 .708 .666 .022 
106 106 106 106 106 106 106 
" 
-.120 -.030 -.024 -.301 .037 -.042 .223 
.220 .757 .806 .002 .708 .666 .022 
106 106 106 106 106 106 106 
-.060 .174 .142 -.235' .174 .474 " .439" 
.541 .075 .146 .015 .075 .000 .000 
106 106 106 106 106 106 106 
-.063 .155 .096 -.204 
, 
.109 .456- .591 -
.521 .112 .326 .035 .264 .000 .000 
106 106 106 106 106 106 106 
TP LF/HF LFITP HFITP LF HF 
HF SSP SSP SSP SSP SSP Gain Gain 
-.062 .177 .332 
.. 
.292 " -.292 - -.263 - -.240' 
.525 .069 .001 .002 .002 .006 .013 
106 106 106 106 106 106 106 
.234 .301 - .278- -.278-
, 
-.245' -.002 -.231 
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Sig.2T .045 .001 .002 .002 .005 .985 .016 .002 .004 .004 .017 .012 
N 106 106 106 106 106 106 106 106 106 106 106 106 
DBP PC -.248 .254- .221 
. 
-.221 
. 
.107 -.075 .074 .203' .187 -.187 -.201 
. 
-.234' 
Sig.2T .010 .009 .023 .023 .274 .445 .448 .037 .055 .055 .039 .016 
N 106 106 106 106 106 106 106 106 106 106 106 106 
RRI PC .361 
.. 
-.286-
-.271 " .271 - -.104 -.023 -.094 -.128 -.097 .097 .449- .551 " 
Sig.2T .000 .003 .005 .005 .289 .813 .335 .192 .325 .325 .000 .000 
N 106 106 106 106 106 106 106 106 106 106 106 106 
PP PC -.066 .150 .160 -.160 .180 .052 .167 .156 .120 -.120 -.060 -.063 
Sig.2T .502 .124 .102 .102 .064 .600 .088 .110 .220 .220 .541 .521 
N 106 106 106 106 106 106 106 106 106 106 106 106 
. 
Age PC .199 .057 .055 -.055 .048 -.005 .040 .056 .030 -.030 .174 .155 
-
Sig.2T .041 .561 .576 .576 .622 .956 .682 .567 .757 .757 .075 .112 
N 106 106 106 106 106 106 106 106 106 106 106 106 
Sex PC .045 .000 .039 -.039 .013 -.090 -.010 .063 .024 -.024 .142 .096 
Sig.2T .647 .995 .690 .690 .892 .358 .922 .519 .806 .806 .146 .326 
N 106 106 106 106 106 106 106 106 106 106 106 106 
BMI PC .004 .299- .219 
. 
-.219 
, 
.392-
.096 .359- .293 
,. 
.301 " -.301 - -.235' -.204' 
Sig.2T .969 .002 .024 .024 .000 .327 .000 .002 .002 .002 .015 .035 
N 106 106 106 106 106 106 106 106 106 106 106 106 
PHV PC .109 .035 .037 -.037 -.016 .022 -.008 -.018 -.037 .037 .174 .109 
Sig.2T .266 .725 .710 .710 .874 .823 .933 .856 .708 .708 .075 .264 
N 106 106 106 106 106 106 106 106 106 106 106 106 
LFRRI PC .80i' -.017 .020 -.020 .215' .157 .221 
, 
.030 .042 -.042 .474- .456-
Sig.2T .000 .864 .836 .836 .027 .107 .023 .762 .666 .666 .000 .000 
N 106 106 106 106 106 106 106 106 106 106 106 106 
HFRRI PC .954- -.426- -.521 - .521 - .100 .297 " .155 -.230 
, 
-.223 
, 
.223' .439- .591 -
Sig.2T .000 .000 .000 .000 .308 .002 .112 .018 .022 .022 .000 .000 
N 106 106 106 106 106 106 106 106 106 106 106 106 
TPRRI PC 1.000 -.306- -.358" .358" .166 .277 " .207 ·-.148 -.132 .132 .491 - .591 " 
Sig.2T .001 .000 .000 .089 .004 .033 .130 .179 .179 .000 .000 
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N 106.00 106 106 106 106 106 106 106 106 106 106 106 
LF/HF RRI PC -.306 - 1.000 .919" -.919- .117 -.243 .044 .492 - .417 - -.417 " -.183 -.348" 
Sig.2T .001 .000 .000 .231 .012 .655 .000 .000 .000 .061 .000 
N 106 106.00 106 106 106 106 106 106 106 106 106 106 
LFITP RRI PC 
" 
-
" 
- - " 
-.358 .919- 1.000 .082 -.271 .007 .460 .418 -.418" -.190 -.392 .. 
1.000 
Sig.2T .000 .000 .000 .404 .005 .944 .000 .000 .000 .051 .000 
N 106 106 106.00 106 106 106 106 106 106 106 106 106 
HFITP RRI PC 
" 
-
- " " " 
.358-
-.919 1.000 -.082 .271 -.007 -.460 -.418 .418- .190 .392 
- 1.000" 
Sig.2T .000 .000 .000 .404 .005 .944 .000 .000 .000 .051 .000 
N 106 106 106 106.00 106 106 106 106 106 106 106 106 
LF SBP PC .166 .117 .082 -.082 1.000 .523 
.. 
.980 
.. 
.473 
.. 
.471 - -.471 - -.457' -.296" 
Sig.2T .089 .231 .404 .404 .000 .000 .000 .000 .000 .000 .002 
N 106 106 106 106 106.00 106 106 106 106 106 106 106 
HFSBP PC .277" -.243' -.271 - .271 
., 
.523" 1.000 .682 
,. 
-.296" -.304" .304- -.219' -.285 
,. 
Sig.2T .004 .012 .005 .005 .000 .000 .002 .002 .002 .024 .003 
N 106 106 106 106 106 106.000 106 106 106 106 106 106 
TPSBP PC .207 
. 
.044 .007 -.007 .980 
,. 
.682 - 1.000 .336" .333 
.. 
-.333 
.. 
-.443 
.. 
-.321 
. . 
Sig.2T .033 .655 .944 .944 .000 .000 .000 .000 .000 .000 .001 
N 106 106 106 106 106 106 106.00 106 106 106 106 106 
LF/HF SBP PC -.148 .492 
.. 
.460 - -.460 
.. 
.473 '. -.296 
., 
.336" 1.000 .837 
.. 
-.837" -.292 - -.034 
Sig.2T .130 .000 .000 .000 .000 .002 .000 .000 .000 .002 .732 
N 106 106 106 106 106 106 106 106.00 106 106 106 106 
LFITP SBP PC 
- -
.. 
-
-
-.132 .417' .418" -.418" .471 -.304 .333 .837' 1.000 -.342 -.010 
-1.000 
Sig.2T .179 .000 .000 .000 .000 .002 .000 .000 .000 .000 .918 
N 106 106 106 106 106 106 106 106 106.00 106 106 106 
HFITP SBP PC .. .. .. .. 
-
-
-
.132 -.417 -.418 .418" -.471 .304 -.333 -.837- 1.000 .342 .010 .. 
1.000 
Sig.2T .179 .000 .000 .000 .000 .002 .000 .000 .000 .000 .918 
N 106 106 106 106 106 106 106 106 106 106.00 106 106 
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-LF Gain PC .491 -.183 -.190 
Sig.2T .000 .061 .051 
N 106 106 106 
- -HF Gain PC .591 -.348- -.392 
Sig.2T 
N 
PC = Pearson correlation 
2T = 2-Tailed 
.000 .000 
106 106 
". Correlation is significant at the 0.01 
level (2T) 
'. Correlation is significant at the 0.05 level 
(2T) 
Interactions 
.000 
106 
.190 -.457-
.051 .000 
106 106 
.392 - -.296-
.000 .002 
106 106 
LF Interaction for BMI and BP category 
Model Summary 
-.219' -.443 
.. 
.024 .000 
106 106 
-
.. 
-.285 -.321 
.003 .001 
106 106 
Adjusted R Std. Error of the 
Model R RSquare Square Estimate 
1 .291 8 .085 .058 6.80382 
a. Predictors: (Constant), newBMlinteraction, bmi, hype 
Model Sum of Squares df Mean Square 
1 Regression 436.472 3 145.491 
Residual 4721.777 102 46.292 
Total 5158.249 105 
a. Predictors: (Constant), newBMlinteraction, bmi, hype 
b. Dependent Variable: gainlfsb 
Coefficientsa 
- -
-.292 -.342 
.002 .000 
106 106 
-.034 -.010 
.732 .918 
106 106 
F 
3.143 
Standardized 
Model Unstandardized Coefficients Coefficients 
-
.. 
.342 1.000 .797 
.000 .000 
106 106.00 106 
.. 
.010 .797 1.000 
.918 .000 
106 106 106.00 
Sig. 
.028a 
t Sig. 
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B Std. Error Beta 
1 (Constant) 19.990 4.166 4.799 .000 
hype -6.326 7.156 -.361 -.884 .379 
bmi -.246 .208 -.183 -1.187 .238 
newBMlinteraction .127 .298 .200 .428 .670 
a. Dependent Variable: gainlfsb 
HF Interaction for BMI and BP category 
Model Summary 
Adjusted R Std. Error of the 
Model R R Square Square Estimate 
1 .275a .076 .048 11.08753 
a. Predictors: (Constant), newBMlinteraction, bmi, hype 
Model Sum of Squares df Mean Square F Sig. 
1 Regression 1025.205 3 341.735 2.780 .045a 
Residual 12539.189 102 122.933 
Total 13564.394 105 
a. Predictors: (Constant), newBMlinteraction, bmi, hype 
b. Dependent Variable: gainhfsb 
Coefficients a 
Standardized 
Unstandardized Coefficients Coefficients 
Model B Std. Error Beta t Sig. 
1 (Constant) 22.953 6.788 3.381 .001 
hype 5.879 11.661 .207 .504 .615 
bmi -.009 .338 -.004 -.026 .979 
newBMlinteraction -.479 .485 -.464 -.988 .326 
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Coefficients3 
Standardized 
Unstandardized Coefficients Coefficients 
Model B Std. Error Beta t Sig. 
1 (Constant) 22.953 6.788 3.381 .001 
hype 5.879 11.661 .207 .504 .615 
bmi -.009 .338 -.004 -.026 .979 
newBMlinteraction -.479 .485 -.464 -.988 .326 
a. Dependent Variable: gainhfsb 
LF Interaction for BMI and SBP 
Model Summary 
Adjusted R Std. Error ofthe 
Model R R Square Square Estimate 
1 .2583 .066 .039 6.87113 
a. Predictors: (Constant), BMlandSBPinteraction, LabFieldAveS, bmi 
Model Sum of Squares df Mean Square F Sig. 
1 Regression 342.585 3 114.195 2.419 .071 3 
Residual 4815.664 102 47.212 
Total 5158.249 105 
a. Predictors: (Constant), BMlandSBPinteraction, LabFieldAveS, bmi 
b. Dependent Variable: gainlfsb 
Coefficients3 
Standardized 
Unstandardized Coefficients Coefficients 
Model B Std. Error Beta t Sig. 
1 (Constant) 33.886 25.657 1.321 .190 
bmi -.472 1.146 -.350 -.412 .681 
LabFieldAveS -.159 .258 -.212 -.614 .540 
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BMlandSBPinteraction .003 .011 .260 
a. Dependent Variable: gainlfsb 
HF Interaction for BMI and SBP 
Model Summary 
Adjusted R Std. Error ofthe 
Model R R Square Square Estimate 
1 .270a .073 .045 11.10465 
a. Predictors: (Constant). BMlandSBPinteraction, LabFieldAveS, bmi 
ANOVAb 
Model Sum of Squares df Mean Square F Sig. 
1 Regression 986.435 3 328.812 2.666 .052a 
Residual 12577.959 102 123.313 
Total 13564.394 105 
a. Predictors: (Constant). BMlandSBPinteraction, LabFieldAveS, bmi 
b. Dependent Variable: gainhfsb 
Coefficientsa 
Standardized 
Unstandardized Coefficients Coefficients 
Model B Std. Error Beta t Sig. 
1 (Constant) 6.923 41.465 .167 .868 
bmi 1.685 1.851 .770 .910 .365 
LabFieldAveS .159 .418 .131 .381 .704 
BMlandSBPinteraction -.018 .018 -1.092 -1.014 .313 
a. Dependent Variable: gainhfsb 
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AppendixH 
Raw data 
ID BP category Gender Age Height Weight BMI PHV SBP 
A1048 0 0 11.85 150.0 39.4 17.51 -2.18 92.50 
AI067 0 0 11.65 149.3 42.4 19.02 -2.65 87.17 
A1127 0 0 12.70 161.0 42.9 16.55 -1.29 87.67 
AI138 0 0 13.85 149.1 36.1 16.24 -1.04 84.50 
Al141 0 0 14.01 160.2 66.0 25.72 -1.34 93.67 
A1291 0 0 14.34 169.1 52.2 18.26 -0.22 91.17 
A1365 0 0 13.33 156.1 40.6 16.66 -1.20 93.50 
A1408 0 0 12.63 166.8 49.6 17.83 -1.10 92.00 
A1441 0 0 13.14 155.5 50.8 21.01 -1.68 86.00 
A148 0 0 12.67 151.3 40.7 17.78 -1.82 97~67 
A1497 1 0 12.51 157.4 90.3 36.45 -2.98 113.50 
A1543 0 1 13.56 173.8 51.7 17.12 -0.45 88.33 
A1565 0 0 12.30 155.5 40.2 16.63 -1.62 94.67 
A1570 0 0 12.28 159.8 63.9 25.02 -2.23 92.83 
A1602 0 0 12.20 151.5 47.6 20.74 -2.33 86.83 
A1622 0 1 13.74 155.9 56.6 23.29 -1.36 97.50 
A1673 0 1 13.76 164.7 49.9 18.40 -0.91 95.67 
A281 1 0 12.81 149.7 38.7 17.27 -1.64 107.17 
A329 0 0 11.77 168.3 68.8 24.29 -2.16 99.50 
A490 0 1 12.14 157.0 45.1 18.30 -1.92 89.83 
A492 0 0 12.13 157.2 49.1 19.87 -2.06 88.67 
A609 0 0 12.56 159.6 53.0 20.81 -1.65 93.83 
A61 0 0 11.91 150.8 34.5 15.17 -2.21 86.67 
A661 1 1 14.35 170.5 68.2 23.46 0.65 109.67 
A687 0 1 12.44 155.9 43.7 17.98 -1.96 81.67 
A693 0 1 12.17 163.0 49.9 18.78 -1.71 86.67 
A728 1 1 12.62 167.5 48.0 17.11 -1.66 115.33 
A759 0 0 13.26 167.5 57.8 20.60 -0.98 88.50 
A871 0 0 12.97 161.0 42.3 16.32 -1.14 90.50 
A872 1 1 13.76 145.2 38.5 18.26 -2.40 98.83 
A886 0 0 12.95 145.7 36.4 17.15 -1.92 85.50 
A890 0 0 13.25 154.9 50.9 21.21 -1.53 97.67 
BI078 1 0 12.05 158.4 61.1 24.35 -2.33 108.17 
BI090 0 0 11.57 139.9 37.6 19.21 -2.93 82.33 
BI099 0 1 12.34 157.6 46.0 18.52 -2.33 88.33 
B1128 0 0 12.96 163.6 39.8 14.87 -0.92 93.00 
BIB 0 0 13.98 168.7 59.2 20.80 -0.51 94.50 
B1180 1 0 14.17 167.5 83.1 29.62 -1.36 106.00 
B1211 0 0 12.53 134.0 28.5 15.87 -2.61 92.67 
B1257 0 0 12.07 154.4 50.3 21.10 -1.94 88.33 
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B1259 0 1 12.22 173.5 87.6 29.10 -1.28 106.00 
B1389 0 1 12.35 150.9 37.5 16.47 -2.27 82.17 
B1421 0 0 13.47 165.4 60.5 22.11 -1.23 94.67 
B1506 0 0 12.32 156.4 62.6 25.59 -2.34 89.83 
B1544 0 0 13.08 148.6 43.8 19.84 -1.94 96.83 
B159 0 1 12.40 165.7 63.6 23.16 -1.36 97.33 
B160 1 0 11.65 155.3 60.2 24.96 -2.60 109.50 
B1618 0 0 12.87 157.7 77.3 31.08 -2.55 96.33 
B1651 0 0 11.88 153.5 59.0 25.04 -2.61 89.00 
B1680 0 0 12.13 137.6 35.9 18.96 -2.82 88.50 
B1688 0 0 11.96 162.5 50.1 18.97 -1.71 92.83 
B1694 0 1 11.80 154.5 37.0 15.50 -2.37 88.00 
B1696 0 0 12.05 146.0 34.4 16.14 -2.34 88.17 
B173 0 0 13.79 172.3 50.1 16.88 -0.04 88.50 
B197 0 1 14.12 174.5 60.8 19.97 -0.57 84.67 
B221 0 0 12.96 159.3 61.1 24.08 -1.69 90.67 
B240 1 1 13.58 164.2 67.5 . 25.04 -0.88 111.83 
B288 0 0 11.43 134.2 29.2 16.21 -3.19 84.67 
B344 0 1 11.76 147.8 42.5 19.46 -2.84 95.67 
B568 0 1 12.20 171.8 47.0 15.92 -1.75 91.17 
B576 0 1 11.86 147.8 36.8 16.85 -2.70 86.67 
B579 0 0 11.75 168.2 60.2 21.28 -1.89 94.67 
B645 0 1 13.42 171.4 94.0 32.00 -0.48 106.00 
B669 0 0 12.45 155.0 40.0 16.65 -1.62 84.83 
B69 1 0 13.52 168.8 59.9 21.02 -0.86 108.83 
B728 0 0 11.48 154.3 59.7 25.08 -2.79 88.00 
B878 0 1 14.12 167.2 57.8 20.68 -4.19 98.50 
B899 1 1 13.47 160.9 93.5 36.12 -1.39 112.67 
B904 0 1 13.07 162.2 49.1 18.66 -1.62 86.50 
B910 0 0 13.20 167.4 55.1 19.66 -0.82 97.50 
B921 0 1 12.22 167.0 53.9 19.33 -1.39 91.17 
B937 0 1 13.95 164.3 54.1 20.04 -1.08 98.00 
B944 0 0 12.89 158.7 62.8 24.93 -1.92 88.33 
B957 0 0 13.22 167.8 54.4 19.32 -1.01 88.33 
B980 0 0 12.29 155.0 41.1 17.11 -1.87 90.67 
B992 0 1 12.28 160.7 54.0 20.91 -1.81 90.00 
B994 0 0 11.21 137.6 38.6 20.39 -3.28 84.67 
C115 0 1 14.32 167.6 80.1 28.52 -0.34 88.00 
C139 1 1 13.77 165.7 60.4 22.00 -0.59 105.17 
C22 0 1 14.31 161.3 48.2 18.53 -0.94 89.67 
C62 0 1 12.84 162.4 54.0 20.47 -1.79 85.50 
C7 0 1 13.99 168.0 46.6 16.51 -0.92 89.17 
D108 0 0 12.01 153.5 48.0 20.37 -2.23 94.00 
D1116 1 1 13.13 150.3 67.6 29.92 -1.86 108.33 
124 
D266 0 0 14.08 166.3 45.7 16.52 -0.22 87.00 
D300 1 1 14.49 165.5 67.0 24.46 -0.85 106.67 
D534 1 1 14.09 172.4 124.6 41.92 -0.37 125.33 
D686 0 1 12.51 150.7 47.1 20.74 -2.13 89.50 
D704 0 0 12.52 155.0 47.0 19.56 -1.93 84.83 
EI137 1 0 12.54 154.7 48.6 20.31 -1.97 107.33 
E199 0 0 13.22 157.9 55.9 22.42 -1.57 91.83 
E231 0 0 12.87 158.0 50.3 20.15 -1.46 94.67 
E236 1 0 12.81 164.1 100.1 37.17 -2.82 114.17 
E307 1 0 11.58 142.3 43.0 21.24 -2.93 100.17 
E315 0 0 11.58 146.9 47.7 22.10 -2.77 90.67 
E396 1 1 13.51 177.1 66.0 21.04 -0.50 119.17 
E442 0 1 13.36 161.6 43.0 16.47 -2.01 90.17 
E443 0 0 13.02 152.3 32.5 14.01 -1.43 83.00 
E544 0 0 14.33 167.7 46.0 16.36 -0.01 87.17 
E635 1 0 11.87 149.0 69.0 31.08 -3.18 117.67 
E639 0 1 11.62 138.5 33.0 17.20 -3.18 84.83 
E708 0 0 13.33 169.1 50.9 17.80 -0.74 99.00 
E828 1 0 11.90 165.1 85.4 31.33 -2.76 107.50 
E871 0 0 13.68 158.9 47.0 18.61 -0.98 87.83 
E876 0 0 13.54 156.0 47.1 19.35 -1.22 97.83 
E927 0 1 12.61 151.2 39.6 17.32 -2.03 92.33 
LF/HF 
ID DBP MAP RRI PP LFRRI HFRRI TPRRI RRI 
AI048 52.67 65.94 861.89 36.67 403.61 581.98 985.59 0.69 
AI067 46.00 59.72 729.32 38.33 732.94 1584.92 2317.86 0.46 
A1127 51.83 63.78 774.60 38.00 287.76 429.68 717.43 0.67 
A1138 48.67 60.61 749.44 36.33 284.11 507.30 791.40 0.56 
A1141 57.17 69.33 874.09 35.00 1792.91 7215.56 9008.47 0.25 
A1291 59.33 69.94 769.00 31.67 1211.54 543.07 855.03 0.57 
A1365 57.00 69.17 1027.17 36.33 1211.54 1328.92 1894.79 0.43 
A1408 53.17 66.11 859.31 35.00 1211.54 246.17 710.53 1.89 
A1441 54.67 65.11 793.29 33.33 334.68 628.36 963.04 0.53 
A148 57.67 71.00 651.34 40.33 522.38 719.18 1241.55 0.73 
A1497 72.33 86.06 701.30 35.67 1220.19 626.87 1847.06 1.95 
A1543 47.83 61.33 1059.45 42.00 1109.33 1293.31 2402.64 0.86 
A1565 61.33 72.44 766.85 31.67 846.22 1351.32 2197.55 0.63 
A1570 56.83 68.83 666.97 32.33 255.55 188.64 444.19 1.35 
A1602 49.17 61.72 806.47 34.67 712.47 702.38 1414.85 1.01 
A1622 54.83 69.06 916.07 38.67 518.25 451.80 970.05 1.15 
A1673 48.50 64.22 860.72 48.33 678.17 852.68 1530.85 0.80 
A281 69.83 82.28 583.13 31.67 86.45 56.20 142.66 1.54 
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A329 60.50 73.50 832.90 42.00 641.63 562.58 1204.21 1.14 
A490 
A492 
A609 
51.67 64.39 954.63 
55.00 66.22 661.49 
58.50 70.28 933.29 
36.00 313.12 1522.04 1835.16 0.21 
33.00 284.01 330.22 614.23 0.86 
32.00 1124.98 1563.71 2688.69 0.72 
A61 51.00 62.89 739.09 30.00 324.42 432.81 757.23 0.75 
A661 76.17 87.33 607.78 30.33 595.37 1280.15 1875.52 0.47 
A687 53.00 62.56 862.59 30.67 239.22 650.84 890.06 0.37 
A693 52.67 64.00 885.36 34.67 808.66 1655.81 2464.47 0.49 
A728 
A759 
74.33 88.00 646.46 
55.17 66.28 819.43 
35.67 431.01 272.98 703.98 1.58 
34.00 312.00 89.34 401.34 3.49 
A871 54.00 66.17 819.43 34.00 1493.33 1455.26 2948.59 1.03 
A872 64.00 75.61 717.94 32.00 567.55 493.50 1061.05 1.15 
A886 55.67 65.61 689.10 34.00 596.08 506.68 1102.76 1.18 
A890 62.83 74.44 820.31 34.00 339.59 429.82 769.42 0.79 
B1078 65.50 79.72 734.70 44.67 915.53 1205.41 2120.94 0.76 
B1090 47.67 59.22 929.50 38.00 651.60 1061.96 1713.56 0.61 
B1099 61.33 70.33 790.64 
B1128 61.00 71.67 708.20 
BIB 61.33 72.39 741.77 
B1180 76.83 86.56 619.94 
B1211 59.17 70.33 794.18 
29.00 590.02 479.87 1069.89 1.23 
34.33 740.98 875.17 1616.15 0.85 
33.00 187.26 316.99 504.25 0.59 
32.33 96.62 64.16 160.78 1.51 
34.67 1657.09 2114.90 3771.99 0.78 
B1257 50.00 62.78 675.40 39.00 609.86 301.60 911.47 2.02 
B1259 63.50 77.67 768.65 40.00 223.01 63.72 286.74 3.50 
B1389 55.17 64.17 805.91 21.67 937.16 514.61 1451.77 1.82 
B1421 47.83 63.44 838.59 42.33 1191.42 1210.50 2401.91 0.98 
B1506 54.00 65.94 818.64 35.00 443.02 988.25 1431.27 0.45 
B1544 64.17 75.06 696.13 26.33 975.73 247.83 1223.56 3.94 
B159 - 59.83 72.33 918.44 
B160 75.00 86.50 835.93 
B1618 64.50 75.11 781.81 
B1651 53.50 65.33 698.72 
36.67 1225.91 713.49 1939.41 1.72 
43.67 302.82 253.94 556.75 1.19 
30.00 786.20 2686.93 3473.13 0.29 
24.33 178.18 216.83 395.02 0.82 
B1680 51.83 64.06 715.66 36.33 426.48 209.35 635.84 2.04 
B1688 57.67 69.39 684.91 32.00 334.19 308.42 642.61 1.08 
B1694 58.00 68.00 738.91 23.00 633.78 768.01 1401.78 0.83 
B1696 51.17 63.50 554.41 36.67 442.01 235.22 677.23 1.88 
B173 50.00 62.83 715.92 34.00 731.44 225.53 956.97 3.24 
B197 50.17 61.67 814.35 32.00 908.74 459.08 1367.82 1.98 
B221 55.17 67.00 810.96 34.67 546.10 487.19 1033.29 1.12 
B240 69.33 83.50 642.29 41.67 245.95 110.20 356.15 2.23 
B288 
B344 
B568 
51.33 62.44 738.23 
53.83 67.78 634.48 
57.83 68.94 987.03 
33.00 349.01 589.52 938.53 0.59 
44.00 564.37 357.06 921.43 1.58 
34.00 684.11 751.33 1435.44 0.91 
126 
B576 
B579 
46.83 60.11 763.96 
61.00 72.22 767.72 
39.00 1823.42 1462.42 3285.84 1.25 
37.00 233.71 176.76 410.47 1.32 
B645 62.17 76.78 895.75 40.67 451.47 1870.08 2321.55 0.24 
B669 50.00 61.61 775.72 37.67 211.44 164.97 376.41 1.28 
B69 65.00 79.61 715.99 43.33 605.90 2495.86 3101.76 0.24 
B728 47.17 60.78 774.82 41.33 807.34 1775.67 2583.02 0.45 
B878 56.33 70.39 975.13 38.33 556.91 687.80 1244.71 0.81 
B899 66.67 82.00 616.81 43.67 95.33 29.32 124.65 3.25 
B904 56.83 66.72 878.45 21.33 1634.68 1433.58 3068.26 1.14 
B910 63.50 74.83 1010.95 34.67 896.58 987.67 1884.25 0.91 
B921 61.17 71.17 799.54 30.00 518.96 505.23 1024.18 1.03 
B937 53.50 68.33 852.79 41.00 1240.47 962.99 2203.46 1.29 
B944 52.00 64.11 912.74 32.33 1711.27 2462.71 4173.98 0.69 
B957 
B980 
B992 
B994 
C115 
C139 
C22 
C62 
C7 
D108 
61.67 70.56 850.82 
55.17 67.00 714.85 
53.33 65.56 805.01 
54.67 64.67 693.27 
47.83 61.22 953.38 
68.67 80.83 978.40 
55.67 67.00 857.61 
49.50 61.50 849.57 
49.33 
58.17 
62.61 
70.11 
1011.72 
698.93 
D1116 69.00 82.11 688.17 
D266 46.00 59.67 789.97 
D300 58.17 74.33 773.72 
D534 72.50 90.11 829.00 
D686 57.67 68.28 895.79 
D704 53.17 63.72 816.25 
El137 72.17 83.89 642.18 
E199 58.83 69.83 755.23 
E231 57.00 69.56 774.31 
E236 69.33 84.28 697.55 
31.00 462.09 772.82 1234.91 0.60 
41.33 248.07 159.57 407.64 1.55 
36.33 180.99 272.23 453.21 0.66 
33.67 264.11 376.91 641.02 0.70 
34.00 2100.20 2488.09 4588.30 0.84 
39.00 383.83 605.79 989.62 0.63 
32.33 745.32 926.90 1672.23 0.80 
37.67 2650.48 1854.94 4505.43 1.43 
43.00 451.91 
36.33 1.78 
616.76 1068.67 
7.48 9.26 
0.73 
0.24 
47.50 343.96 198.88 542.84 1.73 
38.00 1724.01 797.30 2521.31 2.16 
46.00 399.11 271.15 670.25 1.47 
56.33 1049.24 508.12 1557.36 2.06 
28.00 449.35 456.84 906.19 0.98 
27.00 438.06 657.65 1095.71 0.67 
32.50 85.25 192.99 278.24 0.44 
34.67 211.81 190.78 402.59 1.11 
40.67 586.57 925.24 1511.81 0.63 
45.00 878.37 224.96 1103.33 3.90 
E307 72.33 81.61 738.67 24.67 413.82 118.33 532.15 3.50 
E315 59.33 69.78 927.54 30.00 373.36 404.61 777.98 0.92 
E396 
E442 
E443 
E544 
E635 
E639 
E708 
81.67 94.17 698.98 
53.17 65.50 848.21 
49.67 60.78 831.12 
55.33 65.94 784.05 
78.50 91.56 803.92 
57.83 66.83 689.79 
57.33 71.22 739.94 
42.50 222.91 159.09 382.00 1.40 
38.33 519.41 1040.17 1559.58 0.50 
35.67 750.00 2452.91 3202.91 0.31 
28.33 600.07 362.04 962.11 1.66 
55.00 126.82 52.09 178.91 2.43 
26.00 211.21 785.13 996.35 0.27 
35.33 155.47 93.02 248.49 1.67 
127 
E828 71.17 83.28 745.62 34.33 361.57 340.44 702.02 1.06 
E871 59.00 68.61 805.75 27.33 1777.44 2970.93 4748.37 0.60 
E876 60.83 73.17 835.48 40.00 1006.56 404.68 1411.24 2.49 
E927 59.50 70.44 772.94 31.67 1482.42 1726.49 3208.92 0.86 
LF/TP HF/TP LF HF TP LF IHF LF ITP HF ITP 
ID RRI RRI SBP SBP SBP SBP SBP SBP 
A 1048 0.41 0.59 4.11 0.88 4.99 4.69 0.82 0.18 
A1067 0.32 0.68 6.88 3.10 9.98 2.22 0.69 0.31 
A1127 0.40 0.60 10.68 8.53 19.21 1.25 0.56 0.44 
Al138 0.36 0.64 1.68 1.65 3.33 1.02 0.51 0.49 
A1141 0.20 0.80 2.60 2.04 4.64 1.28 0.56 0.44 
A1291 0.36 0.64 1.47 2.06 3.52 0.71 0.42 0.58 
A1365 0.30 0.70 2.08 0.30 2.39 6.92 0.87 0.13 
A1408 0.65 0.35 4.87 1.05 5.92 4.63 0.82 0.18 
A1441 0.35 0.65 11.66 1.67 13.32 6.99 0.87 0.13 
A148 0.42 0.58 2.57 1.44 4.01 1.79 0.64 0.36 
A1497 0.66 0.34 10.20 1.57 11. 77 6.50 0.87 0.13 
A1543 0.46 0.54 2.46 0.83 3.29 2.98 0.75 0.25 
A1565 0.39 0.61 9.30 1.97 11.27 4.72 0.83 0.17 
A1570 0.58 0.42 4.64 2.34 6.98 1.98 0.66 0.34 
A1602 0.50 0.50 6.63 1.40 8.04 4.73 0.83 0.17 
A1622 0.53 0.47 9.31 0.69 10.00 13.47 0.93 0.07 
A1673 0.44 0.56 2.22 1.73 3.95 1.28 0.56 0.44 
A281 0.61 0.39 3.26 0.95 4.21 3.43 0.77 0.23 
A329 0.53 0.47 4.43 0.53 4.96 8.30 0.89 0.11 
A490 0.17 0.83 0.78 1.20 1.98 0.65 0.39 0.61 
A492 0.46 0.54 3.32 1.75 5.07 1.90 0.66 0.34 
A609 0.42 0.58 2.90 0.75 3.65 3.86 0.79 0.21 
A61 0.43 0.57 3.79 0.81 4.60 4.69 0.82 0.18 
A661 0.32 0.68 5.96 1.59 7.55 3.74 0.79 0.21 
A687 0.27 0.73 0.74 0.50 1.24 1.48 0.60 0.40 
A693 0.33 0.67 9.49 2.39 11.88 3.97 0.80 0.20 
A728 0.61 0.39 15.52 1.90 17.42 8.17 0.89 0.11 
A759 0.78 0.22 2.87 0.31 3.18 9.18 0.90 0.10 
A871 0.51 0.49 3.42 1.87 5.29 1.82 0.65 0.35 
A872 0.53 0.47 3.27 0.60 3.87 5.42 0.84 0.16 
A886 0.54 0.46 3.80 1.01 4.81 3.74 0.79 0.21 
A890 0.44 0.56 6.00 1.34 7.33 4.49 0.82 0.18 
B1078 0.43 0.57 9.46 0.80 10.26 11.88 0.92 0.08 
B1090 0.38 0.62 0.69 0.32 1.00 2. I 6 0.68 0.32 
B1099 0.55 0.45 3.85 2.64 6.48 1.46 0.59 0.41 
128 
B1128 
Bl13 
Bl180 
B1211 
B1257 
B1259 
B1389 
B1421 
B1506 
B1544 
B159 
B160 
B1618 
B1651 
B1680 
B1688 
B1694 
B1696 
B173 
B197 
B221 
B240 
B288 
B344 
B568 
B576 
B579 
B645 
B669 
B69 
B728 
B878 
B899 
B904 
B910 
B921 
B937 
B944 
B957 
B980 
B992 
B994 
0.46 0.54 3.17 1.60 
0.37 0.63 7.91 1.39 
0.60 0.40 5.46 1.88 
0.44 0.56 14.56 3.59 
0.67 0.33 5.83 0.62 
0.78 0.22 4.72 1.09 
0.65 0.35 2.23 0.96 
0.50 0.50 16.31 3.05 
0.31 0.69 2.93 0.70 
0.80 0.20 1.11 0.13 
0.63 0.37 9.88 3.87 
0.54 0.46 4.28 1.56 
0.23 0.77 7.26 2.97 
0.45 0.55 11.77 1.84 
0.67 0.33 10.65 1.58 
0.52 0.48 2.69 3.91 
0.45 . 0.55 4.97 1.71 
0.65 0.35 2.74 0.86 
0.76 0.24 5.20 1.18 
0.66 0.34 4.90 0.94 
0.53 0.47 3.86 0.66 
0.69 0.31 10.84 0.72 
0.37 0.63 4.78 1.52 
0.61 0.39 6.49 0.90 
0.48 0.52 0.83 1.09 
0.55 0.45 5.34 0.84 
0.57 0.43 3.35 0.47 
0.19 
0.56 
0.20 
0.31 
0.45 
0.76 
0.53 
0.48 
0.51 
0.56 
0.41 
0.37 
0.61 
0.40 
0.41 
0.81 22.83 5.42 
0.44 3.98 1.22 
0.80 11.04 4.55 
0.69 7.58 2.91 
0.55 3.59 1.77 
0.24 5.76 0.69 
0.47 13.11 1.40 
0.52 
0.49 
0.44 
0.59 
0.63 
0.39 
0.60 
0.59 
1.25 
2.02 
2.70 
12.05 
5.47 
1.71 
1.38 
1.10 
0.43 
0.92 
0.49 
5.36 
0.66 
1.31 
0.64 
0.66 
4.77 1.99 
9.29 5.71 
7.34 2.90 
18.15 4.05 
6.45 9.39 
5.81 4.35 
3.19 2.32 
19.36 5.35 
3.63 4.20 
1.23 8.66 
13.75 2.55 
5.84 2.75 
10.22 2.45 
13.61 6.38 
12.22 6.75 
6.61 0.69 
6.68 2.91 
3.61 3.19 
6.38 4.40 
5.84 5.20 
4.52 5.88 
11.55 15.06 
6.30 3.14 
7.40 7.18 
1.92 0.76 
6.18 6.36 
3.82 7.12 
28.25 - 4.21 
5.21 3.26 
15.59 2.43 
10.49 2.60 
5.36 2.03 
6.44 8.38 
14.51 9.39 
1.68 2.93 
2.94 2.20 
3.20 5.46 
17.40 2.25 
6.13 8.27 
3.02 1.30 
2.02 2.15 
1.77 1.66 
0.67 
0.85 
0.74 
0.80 
0.90 
0.81 
0.70 
0.84 
0.81 
0.90 
0.72 
0.73 
0.71 
0.86 
0.87 
0.41 
0.74 
0.76 
0.81 
0.84 
0.85 
0.94 
0.76 
0.88 
0.43 
0.86 
0.88 
0.81 
0.77 
0.71 
0.72 
0.67 
0.89 
0.90 
0.75 
0.69 
0.85 
0.69 
0.89 
0.57 
0.68 
0.62 
0.33 
0.15 
0.26 
0.20 
0.10 
0.19 
0.30 
0.16 
0.19 
0.10 
0.28 
0.27 
0.29 
0.14 
0.13 
0.59 
0.26 
0.24 
0.19 
0.16 
0.15 
0.06 
0.24 
0.12 
0.57 
0.14 
0.12 
0.19 
0.23 
0.29 
0.28 
0.33 
0.11 
0.10 
0.25 
0.31 
0.15 
0.31 
0.11 
0.43 
0.32 
0.38 
129 
C115 0.46 
C139 0.39 
C22 0.45 
C62 0.59 
C7 0.42 
D108 0.19 
Dl116 0.63 
D266 0.68 
D300 0.60 
D534 0.67 
D686 0.50 
D704 0.40 
El137 0.31 
E199 0.53 
E231 0.39 
E236 0.80 
E307 0.78 
E315 0.48 
E396 0.58 
E442 0.33 
E443 0.23 
E544 0.62 
E635 0.71 
E639 0.21 
E708 0.63 
E828 0.52 
E871 0.37 
E876 0.71 
E927 0.46 
0.54 6.44 1.55 7.98 4.16 
0.61 2.22 0.73 2.95 3.06 
0.55 3.04 0.73 3.77 4.18 
0.41 12.84 2.02 14.86 6.37 
0.58 1.42 0.23 1.65 6.28 
0.81 1.43 0.65 2.08 2.20 
0.37 11.06 0.89 11.95 12.44 
0.32 11.49 1.21 12.70 9.47 
0.40 7.76 1.34 9.10 5.80 
0.33 9.71 1.85 11.56 5.25 
0.50 2.47 0.51 2.98 4.84 
0.60 15.65 2.00 17.65 7.80 
0.69 6.71 1.50 8.21 4.48 
0.47 1.83 0.74 2.58 2.46 
0.61 1.70 1.57 3.27 1.09 
0.20 21.39 1.97 23.36 10.85 
0.22 3.69 0.29 3.99 12.56 
0.52 1.73 0.56 2.30 3.07 
0.42 0.25 0.08 0.33 2.99 
0.67 2.20 1.80 4.00 1.22 
0.77 3.80 1.72 5.52 2.21 
0.38 1.94 1.26 3.20 1.54 
0.29 7.52 1.40 8.92 5.38 
0.79 3.30 1.15 4.44 2.88 
0.37 1.65 0.78 2.43 2.13 
0.48 4.15 1.40 5.55 2.96 
0.63 1.32 0.96 2.28 1.37 
0.29 4.36 0.86 5.22 5.05 
0.54 3.23 2.42 5.66 1.33 
0.81 
0.75 
0.81 
0.86 
0.86 
0.69 
0.93 
0.90 
0.85 
0.84 
0.83 
0.89 
0.82 
0.71 
0.52 
0.92 
0.93 
0.75 
0.75 
0.55 
0.69 
0.61 
0.84 
0.74 
0.68 
0.75 
0.58 
0.83 
0.57 
LF HF BMI Categories Parent with HBP 
0.19 
0.25 
0.19 
0.14 
0.14 
0.31 
0.07 
0.10 
0.15 
0.16 
0.17 
0.11 
0.18 
0.29 
0.48 
0.08 
0.07 
0.25 
0.25 
0.45 
0.31 
0.39 
0.16 
0.26 
0.32 
0.25 
0.42 
0.17 
0.43 
ID Gain Gain (1 =NW, 2=OW, 3=OB) 
Al 048 11.03 24.06 1 
(1 = 1 parent 2=both) 
1 
A1067 11.44 19.32 1 o 
Al127 7.49 7.10 1 o 
Al138 14.40 16.50 1 o 
A1141 26.26 57.64 2 o 
A1291 16.29 13.54 1 o 
A1365 23.18 61.68 1 o 
A1408 12.42 12.36 1 o 
A1441 5.77 18.57 1 o 
A148 15.89 17.97 1 1 
130 
A1497 13.76 13.29 3 1 
A1543 24.80 35.17 1 0 
A1565 13.95 25.15 1 0 
A1570 9.73 8.67 2 0 
A1602 10.93 20.23 1 0 
A1622 8.20 24.18 2 0 
A1673 18.68 21.44 1 0 
A281 3.79 6.72 1 0 
A329 15.90 30.88 2 0 
A490 31.22 36.62 1 1 
A492 9.26 13.39 1 0 
A609 18.98 39.08 1 0 
A61 - 9.08 19.40 1 0 
A661 14.05 25.10 1 0 
A687 17.09 32.13 1 0 
A693 8.21 23.78 1 0 
A728 5.82 11.34 1 0 
A759 10.88 16.69 1 0 
A871 18.75 23.36 1 0 
A872 16.79 26.88 1 0 
A886 15.49 19.89 1 0 
A890 6.13 15.31 1 0 
B1078 16.81 35.09 2 0 
BI090 35.71 52.53 1 0 
B1099 14.53 10.61 1 0 
B1128 20.91 20.84 1 0 
BIB 9.00 13.55 1 0 
B1180 4.82 5.05 3 1 
B1211 12.44 21.47 1 0 
B1257 12.55 17.94 1 0 
B1259 5.82 6.53 3 0 
B1389 17.89 18.67 1 0 
B1421 11.69 17.93 1 0 
B1506 12.40 33.85 0 0 
B1544 29.68 35.62 1 0 
B159 11.58 9.79 2 0 
B160 7.40 12.15 3 0 
B1618 13.91 26.25 3 0 
B1651 4.10 8.99 2 0 
B1680 6.68 12.61 1 0 
B1688 10.72 8.69 1 1 
B1694 12.53 18.59 1 0 
131 
B1696 13.23 13.69 1 0 
B173 10.58 11.86 1 0 
B197 16.05 20.62 1 1 
B221 16.87 22.98 2 1 
B240 5.95 10.04 2 0 
B288 10.72 19.02 1 0 
B344 10.71 17.41 1 0 
B568 22.75 19.42 1 0 
B576 20.95 36.12 1 1 
B579 10.71 17.65 2 0 
B645 10.31 17.43 3 0 
B669 7.33 10.27 1 1 
B69 13.14 21.46 2 0 
B728 12.90 24.30 3 0 
B878 12.90 18.01 2 0 
B899 3.48 5.85 3 1 
B904 10.36 22.79 1 0 
B910 29.29 41.67 1 0 
B921 15.22 21.13 1 0 
B937 24.09 43.47 1 0 
B944 15.38 20.09 2 0 
B957 10.66 26.86 1 0 
B980 12.55 8.76 1 0 
B992 12.79 18.07 1 
B994 18.29 21.60 2 0 
C1l5 27.28 37.29 3 0 
C139 15.76 26.37 2 0 
C22 19.08 32.05 1 0 
C62 18.16 26.06 1 0 
C7 21.13 46.09 1 0 
DI08 1.51 3.25 1 1 
Dll16 6.85 13.60 3 0 
D266 13.69 23.17 1 0 
D300 7.48 12.58 2 0 
D534 14.70 13.90 3 0 
D686 18.98 26.16 1 0 
D704 5.77 16.08 1 0 
EI137 1.88 10.47 1 1 
E199 14.91 15.86 2 0 
E231 26.55 22.68 1 0 
E236 7.96 9.64 3 1 
E307 13.43 17.41 1 
132 
E315 12.67 25.50 2 
E396 31.64 37.83 1 0 
E442 16.41 23.26 1 0 
E443 20.24 35.73 1 0 
E544 16.25 15.13 1 0 
E635 4.41 5.12 3 0 
E639 12.71 22.84 1 0 
E708 9.74 10.32 1 1 
E828 11.02 15.30 3 0 
E871 33.89 49.10 1 0 
E876 16.42 21.63 1 1 
E927 21.98 22.19 1 0 
133 
